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Abstract 
The CD4+ T cell response during malaria is critical for control of Plasmodium infection. 
Unfortunately, this response is commonly dysfunctional or absent in individuals living in 
malaria endemic regions, and current vaccination efforts have been unable to effectively 
overcome these short comings. Therefore, a better understanding of host immune 
responses during Plasmodium infection is required if we are to improve vaccine efficacy and 
promote long-lived protective immunity. To improve our understanding of the CD4+ T cell 
response, we assessed changes in the transcriptional profile of these cells, over the course 
of Plasmodium falciparum infection, in volunteers who had not previously been exposed to 
Plasmodium, who were taking part in controlled human malaria infection (CHMI) studies. 
Bioinformatic analysis identified CXCL8 expression as a biomarker of sub-microscopic 
infection. Additionally, the degree of CXCL8 expression was indicative of initial parasite 
growth rate. We also identified the emergence of a significant regulatory profile in the CD4+ 
T cell population which developed with drug-mediated clearance of infection. This profile 
included checkpoint inhibitors PD-1, LAG-3, TIM-3, and CTLA-4. The degree of PD-1 
expression on putative Tr1 (CD49b+ LAG-3+) cells negatively correlated with initial parasite 
growth rate. However, only PD-1 blockade affected antigen specific expression of the Tr1 
cell related cytokines IFNγ and IL-10 by peripheral blood mononuclear cells (PBMCs) from 
CHMI study volunteers. 
Another transcriptional change following drug-mediated control was down-regulation of the 
master transcription factor BACH2. BACH2 plays an important role in T cell homeostasis 
and facilitates the stability and function of the FOXP3+ regulatory T (Treg) cell population 
while modulating effector T cell differentiation. Using transgenic mice with T cell specific 
BACH2 deficiency we showed that BACH2 was an important intrinsic factor in CD4+ T cells 
during cell differentiation in vitro. In the context of experimental malaria and a second 
parasitic infection, visceral leishmaniasis (VL), we showed that T cell-specific BACH2 
modulated Th2, Th17 and Tfh cell differentiation, and suppressed effector CD4+ T cell 
responses. However, BACH2 was also important for the expansion and/or maintenance of 
splenic Treg cells during parasitic infection. 
Using pathway analysis to further assess the Plasmodium induced change in the 
transcriptional profile of CD4+ T cells we identified differential regulation of the IL-10 
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signalling pathway after drug-mediated clearance of infection. In a number of parasitic 
infections, IL-10 signalling is primarily mediated by a FOXP3- IL-10-producing regulatory 
CD4+ T (Tr1) cell subset. Tr1 cell frequency has been positively correlated with chronic 
malaria exposure in Ugandan children, and in mouse models of VL and malaria. We recently 
reported that Tr1 cells suppressed anti-parasitic immune responses, but also played a key 
role in preventing immunopathology. To investigate this population further we used RNAseq 
to compare gene signatures in Tr1 and Th1 cells from CHMI studies, as well as from mice 
with experimental VL. This enabled us to define a parasite-induced Tr1 cell molecular 
signature which was independent of host and infection type. Within the Tr1 cell population 
we saw up-regulation of a number of regulatory molecules, which were also up-regulated at 
the protein level, including LAG3 and CTLA4. Additionally, we identified transcriptional 
changes in the expression of a number of chemokine receptors, and up-regulation of the 
pioneering transcription factor PBX1. Using a transgenic mouse model which had a T cell 
specific deficiency for Pbx1 we showed that PBX1 also suppressed CD4+ T cell inflammation 
(IFNγ, and TNF expression), as well as parasite control in the liver during experimental VL. 
Together, these results show that blood-stage P. falciparum infection promotes a regulatory 
CD4+ T cell phenotype early in infection, which can be modified by selective immune check 
point blockade. They also show that different transcription factors, including BACH2 and 
PBX1 suppress T cell inflammation during parasitic infection, and in the case of PBX1 can 
also suppress parasite clearance. Our findings highlight the need to incorporate strategies 
that avoid or overcome established anti-parasitic immunoregulatory pathways into malaria 
vaccine and drug treatment protocols.  
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1.1 Malaria overview 
Malaria is caused by infection with the protozoan parasite Plasmodium, the world’s deadliest 
family of parasites1. It puts just under half of the world’s population at risk of disease, and in 
2016 resulted an 216 million cases of malaria and 454,000 deaths2. Sub Saharan Africa 
carries the majority of the malaria burden. However, it is also prevalent in other tropical and 
sub-tropical countries which host the malaria vector, the Anopheles mosquito. 
1.2 Demographics 
Malaria primarily affects pregnant women, and children under the age of 5 years old. This 
may be the result of a suppressed, or immature immune response. It may also arise from 
variance in their hormonal milieu, which may make them more prone to infection. Resistance 
to severe malaria is associated with degree and frequency of infection. Consequently, 
younger, less exposed individuals are more prone to severe disease3,4. Pregnant women 
are also reported to be more prone to mosquito bites and therefore have an increased risk 
of infection, resulting in life-threatening malaria5. 
1.3 Disease physiology 
Initial symptoms include headaches, diarrhoea, and loss of appetite in conjunction with a 
distinctive cycling fever. This fever is one of the primary symptoms used to diagnose malaria, 
and is used alone for diagnosis in cases where treatment is urgent, or in the absence of 
more definitive tests such as rapid tests, microscopy or PCR of blood samples. Fevers 
typically cycle every 2-3 days, depending on the Plasmodium species causing disease, and 
are often a precursor to more severe malaria, including anaemia, lung and liver 
complications, renal failure and cerebral malaria. Severe malaria is almost exclusively 
caused by P. falciparum, however P. vivax can also cause severe pathology. Aside from 
anaemia, which results from substantial red blood cell (RBC) loss due to parasite egress 
from erythrocytes and clearance of uninfected and infected RBC by phagocytes, most of 
these severe symptoms are immune pathologies. Immune cell clearance of infection is often 
non-specific and results in inflammation-mediated damage to surrounding tissue. 
Progression to severe malaria can be prevented by anti-malarial drugs, but sadly, availability 
of these lifesaving medications are often limited in regions most affected by malaria.  
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Relapse is another common feature of malaria. In part, this can be attributed to inadequate 
treatment availability and drug non-compliance. However, fevers can re-occur for months 
after initial infection, highlighting the difficulty the immune system faces in clearing 
Plasmodium infection. Plasmodium has a number of immune evasion techniques which 
contribute to this phenotype. These include antigen switching, and the ability of parasites to 
enter into a dormant phase of infection (hypnozoites) in the case of P. vivax and P. ovale6,7. 
As yet we have no effective treatment for this phase of infection. 
1.4 Parasite life cycle 
Five Plasmodium species are known to infect humans, P. falciparum, P. vivax, P. knowlesi, 
P. malariae and P. ovale (now recognised as two distinct species; P. ovale curtisi and P. 
ovale wallikeri), with many others infecting rodents, non-human primates, birds and reptiles. 
P. falciparum is the main cause of severe malaria and death in humans, along with P. vivax, 
although the latter is not the main source of cerebral malaria8.  
Plasmodium infection is transmitted by the female Anopheles mosquito. Parasite 
gametocytes are taken up by the mosquito in a blood meal. Gametocytes then migrate to 
the mosquito gut where they develop into sporozoites, the infective stage of the parasite. 
These then migrate to the salivary glands and are transferred by saliva into the skin of the 
next individual the mosquito bites. The majority of sporozoites released into the host stay in 
the dermal layer, at the site of entry, and do not contribute to infection9-12. However, 
approximately 35% of injected parasites migrate away from the site of infection via the 
lymphatics or the blood. Plasmodium parasites are cleared from the lymphatic system 
without developing infection. However, parasites which reach the blood, migrate to the liver 
where they establish pre-erythocytic infection13. Parasites pass into the liver parenchyma 
via Kupffer cells and invade host hepatocytes14,15. Invading parasites traverse hepatocytes 
for some time before choosing one cell to infect. This traversing is essential for priming the 
parasite for cell invasion16. Over the course of 7-10 days, schizonts develop into merozoites, 
and upon an unknown trigger they bud off from the hepatocyte in merozomes and migrate 
into the blood stream where merezoites are released and invade erythrocytes17. The hepatic 
phase of infection offers the best opportunity for development of an immune response, as 
infected hepatocytes are able to present antigen via MHCI molecules. Once parasites leave 
the hepatocyte, merozomes are immunologically invisible, disguised by host membrane, 
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and upon RBC invasion they reside in a cell type which is incapable of presenting antigen 
via MHC molecules.  
Erythrocyte invasion is a complex and tightly controlled process. There is a requirement for 
polarised orientation of merizoites on the surface of RBCs, along with controlled and timed 
release of molecules which help mediate piercing of the RBC surface and RBC invasion 18. 
Merizoites then exploit the RBC for asexual replication. Mature parasites burst from the RBC 
and the cycle of invasion, replication and release repeats.  
1.5 Malaria models 
The majority of human malaria studies assess symptoms, and body fluids such as blood 
and urine, while severe malaria pathology is sometimes assessed post-mortem. This limits 
what can be learned about disease progression and pathology. For this reason, rodent and 
non-human primate models have been developed to study malaria. These models (rodents 
in particular) have the added benefit of a uniform genetic background, which eliminates 
some of the variability we see between humans. Different rodent strains are also able to be 
exploited for their varying susceptibility and resistance to the Plasmodium parasite. For 
example C57BL/6J mice are susceptible to severe malaria caused by P. berghei ANKA, 
while DBA/2 mice are resistant 19-21. Using these two models allows the dissection of the 
biology and genetics governing disease susceptibility and resistance. 
Various strains of Plasmodium parasites are also used to understand different aspects of 
malaria. For example the parasite P. berghei ANKA (P. berghei) is used for the study of 
malaria induced anaemia and cerebral malaria, as it causes disease symptoms similar to 
those observed in humans with severe malaria. P. chabaudi chabaudi AS (P. chabaudi) and 
non-lethal P. yoelii (P. yoelli NL) induce mild but chronic infections which allow a larger 
window in which to examine immune responses, as well as study protective immunity. They 
are also used to study recrudescence of infection, and the typical shift in immune response 
from a T cell mediated immunity to B cell and antibody mediated immunity.  
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Table 1.1 | Malaria mouse models in correlation with human findings. 
Mouse model 
(mouse strain 
and 
Plasmodium 
species used 
for infection) 
Disease 
phenotype 
Biological 
phenotypes 
Observation 
in mouse 
model 
Observation 
in humans 
(P. 
falciparum 
or P. vivax) 
C57BL/6, P. 
berghei 
Severe 
malaria 
(including 
cerebral 
malaria) 
Cerebral parasite 
sequestration 
22  23,24 
Neurological 
symptoms 
22 25 
Roles for pro- and 
anti- inflammatory 
molecules 
20,26-28  
29,30 
Blood brain barrier 
disruption 
31 32 
Leukocyte migration 
to the brain 
33 34 
Severe respiratory 
distress 
35 36 
T cell biology (e.g. 
Tr1 cells, 
polyfunctional CD4 
T cells, and cross-
presentation to CD8 
T cells) 
37-39 40-44 
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C57BL/6, P. 
yoelli 17XL 
Severe 
malaria 
(including 
cerebral 
malaria) 
Cerebral parasite 
sequestration 
45 23,24 
Severe lung 
pathology, or severe 
respiratory distress 
45 36 
Severe anemia 45 46 
T cell biology (e.g. 
Tr1 cells) 
47 40,41 
C57BL/6, P. 
yoelli 17XNL 
Mild malaria  
45 48 
C57BL/6, P. 
chabaudi 
Mild malaria 
Mild malaria 49 48  
Receptor 
involvement in iRBC 
sequestration to 
endothelial cells  
50 51 
T cell biology (e.g. 
Th1 cell, Treg cell, 
and IL-10 response) 
52-54 42,55,56 
Severe anemia 57 46 
DBA/2, P. 
berghei 
Severe 
malaria 
Severe respiratory 
distress syndrome 
58 36 
BALB/c, P. 
berghei 
Mild malaria 
Resistance to 
cerebral malaria 
28 3 
CBA/2, P. 
berghei 
Mild malaria 
Resistance to 
cerebral malaria 
28 3 
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Genetic modification of mice also enables interrogation of very specific genetic contributors 
to disease and immunity. For example, the Ifnar1-/- mouse (lacking type I IFN signalling 
capacity) has been used to show the requirement of the type-I IFNs for severe pathology 
and disease20. Cell-specific gene knockouts using the cre-floxed system and diphtheria toxin 
system have also been widely used to further define which cells these genes play a role in20. 
Other T cell receptor (TCR) transgenic mice have enabled the study of antigen-specific 
responses, and still other mice which have been humanised and express Homo sapien 
genes, have allowed a closer comparison and translation to human disease59,60. 
1.6 Prevention and intervention 
In 2000, the United Nations included as one of their millennium goals to halt and begin the 
reversal of malaria incidence by 2015. Since then, significant effort and resources have been 
poured into global eradication of malaria. Malaria prevention schemes have included the 
removal or poisoning of mosquito breeding areas, supply of insecticide-treated nets (ITNs) 
to people living in malaria endemic regions, stabilisation and reduced pricing in the malaria 
drug market, and better diagnosis and treatment. As a result, global incidence of malaria 
was reduced by 30% between 2000 and 2013, and strikingly, mortality dropped by 47%2. 
Unfortunately, we are now seeing the emergence of insecticide resistance in mosquitos61. 
ITNs have also provided selective pressure, driving mosquito feeding times to earlier in the 
evening 62. Continued effort will be required to achieve world-wide eradication of malaria. 
Rapid diagnosis and effective treatments are important for reducing transmission 
opportunities and increased recovery and survival. Currently, definitive diagnosis is slow, 
and requires expensive equipment, such as microscopes and PCR machines for more 
accurate diagnosis. PCR often takes days to return results, by which time patients have 
already received treatment, or returned home, and microscopy, though effective for high-
level infection, cannot detect sub-microscopic infection. Recently, advances in diagnostic 
tools have brought some much needed improvements to the field. Rapid diagnostic testing 
for malaria (mRDT) is able to identify Plasmodium infection within minutes, by detecting 
parasite bi-products in patients’ blood. Breath tests detecting sulphur compounds expelled 
specifically in relation Plasmodium infection are also in trial, and have been highly effective 
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so far63. All of these diagnostic advancements will be critical for improving malaria treatment, 
and reducing transmission. 
1.6.1 Anti-malarial drugs 
Quinines, amphoterisins, artemisinins and their derivatives are common anti-malarial 
treatments. Doxycycline, a common antibiotic, is also used prophylactically by individuals 
with low exposure entering malaria endemic regions. Unfortunately, we are now seeing the 
emergence of resistance to these treatments – a phenomenon which has been accelerated 
by incorrect drug use (non-compliance, or treatment for an unrelated disease). Fortunately, 
continued research has enabled the development of a number of new anti-malarial drugs 
which can be used as second and third line treatments64. 
1.6.2 Vaccines 
A high efficacy vaccine against Plasmodium infection will be necessary to achieve malaria 
eradication. Many malaria vaccine trials have been carried out with this goal in mind. 
However, generating long term protection is proving to be difficult. 
The RTS,S vaccine is the most progressed vaccine candidate 65. This vaccine only produces 
moderate protection of 20-50%66,67. It is a subunit vaccine comprised of a section of the 
highly conserved and immunogenic circumsporozoite protein (CSP) conjugated to a 
Hepatitis B surface antigen65. This vaccine induces a potent Th1 cell and antibody response 
specific to CSP which is able to provide immunity to primary infection. However, it does not 
generate a robust memory response. A number of trials have attempted with some success 
to increase the efficacy of the vaccine by using various prime-boost regimes, adjuvants, 
target antigens and platforms68-70. However, there is still much room for improvement. 
The gold-standard in malaria vaccination has been intravenous administration of live-
attenuate sporozoites. Studies as early as the 1970s used irradiated sporozoites injected 
into humans, with a 10 week booster, to induce sterilising immunity to primary infection. This 
type of vaccination has been able to generate immune memory, and protect for up to 10 
months post-infection71-73. Partial functionality or infectivity of the parasite appears to be 
important for this immunity74,75. Attenuated parasites in these vaccines were still able to 
migrate to the liver and infect hepatocytes. However, their capacity to replicate was 
Chapter 1  
 
42325972 32 
hampered. No other vaccine type has been able to match this degree of immunity, indicating 
that a key immunogenic feature is lost without exposure to a metabolically active parasite. 
Unfortunately, immunity generated by live attenuated sporozoites also wanes with time. In 
a more recent study vaccination only achieved 67% protection two years after vaccination73.  
Another area of exploration in Plasmodium vaccine development has been the route of 
vaccine administration. Live attenuated sporozoite vaccines are administered intravenously 
and therefore bypass the dermal phase of infection. The majority of parasites from mosquito 
bites have been shown to be trapped around the wound site and are cleared by host immune 
cells. Because the parasites sit in the tissue for a while, it has been suggested that this 
provides an ideal window for sampling and presentation by APCs and therefore, 
development of an adaptive immune response76. Dermal immunity would be ideal as 
infection would be cleared before it could be established. Some studies have looked at 
dermal vaccination by mosquito bites. Using this method, sterilising immunity was also 
achieved72. However, this method is impractical as it requires hundreds of mosquito bites. 
Potentially, nano-patch technology could be implemented to mimic this effect.  
Interestingly, naturally acquired immunity is not sterile. Individuals immune to severe malaria 
often carry persistent, asymptomatic infection, indicating that concomitant immunity is 
important for protection against disease. This knowledge may be key to developing effective 
vaccines in the future. 
1.7 Immune response to Plasmodium infection 
1.7.1 Naturally acquired immunity 
Immunity to malaria is thought to be difficult to acquire because of constant antigen switching 
on the surface of the parasite and high genetic variability between parasite infections. 
Consequently, antigen specific immunity to one infection is likely to be rendered ineffective 
in a subsequent infection. Therefore, a build-up in the repertoire of antigen-specific immune 
responses over time is suggested to naturally increase the range of malaria resistance in an 
individual and consequentially reduce susceptibility to infection and severe malaria in older 
individuals. It is also apparent that Plasmodium infections suppress immune responses and 
long-term memory, resulting in poor immunity77-79. Though immunity is difficult to actively 
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induce, naturally (or passively) acquired immunity is found at high levels in previously 
exposed individuals in malaria endemic regions. This immunity is associated with frequent 
Plasmodium infection and is positively associated with age. Increased immunity is also seen 
after the wet season (a season of high malaria transmission), and those which sustain 
asymptomatic infection over the dry season (a season of low malaria transmission) are less 
likely to be infected over the following wet season40,80,81. These protective immune 
responses are characterised by antigen-specific IFNγ producing CD4+ T cells and parasite-
specific antibody production40,80.  
1.7.2 Type-I IFN 
The immune system mounts a number of innate and adaptive responses to Plasmodium 
infection. Adaptive immunity is critical for long term protection, but Plasmodium is also able 
to interfere with this activation. Type-I IFNs (IFN1) are best known for their role in anti-viral 
immunity, however in malaria they can have a pathogenic role. This is indicated by studies 
in mice showing that mice which lack functional IFN1 receptors are resistant to experimental 
cerebral malaria (ECM)20. Furthermore, IFN1 gene polymorphisms in humans are 
associated with resistance to severe malaria82,83.  The pathway leading to IFN1 induction is 
not completely defined, although Plasmodium DNA is thought to trigger IFN1 through the 
STING/TBK1/IRF3-IRF7 axis84. In mice, Plasmodium induced IFN1 has been shown to 
suppress CD8- dendritic cell (DC) priming, leading to substantial suppression of the Th1 
pathway84,85 which is critical in controlling acute Plasmodium parasitic infection20. In 
humans, IFN1 have been shown to promote the development of IL-10-producing Th1 (Tr1) 
cells during blood stage infection, and blockade of this signalling axis increased antigen-
specific pro-inflammatory cytokine production30. 
1.7.3 Dendritic Cells 
DCs are a vital link between innate and adaptive immunity and play an important role in the 
cellular response to infection. They are particularly important for mediating parasite 
clearance during acute blood stage infection86,87. Plasmodium antigen presentation by DCs 
occurs via both classical and cross-presentation pathways and is able to induce a range of 
Plasmodium specific CD4+ and CD8+ T cell responses88,89. Unfortunately, the Plasmodium 
parasite is also able to suppress DC function90,91. In a number of cases, it suppresses 
antigen presentation pathways and prevents cDC-mediated Th1 cell responses during 
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infection89,92. Although DCs are important for mediating parasite clearance, their 
suppression has also resulted in reduced inflammation and consequently reduced 
immunopathology93,94. Interestingly, this is exploited by the anti-malarial drug Chloroquine 
which prevents ECM by inhibiting TLR signalling and consequently DC-induced T cell 
mediated ECM95,96. 
1.7.4 B cells 
Humoral immune control of Plasmodium infection was first described in the 1960s where 
passive serum transfer showed the presence of soluble anti-parasitic factors in the blood 
during malaria97. Since then, these factors have been identified as antigen-specific 
antibodies which are important for anti-sporozoite immunity, as well as protection against 
the blood stage of infection98,99. These antibodies have a diverse range of functions which 
lead to suppression of parasite development. For example, antibodies are able to block 
merozoite invasion of RBCs by binding to the merozoite entry protein MSP1100. They are 
also able to target surface proteins specific to infected red blood cells (RBC), as well as 
mediate opsonisation of infected cells and induce phagocyte-mediated killing99,100. 
Furthermore, combinations of antibodies have been shown to be more effective at clearing 
infection than a monoclonal response99,101,102. Plasmodium-specific antibodies have also 
been shown to be immunologically active across different ethnic groups, suggesting the 
conservation of immunogenic antigens carried by the Plasmodium parasites103. 
1.7.5 CD8+ T cells 
CD8+ T cells are another critical arm of the adaptive immune system and play an important 
role in immunity against both pre-erythrocytic and erythrocytic stages of Plasmodium 
infection104,105. This was demonstrated in sporozoite vaccination studies where sterilising 
immunity was dependant on effector CD8+ T cells. This CD8+ T cell response was 
dependant on hepatic infection and sporozoite antigen presentation by draining lymphoid 
DCs59,106. Plasmodium-specific CD8+ T cells mediate their anti-parasitic effect via the 
release of cytotoxins such as granzyme B and perforin107. In the liver, antigen specific CD8+ 
T cells form clusters around infected hepatocytes where they directly mediate killing of 
infected cells. They also recruit non-specific CD8+ T cells to these clusters to aid hepatocyte 
killing108,109.  
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Immunity to erythrocytic infection is not as well understood. Erythrocytes do not express 
major histocompatibility (MHC) molecules, and therefore, are not able to present parasite 
antigen to T cells. However, some CD8+ T cell responses to the erythrocytic phase of 
infection have been reported. For example, Plasmodium parasites are able to infect 
erythroblasts (precursors to erythrocytes) which still express MHC molecules allowing them 
to present antigen and induce immune-mediated killing by CD8+ T cells110-112.  
A number of vaccine trials have aimed to enhance the effector CD8+ T cell response to 
Plasmodium infection. This has been achieved with some success. Recently, a trial testing 
a recombinant CSA and AMA1 vaccine in Rhesus monkeys was able to significantly 
enhance antigen-specific effector CD8+ T cell responses113. Interestingly, a similar human 
recombinant vaccine was able to induce a distinct, protective CD8+ T cell memory 
population114, and rodent memory CD8+ T cells have been shown to be important for long 
term sterile immunity115, suggesting that targeting CD8+ T cell responses by vaccination is 
an effective way to induce a protective immune response against Plasmodium.  
Unfortunately, CD8+ T cell cytotoxicity also contributes to localised pathology and is the 
cause of the severe pathology seen in experimental cerebral malaria in mice caused by P. 
berghei20,82,116. There is a need to take this into consideration during the development of 
CD8+ T cell-targeted vaccines. It also highlights a need to target other immune cell 
populations. 
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Figure 1.1 | Adaptive immune response to parasitic infection.  
1) The host is infected with parasites e.g. Plasmodium or Leishmania, via their respective 
vectors. 2) Parasites travel to key organs for initial proliferation and dissemination, e.g. the 
liver in the case of malaria, or the liver, bone marrow and spleen in the case of Leishmania. 
3) Plasmodium specifically infects kupffer cells in the liver while Leishmania infects 
monoculear phagocytic cells in any of the afore mentioned organs. CD8+ T cells play a key 
role infection control in the liver via cytotoxic mechanisms. 4) Plasmodium then spreads to 
the blood stream, propagating through the red blood cell population. 5) Upon detection by 
antigen presenting cells, such as macrophages and dendritic cells an adaptive immune 
response is initiated against the invading parasites; this includes a range of T cell and B cell 
responses. 6-7) Th1 cells differentiate in response to IL-12 stimulus, their production of IFNγ 
and TNF is critical for macrophage and CD8+ T cell mediated parasite killing. Th17 cells 
develop in response to IL-6 and TGFβ, while IL-21 and IL-6 are important for Tfh cell 
development, and IL-4 for Th2 cell development. Tfh cells are the predominant drivers of B 
cell production of anti-parasitic antibodies, though Th2 cells also facilitate B cell activation 
and anti-parasitic function. 8) A population of highly suppressive Th1 like regulatory (Tr1) 
cells also develop, antagonistic to the inflammatory response, and mediate their regulatory 
effect via IL-10 production. Classical Foxp3+ T regulatory (Treg) cells also modulate 
inflammatory response primarily via TGFβ. These cells function in concert to control 
infection, and mitigate immune mediated damage to the host. 
1.7.6 CD4+ T cells 
CD4+ T cells also influence a number of aspects of the host immune response during 
malaria. They are important for the development and survival of effector and memory CD8+ 
T cell responses117-121. They also support antibody responses and phagocyte mediated 
clearance of infection122. 
Th2 and Tfh cells 
Different CD4+ T helper cell subsets develop depending on the immunological stimuli a naïve 
cell receives. Th2 cells, characterised by expression of the GATA3 transcription factor and 
IL-4 cytokine, typically develop in response to extracellular infections such as helminths. 
However, they also develop in response to Plasmodium infection, and IL-4 is known to aid 
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Plasmodium specific CD8+ T cell development123. These Th2 cells can also support B cell 
development and the generation of Plasmodium-specific antibodies, though they are not the 
primary source of B cell activation during malaria124. However, there is increasing evidence 
that the follicular helper T cell subset (Tfh cells), which is characterised by the Bcl6 
transcription factor and IL-21 expression, plays a more important role in antibody induction 
during malaria, and it is likely that infection-mediated effects on this subset contribute to 
suboptimal B cell responses during malaria122,124. 
Th17 cells 
Th17 cells and the Th17 cytokine IL17A have also been associated with protection against 
severe malaria. Th17 cell responses have been found to increase in both complicated and 
uncomplicated forms of Plasmodium infection125. High levels of IL-17A in exposed 
individuals have correlated with increased protection months after infection 126. Conversely, 
in pregnancy, increased parasitemia was associated with reduced IL-17A levels, as well as 
reduction in IFNγ, which is known to control parasite growth127. 
Th1 cells 
The dominant T helper cell response in Plasmodium infection comes from Th1 cells. Th1 
cells express the T-bet transcription factor and typically produce IFNγ and TNF in response 
to Plasmodium. Th1 cell development during malaria is dependent on classical MHCII 
engagement, co-stimulatory receptor-ligand interactions, and IL-12 signalling. Th1 cell-
derived IFNγ is critical for parasite clearance and is important for the maintenance of 
protective memory CD4+ T cells128-131. Unfortunately, Th1 cells also promote immune 
pathologies such as those observed in experimental cerebral malaria caused by P. berghei 
in mice132.  
Treg cells 
Thymus-derived Foxp3+ CD4+ T (Treg) cells can suppress Th1 cell responses to 
Plasmodium, and have been associated with protection against experimental cerebral 
malaria caused by P. berghei in mice133. However, this immune suppression also reduces 
the host’s capacity to control infection. Interestingly, the presence of Treg cells in 
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Plasmodium infection is inversely proportional to the amount of the Th1 cell-polarising 
cytokine IL-12, and positively correlates with production of the anti-inflammatory cytokine IL-
10134. Treg cell numbers are also inversely correlated with development of memory T cells55. 
This balance between regulation and inflammation is critical for disease outcome and future 
immunity to malaria.  
IL-10 and Tr1 cells 
IL-10 is an important regulator of Plasmodium-induced inflammation, and is able to protect 
against experimental cerebral malaria in mice during P. berghei infection47. Studies have 
shown that lower ratios of IL-10 to the pro-inflammatory cytokine TNFα are associated with 
severe malaria135. Additionally, IL-10-deficient mice have increased pathology and mortality 
when infected with P. chabaudi, which normally only induces mild malaria in control C57BL/6 
mice136.  
IL-10 is produced by multiple different immune cells, and multiple different T cell subsets, 
including Treg cells137. However, in a number of parasitic infections IL-10-producing Th1 
(Tr1) cells are a major source of IL-1037,42. Tr1 cells are not clearly defined. In some cases 
they broadly classified and include all CD4+ IFNγ+ T cells which co-produce IL-10 (including 
Foxp3+ Treg cells). They have also been more specifically defined as being CD25- Foxp3- 
IL-2lo IL-4lo IFNγ+ IL-10+ and CD25- Foxp3- IL-2lo IL-4lo IFNγ- IL-10+ CD4+ T cells42,47,138. 
However, the majority of studies in the malaria field have defined Tr1 cells as being Foxp3- 
IL-10+ IFNγ+ CD4+ T cells. These cells develop in response to Plasmodium infection; in 
particular, they increase in conjugation with seasonal increases in Plasmodium exposure 
and immunity, and are lost in association with reduced exposure and reduced 
immunity4,40,42. Their dual production of IL-10 and IFNγ suggests that they play dual roles in 
inflammation and immune suppression. As such, they are an ideal candidate for therapeutic 
modulation in malaria. 
BLIMP1 is known to bind the IL-10 promoter, and promote IL-10 production in both 
Plasmodium and Leishmania infections37,139. In T. gondii infection BLIMP1 induction of IL-
10 is driven by IL-12, STAT4, and IL-27, and regulated by TGFβ. The transcription factor 
cMAF also works in synergy with BLIMP1 to enhance the IL-10 response in this parasitic 
infection139. cMAF has also been reported to drive IL-10 production in Th1 and Th2 cells 
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during malaria140; additionally, IL-27 receptor signalling has been shown to systemically 
control IL-10 production by Tr1 cells throughout Plasmodium infection141. These factors may 
act via the BLIMP1 pathway as seen in T. gondii infection. 
1.8 Leishmania overview 
Leishmaniasis is a parasitic disease which also induces a strong CD4+ T cell response. 
Therefore, we studied this disease in parallel with malaria to strengthen our understanding 
of the CD4+ T cell response during parasitic infections. 
Leishmaniasis is caused by infection with parasites of the genus Leishmania. Similar to the 
Plasmodium parasite, Leishmania is vector borne. However, is it transmitted by female sand 
flies (Phlebotomus and Lutzomyia). It is found in tropical and sub-tropical regions of the 
world, including the Indian sub-continent, East Africa, the Mediterranean, and Central and 
Southern America. A number of species of Leishmania cause disease, these vary in 
prevalence depending on geographical location142. Disease can manifest in 3 broad forms; 
cutaneous (CL), mucosal-cutaneous (ML), and visceral (VL) leishmaniasis. VL is lethal if left 
untreated, and can develop into a complication called Post-kala azar dermal leishmaniasis 
(PKDL), a late cutaneous manifestation of VL that presents with accumulation of heavily 
parasitised macrophages in the skin, thereby assisting parasite transmission to sand fly 
vectors143. L. donovani is the most prominent cause of VL in India and East Africa, while L. 
infantum (chagasi) causes the majority of cases seen in the Mediterranean, and South and 
Central America144.  
L. donovani is also able to infect non-human hosts including mice. As such we were able to 
use the human parasite to initiate a pre-clinical model of VL in C57BL/6J mice. VL primarily 
affects the spleen, liver, bone marrow (BM), and lymph nodes, where the parasite resides 
in tissue-resident macrophage populations. In the mouse, the outcome of infection is organ 
specific, with an acute, resolving infection occurring in the liver, and a chronic infection 
established in the spleen and BM145. We were able to use this to our advantage to better 
understand the immune responses leading to both positive and negative disease outcomes.  
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Table 1.2 | Leishmaniasis 
Mouse model 
(mouse strain 
and 
Leishmania 
species used 
for infection) 
Disease 
phenotype 
Biological 
phenotypes 
Observation 
in mouse 
model 
Observation 
in humans 
(various 
Leishmania 
spp.) 
CBA, L. 
donovani 
Resistance  146 147 
C57BL/6, L. 
donovani 
Visceral 
leishmaniasis 
Hepato-
splenomegally 
148 149 
  
Pro- and anti- 
inflammatory 
responses 
37 150,151 
  
T cell biology (e.g. 
Tr1 cells) 
152,153 154 
C57BL/6, L. 
major 
Cutaneous 
leishmaniasis 
Cutaneous lesions 155-157 157 
  
T cell biology (e.g. 
Tr1cells, and 
polyfunctional CD4 T 
cells) 
155,156,158 159,160 
 
1.9 Immune response during VL 
A number of immune mechanisms contribute to VL control. In the liver of genetically 
susceptible mice, such as C57BL/6 mice, control of infection is mediated by the formation 
of granulomas around infected kupffer cells. This facilitates killing of parasites in infected 
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cells with the help of infiltrating monocytes and T cells (reviewed in161). In the spleen of these 
animals, a chronic infection is established and is associated with severe immunopathology, 
including TNF-mediated disruption of splenic architecture162. 
1.9.1 CD8+ T cells 
Antigen-specific CD8+ T cells play little role in the control of a primary infection in the liver163. 
However, they appear to be important to protect against re-infection164. In addition, some 
anti-parasitic, pre-clinical vaccines require CD8+ T cell activity for protection in the liver164-
167. They can secrete cytotoxic molecules which mediate direct killing of Leishmania infected 
macrophages168. In addition to this, they produce the inflammatory cytokine IFNγ which is 
important for the development of the Th1 cell response168. 
1.9.2 CD4+ T cells 
CD4+ T cells are essential for control of VL, and play a critical role in granuloma formation 
and parasite killing in the liver164. 
Th1 cells 
The Th1 cell inducing cytokine IL-12 is important for VL control. In a Leishmania susceptible 
mouse model (BALB/c), IL-12 was important for control of parasite growth in the liver169. 
Additionally, in ex vivo cultures of PBMCs from VL patients, antigen-specific inflammatory 
responses were shown to be IL-12-dependent170. Th1 cell-derived IFNγ is particularly 
important for macrophage mediated clearance of parasite171-173. Unfortunately, this anti-
parasitic Th1 response is often absent or impaired in VL patients170,174.  
IL-10 
Anti-inflammatory cytokines induced during VL contribute to the suppression of parasite-
specific Th1 cell responses. In particular, IL-10 is up-regulated and has been shown to 
impair these responses175,176. This effect was reversed by blocking IL-10170,174. IL-10 
neutralisation was also able to enhance parasite killing in human splenic aspirate cultures 
in association with an increased IFNγ response176. Macrophages are a relevant source of 
IL-10 during leishmaniasis; macrophage derived IL-10 has been demonstrated to impair 
parasite control in cutaneous leishmaniasis by autoregulating production of IL-12 and TNFα, 
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which are critical for parasite clearance177. We also find that IL-10 prevents parasite control 
in VL, but protects macrophages from TNFα mediated death in a similar manner37. As with 
malaria, it may be possible to manipulate IL-10 producing cells to alter disease outcome. 
Treg and Tr1 cells 
IL-10 is produced by a number of CD4+ T cell subsets including Foxp3+ CD4+ T (Treg) cells. 
Treg cells accumulate in post kala azar dermal leishmania lesions, and are thought to be 
associated with promotion of parasite persistence178. However, there is conflicting evidence 
for the role of Treg cells in VL. In Indian VL patients, Treg cells didn’t accumulate or expand 
in the spleen or blood 152,179. However, Treg cells were enriched in the BM of VL patients in 
a different study in the same region180. These Treg cells contributed to IL-10 production. 
However, Tr1 cells were also found to contribute to IL-10 production, and another study 
showed that Tr1 cells were the main source of IL-10 in the spleen of VL patients152. We also 
find Tr1 cells to be the predominant source of IL-10 in murine VL37. It is becoming more 
apparent that multiple mechanisms feed into IL-10 production by Tr1 cells. In leishmania IL-
6 and IL12p40 act in a host protective manner to limit Tr1 cell development181. Additionally, 
the trascription factor AHR regulates IL-10 production, while BLIMP1 promotes IL-10 during 
leishmaniasis37,182. Other mechanisms involving IL-27 and cMAF likely also modulate IL-10 
production and Tr1 cell development, and influence the outcome of Leishmania infection. 
Th17, Tfh and Th2 cells. 
Other T helper cell populations have also been implicated in the immune response to VL, 
though they are less prominent than Th1 and Tr1 cells. Th17 cells are predominantly 
associated with protection183-185. Vaccination using live attenuated L. donovani in mice was 
able to induce an IL-23 dependent protective Th17 cell response186, and Th17 cell-
associated cytokine production (IL-17A and IL-22) in human PBMCs has been strongly 
associated with protection against VL187. IL-17A likely contributes to Th17 cell-mediated 
protection as it has been shown to potentiate Leishmania specific CD4+ T cell IFNγ 
production and macrophage nitric oxide mediated parasite killing, as well as inhibit 
regulatory responses, including Treg cells and IL-10 production during VL188. Not much is 
known about the role of Tfh cells in VL. However, they have been associated with 
Leishmania-specific antibody development, and it is postulated that their response to chronic 
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infection is impaired or dysfunctional189.  Th2 cells don’t appear to play a strong role in VL, 
despite upregulation of Th2 cytokines during disease174,190. However, these cells may be 
involved in granuloma development, as IL-4 deficient mice failed to develop mature and fully 
functional granulomas191. 
1.10 Characterising anti-parasitic CD4+ T cell responses during 
Plasmodium and Leishmania infection. 
The CD4+ T cell response during VL and malaria is complex, and plays significant protective 
and pathogenic roles in disease. Inflammation is critical for pathogen clearance, but if not 
controlled, can damage tissue. The naturally acquired protection observed in individuals 
living in VL and malaria endemic regions appears to strike a balance between inflammation 
and immune suppression. However, we are unable to actively induce this type of protection 
using current vaccination strategies. Therefore, there is a need to better understand the 
immune response during these parasitic diseases to enable more targeted and effective 
prophylactic and therapeutic interventions. As highlighted, CD4+ T cells play an important 
role in this response, and a number of genes/molecules influence the function of these cells. 
As such we hypothesised that genes which transcriptionally change in CD4+ T cells over the 
course of infection play an important role in the function of these cells, and can be 
therapeutically modified to alter disease outcome. In particular we hypothesised that a) 
infection would induce a distinct transcriptional profile in CD4+ T cells over the course of 
infection, b) that this transcriptional profile would include transcription factors key to the 
phenotype of these cells, and c) that the distinct transcriptional profile would influence the 
functional profile of these cells, for example cytokine production. Therefore, the overall aim 
of this body of work was to characterise anti-parasitic CD4+ T cell responses during 
Plasmodium infection, and identify molecules which could be targeted therapeutically to 
improve immunity. We have also used VL as a complimentary model to corroborate our 
findings in the broader context of parasitic infection, particularly with regards to the 
characterisation of Tr1 cells, which develop a more robust response in the VL model. 
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1.11 Research hypotheses: 
Overarching hypothesis: Genes which transcriptionally change in CD4+ T cells 
over the course of infection play an important role in the function of these cells, 
and can be therapeutically modified to alter disease outcome.  
 Chapter 3 addresses sub-hypothesis a) Infection induce a distinct 
transcriptional profile in CD4+ T cells over the course of infection, in 
particular, changes early on in infection. 
 Chapter 4 addresses sub-hypothesis b) This transcriptional profile 
includes transcription factors key to the phenotype of these cells, 
specifically the transcription factor BACH2. This hypothesis is also 
addressed in chapter 5 where the transcription factor PBX1 is 
assessed. 
 Chapter 5 addresses sub-hypothesis c) The distinct transcriptional 
profile influences the functional profile of these cells, for example 
cytokine production. Specifically with regards to IL-10 and the Tr1 cell 
population. 
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Materials and Methods 
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2.1 Buffers, media and other reagents 
Table 2.1.1 | Buffers, media and other reagents 
Reagent Details 
30% sucrose 30% sucrose (Chem-Supply), in milliQ water 
33% Percoll 33% Percoll (GE Healthcare, Uppsala, Sweden) in PBS 
BFA 
10µg/mL Brefeldin A (Sigma-Aldrich) in cRPMI (h.cRPMI for use 
with human cells, m.cRPMI for use with mouse cells) 
D-PBS 
1x Dulbecco`s Phosphate-Buffered Saline, no calcium, no 
magnesium (Life Technologies, Australia) 
FACS buffer 
0.01% FBS, EDTA (2.6mg/mL, Chem-Supply, Pty Ltd, SA, 
Australia), in PBS 
FBS Fetal Bovine Serum (US origin, Gibco, NK, USA) 
Freezing 
medium 
10% Dimethyl Sulfoxide Hybri-Max™ (Sigma-Aldrich), 90% FBS 
(Gibco) 
h.cRPMI 10% FBS, Gentamycin (20μg/mL, Sigma-Aldrich), in RPMI1640 
Heparin Media 
5IU Heparin (Pfizer, NSW, Australia), Penicillin Streptomycin 
(100U/mL, Gibco), in RPMI 
m.cDMEM 
10% FBS, 20μM Sodium Pyruvate (Sigma-Aldrich, MO, USA), 
2μM HEPES (QIMR Berghofer), 0.5μM 2-Mercaptoethanol 
(Sigma-Aldrich), PS (100 U/mL Life Technologies), in DMEM (high 
glucose, pyruvate, Gibco) 
m.cRPMI 10% FBS, PS (100U/mL), in RPMI 
PBS 
1x Phosphate-Buffered Saline (QIMR Berghofer Medical Research 
Institute, QLD, Australia) 
PFA 
Paraformaldyhyde (MP Biomedicals, Australia), made to desired 
concentration in milliQ water 
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PI media 
50ng/mL Phorbol 12-myristate-13-acetate (Sigma-Aldrich), 
1μg/mL Ionomycin (Sigma-Aldrich) in cRPMI (h.cRPMI for use 
with human cells, m.cRPMI for use with mouse cells) 
PIB media 
50ng/mL Phorbol 12-myristate-13-acetate (Sigma-Aldrich), 
1μg/mL Ionomycin (Sigma-Aldrich), 10µg/mL Brefeldin A (Sigma-
Aldrich) in cRPMI (h.cRPMI for use with human cells, m.cRPMI for 
use with mouse cells) 
PIM media 
50ng/mL Phorbol 12-myristate-13-acetate (Sigma-Aldrich), 
1μg/mL Ionomycin (Sigma-Aldrich), 1x Monensin solution 
(InvitrogenTM, CA, USA) in cRPMI (h.cRPMI for use with human 
cells, m.cRPMI for use with mouse cells) 
RMPI/PS PS (100 U/mL), in RPMI 
RPMI 
Roswell Park Institute Medium (QIMR Berghofer Medical 
Research Institute, QLD, Australia) 
RPMI1640 RPMI1640 (+) L-glutamine (Gibco, Paisley, UK) 
Trypan Blue 1x (MP Biomedicals) 
2.2 Mice 
Mice were 6-12 weeks old when used in experiments. All C57BL/6J mice were purchased 
from the Walter and Eliza Hall Institute (WEHI, VIC, Australia). Breeders used to develop 
the B6.pbx1fl/fl line were purchased from The Jackson Laboratory (B6.129S-Pbx1tm3.1Mlc/J, 
ME, USA). Breeders used to develop the B6.bach2fl/fl line were acquired from Professor Axel 
Kallies (WEHI, VIC, Australia). All other lines were bread at QIMR Berghofer Medical 
Research Institute (QIMR Berghofer, QLD, Australia). Mice were housed in specific-
pathogen free conditions in accordance with QIMR Berghofer animal ethics standards and 
the “Australian Code of Practice for the Care and Use of Animals for Scientific Purposes” 
(Australian National Health and Medical Research Council) and approved by the QIMR 
Berghofer Animal Ethics Committee (Herston, QLD, Australia; approval numbers: A02‐633M 
and A02-634M, appendix 1). 
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Table 2.2.1 | Mouse lines 
Line Brief description 
C57BL/6J Wild type 
B6.Rag1-/- T and B cell deficient 
B6.Cd4-cre T cell specific Cre positive 
B6.Bach2fl/fl Cre negative litter mate controls for B6.bach2ΔT 
B6.Bach2ΔT T cell specific bach2 deficient 
B6.Pbx1fl/fl Cre negative litter mate controls for B6.Pbx1ΔT 
B6.Pbx1ΔT T cell specific pbx1 deficient 
Mouse lines are further detailed in results chapters. 
 
Development of B6.Bach2ΔT and B6.Pbx1ΔT lines 
B6.Cd4-cre mice were crossed with either B6.Bach2-floxed or B6.Pbx1-floxed animals for 3 
generations before they were used in experiments. PCR analysis was used to ensure 
maintenance of the flox and Cd4-cre modifications with each cross (Table 2.7.1. The 
following primers were used for assessing the cre insert: 5’-
GCGGTCTGGCAGTAAAAACTATC-3’, 5’-GTGAAACAGCATTGCTGTCACTT-3’, 5’-
CTAGGCCACAGAATTGAAAGATCT-3’, and 5’-GTAGGTGGAAATTCTAGCATCATCC-3’. 
The following primers were used to assess the Pbx1 flox insert: 5’-
GAGTTTGTCAGAGGATTTTGTAGATCTCAG-3’, and 5’-
CACGTACAAATTGAGTTGATACAGTGGGG-3’. The following primers were used to 
assess the Bach2 flox insert: 5’- CCTTACTGGATTCGGATGAGAAGCC -3’ and 5’- 
CTCTGTACACAGTGGGATCCACGGG -3’. Cre-positive Floxed-positive mice were defined 
as either B6.Bach2ΔT or B6.Pbx1ΔT, and their litter mate controls Cre-negative Floxed-
positive mice were defined as B6.Bach2fl/fl or B6.Pbx1fl/fl. 
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Table 2.2.2 | PCR system settings for genotyping  
 Bach2-flox settings Cre and Pbx1-flox settings 
Step Temperature Time (minutes) Temperature Time (minutes) 
1 94⁰C 4:00 94⁰C 4:00 
2 94⁰C 0:45 94⁰C 0:30 
3 60⁰C 0:45 51.7⁰C 1:00 
4 72⁰C 1:00 72⁰C 1:00 
5 Repeat steps 2-4 x40 Repeat steps 2-4 x35 
6 72⁰C 10:00 72⁰C 2:00 
7 10⁰C Hold 10⁰C Hold 
8 END END 
2.3 Parasites and infections 
2.3.1 Assessing Plasmodium parasite burden in mice 
Murine blood parasite burden was assessed using flow cytometry. One drop of blood was 
suspended in 200uL of Heparin Media. Dilute blood was incubated with Syto84 (5uM, Life 
Technologies) and Hoechst33342 (10ug/mL, Sigma) for 30 minutes, at room temperature, 
protected from light. This was then diluted out to 6 times the original volume with RPMI, and 
sample was analysed on one of three BD flow cytometers (Canto II, Fortessa 4, or Fortessa 
5). FlowJo software (v.8, Treestar, CA, USA) was used to quantify parasitemias. 
2.3.2 Plasmodium chabaudi chabaudi AS (P. chabaudi) and Plasmodium 
berghei ANKA (P. berghei) 
One passage mouse was infected with 200µL cryo-preserved iRBC inoculum. P. chabaudi 
inoculum was administered via intravenous tail injection, P. berghei inoculum was 
administered via intraperitoneal injection. When passage parasitemia reached 2-4% 
(typically 2-4 days post inoculation) blood was harvested and prepared for inoculation of 
experimental mice; briefly, passage mice were euthanized using CO2 inhalation, blood was 
harvested via cardiac bleed and washed in Heparin Media. Infected red blood cell (iRBC) 
concentration was adjusted to 5x105 per mL in RPMI/PS (Fig. 2.3.1A-B). Experimental mice 
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were infected with 1x105 iRBC via intravenous tail injection, and infection was monitored via 
flow cytometry as described above (Section 2.3). 
Mice infected with P. berghei were assessed 1-2 times daily from day 3 onwards for the 
following clinical pathologies: ruffling of fur, hunching, wobbly gait, limb paralysis, and 
convulsions or coma. Mice received a score of one for every symptom they presented with. 
Upon reaching an additive score of four, or if they had neurological symptoms (paralysis, 
convulsions, or coma) mice were euthanized by CO2 asphyxiation. 
2.3.3 Leishmania donovani in mice 
Leishmania donovani parasites were maintained by passage in Rag1-/- mice. L. donovani 
amastigotes were isolated from the spleens of infected passage mice. Briefly, spleens were 
homogenised, and parasites were separated from cell debris by centrifugation (130 relative 
centrifugal force (rcf), 5 minutes). Red blood cells were lysed using red blood cell lysis buffer 
(as described in section 2.4.1). Amastigotes were then washed three times in RPMI/PS, and 
adjusted to a concentration of 1x108 parasites per mL in RPMI/PS. C57BL/6J mice were 
infected with 2x107 L. donovani amastigotes by intravenous injection (Fig. 2.3.1C). Parasite 
burden was measured by qPCR (described in Sudarshan et al. 2011, 2014192,193), or by 
calculating ratios of parasites to hepatocytes (Leishman-Donovan Unites, LDU) by 
microscopic examination of organ impression smears (described in Montes de Oca et al. 
201637). 
In-vivo antibody blockade 
Mice were injected with αLAG-3 (0.1mg, Bio-Excel), or isotype control (rIgG, 0.1mg, Bio-
Excel), every three days starting from 14 days post-infection with L. donovani. Hepatocytes 
and liver parasite burdens were assessed 28 days post-infection. 
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Figure 2.3.1 | Parasite infection models, as described in section 2.3.  
Timeline indicates number of days post-infection, black circles indicate time points at which 
samples were taken for immune cell analysis. 
2.3.4 Controlled Human Malaria Infection (CHMI) studies 
As part of a series of clinical trials testing the efficacy of various antimalarial drugs in early-
stage malaria, naïve healthy individuals, aged 18-56 years with no prior exposure to malaria 
(Table 2.3.1) underwent controlled infection with P. falciparum (clone 3D7, drug-sensitive 
strain). 1,800-2,800 P. falciparum infected RBCs were intravenously injected into individuals 
at day 0 (Fig. 2.3.1D). From 4 days post-infection, blood parasite burden was measured 
daily by qPCR194 and then twice daily, once a PCR positive result was obtained. Trial drug 
was administered 7-8 days post-infection when the threshold for commencement of 
treatment was reached (i.e. ≥ 1,000 parasites/mL). Parasite multiplicity rate (PMR) was 
calculated from pre-infection to drug treatment (0-7, or 0-8 days post infection), as previously 
described195. Blood was collected from naïve volunteers (prior to infection), and from the 
same volunteers pre-anti-malarial drug treatment (7-8 days post-infection), post-treatment 
(13-15 days post-infection), and at 28-37 days post-infection, into lithium heparin tubes for 
cellular processing and analysis. The CHMI studies were undertaken at Q-Pharm Pty Ltd 
(Brisbane, Australia) under the approval of the QIMR Berghofer Human Research Ethics 
Committee (QIMRB-HREC) (Appendix 2). All studies were registered with the Australian and 
New Zealand Clinical Trial Registration scheme (ANZCTR: ACTRN12613000565741, 
ACTRN12612000323820) or with the U.S. NIH ClinicalTrials.gov (NCT: NCT02281344, 
NCT02867059, NCT02783833, NCT02389348, NCT02431650, NCT02431637, 
NCT02573857). 
2.3.5 Blood collection from human Visceral Leishmaniasis study 
Whole blood was collected from patients with active VL, into heparinised tubes prior to 
assessment by whole blood assay (described in section 2.6.2). These studies were 
undertaken at the Kala-azar Medical Research Center (KAMRC, Muzaffarpur, Bihar, India) 
with ethical approval from the ethical review board of Banaras Hindu University, Varanasi, 
India, and the QIMRB-HREC (Appendix 3). 
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Table 2.3.1 | Controlled Human Malaria Trial Cohorts 
Cohort Trial registration code Year of Study Trial cohort no. 
Age 
(Years) 
Gender 
1 ACTRN12613000565741 2014 3A 
22 M 
24 M 
19 F 
20 F 
25 F 
2 ACTRN12613000565741 2014 3B 
18 M 
23 M 
22 F 
32 F 
3 NCT02281344 2014 1 
29 M 
24 M 
19 M 
4 NCT02867059 2016 1B 
45 M 
27 M 
21 M 
21 M 
22 M 
23 M 
30 M 
5 NCT02867059 2016 2 
20 M 
25 M 
52 M 
19 M 
30 M 
29 M 
18 M 
22 M 
6 NCT02783833 2016 B1 
24 M 
29 M 
Chapter 2  
 
42325972 55 
24 M 
34 M 
47 M 
23 M 
34 M 
7 NCT02783833 2016 B2 
23 M 
31 M 
48 M 
21 M 
38 M 
39 M 
27 M 
20 M 
8 ACTRN12612000323820 2012 1 
30 M 
26 M 
9 NCT02389348 2015 1 
20 F 
25 F 
10 NCT02431650 2016 1 
56 M 
27 M 
30 M 
11 NCT02431650 2016 2B 
26 M 
20 M 
12 NCT02431650 2016 3 
34 M 
26 M 
20 M 
13 NCT02431637 2016 1 
20 M 
26 M 
14 NCT02431637 2016 3B 
32 F 
22 F 
15 NCT02573857 2015 1A 32 M 
n= 60; M, male; F, female. 
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2.4 Sample processing 
2.4.1 Mouse samples 
Murine leukocytes were isolated from mouse spleens by homogenising spleens and lysing 
red blood cells by incubating for 5-7 minutes at room temperature in Red Blood Cell Lysis 
Buffer (Sigma). Liver mononuclear cells (MNCs) were isolated from mouse livers by 
homogenising livers, removing hepatocytes by 33% Percoll density gradient centrifugation, 
and lysing red blood cells in the remaining pellet as described above. Cells were washed 
with either RPMI/PS (spleen cells), or 1% FBS/PBS prior to counting and staining. 
2.4.2 Human samples 
Plasma was separated from red blood cells by centrifuging lithium heparin tubes containing 
volunteer blood at 800rcf for 10 minutes. The plasma layer was removed and stored at -
20⁰C. Peripheral blood mononuclear cells (PBMCs) were isolated from blood by Ficoll-
Paque density gradient separation (GE Healthcare Life Sciences). PBMCs were then 
washed in D-PBS and stored at -80⁰C or in liquid nitrogen in freezing medium prior to 
analysis. In some cases CD4+ cells were isolated from PBMCs by magnetic-activated cell 
sorting (MACS) purification using CD4 (L3T4) MicroBeads (Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to the manufacturer’s guidelines. CD4+ cells were stored at 
-80⁰C in RNAlater (Sigma-Aldrich). 
2.4.3 Cell counting 
Cells were stained with trypan blue (MP Biomedicals Pty Ltd, for manual counting, 
InvitrogenTM, or Countess counting) as per manufacturer’s instructions. Cells were then 
either counted manually using a haemocytometer, or automatically using the Countess II FL 
Automated Cell Counter (InvitrogenTM). 
2.5 Flow cytometry 
2.5.1 Cytokine analysis 
Cytokine concentrations were assessed in cell culture supernatants and plasma using the 
following BD Biosciences mouse and human Cytometric Bead Arrays: Inflammatory 
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Cytokine CBA Kit, Th1/Th2/Th17 Cytokine Kit, and IFN-gamma and IL-10 Flex Sets. Bead 
arrays were performed according to manufacturer’s guidelines. 
2.5.2 Cellular analysis 
Incubation with BFA, PI, PIM, or PIB causes a loss in detection of certain surface molecules. 
Therefore, cells were first incubated with a primary surface stain for 30 minutes at 37⁰C, 5% 
CO2 to detect sensitive molecules. They were then incubated in cRPMI with either BFA, PI, 
PIM, or PIB for 3 hours (mouse) or 5 hours (human) at 37⁰C, 5% CO2. After this they were 
stained with a secondary surface stain for 20 minutes, at room temperature. Cell membranes 
were then permeabilised using Permeabilisation Reagent (eBioscience), or Cytofix, (Becton 
Dickinson) for 20 minutes at room temperature. After this, cells were stained with an 
intracellular stain for 45 minutes at 37⁰C, 5% CO2, or at room temperature. . All surface 
stains were made up in FACS Buffer, and all intracellular stains were made up in Perm/Wash 
Buffer (eBioscience, or Becton Dickinson). Samples were either acquired immediately as 
described below, or were fixed in 1% PFA overnight before acquisition. 
Mouse antibodies used: FITC conjugated to anti-CD11a (M17/4), anti-CD45.1 (A20), anti-
Ly6C (HK1.4), or anti-TCRβ (H57-597). PerCP/Cy5.5 conjugated to anti-TCRβ (H57-597), 
streptavidin, anti-CD127 (A7R34), anti-CD11b (M1/70), anti-CCR5 (HM-CCR5), anti-
CD90.2 (30-H12), or anti-CD8α (53-6.7). PerCP-efluor 710 conjugated to anti-Gata-3 
(TWAJ). APC conjugated to anti-IL-10 (JES5-16E3), I-Ab–PEPCK335–351 tetramer196 
(National Institutes of Health Tetramer Facility, Atlanta, GA), anti-CXCR5 (L138D7), anti-
CD11c (N418), or anti-IFNγ (XMG1.2). Efluor 660 conjugated to anti-Gata-3 (TWAJ), or anti-
T-bet (4B10). AF488 conjugated to anti-Foxp3 (MF-14), or anti-Galectin-3 (M3/38). Alexa 
Fluor 647 conjugated to anti-Foxp3 (MF-14), or anti-TIM-3 (B8.2C12). Alexa Fluor 700 
conjugated to anti-CD8α (53-6.7), anti-CD44 (IM7), or anti-CD45.1 (A20). APC/Cy7 
conjugated to anti-CD4 (GK1.5), anti-TCRβ (H57-597), anti-NK1.1 (PK136), anti-B220 
(RA3-6B2), anti-Ly6G (1A8), or anti-Bcl-6 (K112-91). Pacific Blue conjugated to anti-B220 
(RA3-6B2), or anti-IA/IE (M5/114.15.2). BV421 conjugated to anti-IFNγ (XMG1.2), anti-
CD279 (PD-1, 29F.1A12), anti-IL-10 (JES5-16E3), anti-CD19 (6D5), anti-CD4 (GK1.5), anti-
or anti-CD192, (CCR2, SA203G11). BV605 conjugated to anti-CD4 (RM4-5), anti-T-bet 
(4B10), anti-IL-17A (TC11-18H10), anti-TCRβ (H57-597), anti-NK1.1 (PK136), or anti-Ly6C 
(HK1.4). BV650 conjugated to anti-CD183 (CXCR3, CXCR3-173), anti-B220 (RA3-6B2), or 
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anti-TNF-α (MP6-XT22). BV785 conjugated to anti-CD223 (LAG-3, C9B7W), or anti-CD11c 
(N418). BV786 conjugated to anti-IL-4 (11B11). BUV395 conjugated to anti-CD4 (GK1.5), 
or anti-CD45.2 (104). BUV737 conjugated to anti-TCRβ (H57-597). PE conjugated to anti-
RORγt (B2D), anti-CD45.2 (104), anti-CD44 (IM7), anti-CD62L (MEL-14), anti-IL-10 (JES5-
16E3), anti-CCR6 (29-2L17), anti-Bcl-6 (K112-91), anti-CD45.1 (A20), anti-CTLA-4 (UC10-
4B9), or anti-I-A/I-E (MHCII, M5/114.15.2). PE/Dazzle conjugated to anti-CTLA-4 (UC10-
4B9), anti-IL-10 (JES5-16E3), anti-F4/80 (BM8), or anti-IFNγ (XMG1.2). PE/Cy7 conjugated 
to anti-CD49d (R1-2), anti-T-bet (4B10), anti-CD45.2 (104), anti-F4/80 (BM8), anti-IFNγ 
(XMG1.2), anti-Ly6G (1A8). PE/Cy5 conjugated to streptavidin. Biotin conjugated to anti-
CD127 (SB/199), anti-CD278 (ICOS, 7E.17G9), or anti-CD19 (6D5).  
Human antibodies used: FITC conjugated to anti-CD49b (eBioY418), anti-CD3 (SK7), anti-
CD16 (3G8), anti-CD19 (HIB19), anti-CD14 (HCD14), or anti-LAG-3 (11C3C65). 
PerCP/Cy5.5 conjugated to anti-CD8α (RPA-T8), anti-CD4 (OKT4), anti-CCR7 (G043H7), 
or anti-CD56 (HCD56). APC conjugated to anti-CD8α (RPA-T8). Alexa Fluor 647 conjugated 
to anti-FOXP3 (150-D), or anti-Galectin-3 (B2C10). Alexa Fluor 700 conjugated to anti-
CXCR3 (anti-CD183, G025H7), anti-CD8α (RPA-T8), or anti-CD16 (3G8). APC/Cy7 
conjugated to anti-CCR2 (anti-CD192, K036C2), or anti-CD4 (RPA-T4). BV421 conjugated 
to anti-CXCR5 (RF8B2), anti-CD56 (NCAM16.2), or anti-CD183 (CXCR3, 1C6/CXCR3). 
BV605 conjugated to anti-TIM-3 (anti-CD366, F38-2E2), or anti-CD4 (RPA-T4). BV650 
conjugated to anti-CCR6 (11A9), or anti-CD195 (CCR5, 3A9). BV786 conjugated to anti-
CTLA-4 (anti-CD152, BNI3). BUV395 conjugated to anti-CD3 (UCHT1). BUV563 conjugated 
to anti-CD45RA (HI100). BUV737 conjugated to anti-CD4 (SK3), PE conjugated to anti-
LAG3 (3DS223H), or anti-IL-10 (JES3-19F1). PE/Dazzle conjugated to CCR5 (anti-CD195, 
J418F1). PE-CF594 conjugated to anti-Bcl6 (K112-91). PE/Cy7 conjugated to anti-PD-1 
(anti-279, EH12), anti-CD45RA (HI100), anti-CCR7 (G043H7), or anti-IFNγ (4S.B3).  
Antibodies were purchased from either Biolegend (CA, USA), eBiosciences (CA, USA), or 
BD Biosciences (NJ, USA). The Zombie Aqua Fixable Viability Kit (Biolegend) was used to 
assess cell viability. 
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2.5.3 Cell sorting 
MACS purified CD4+ cells were restimulated with PI media at 37⁰C, 5% CO2, for 3-5 hours. 
IL-10 and IFNγ cytokines were then captured on the surface of the cells using the Miltenyi 
Biotec IL10 (PE) and IFNγ (APC, or FITC) Secretion Assays, according to the 
manufacturer’s guidelines. Cells were then stained with surface antibodies for 20 minutes, 
at room temperature. Using the BD FACSARIA III (BD Biosciences) IL10- IFNγ-, IL10- IFNγ+, 
IL10+ IFNγ+, IL10+ IFNγ- cells were sorted from CD8- mouse cells. IL10- IFNγ+, IL10+ IFNγ+, 
and IFNγ- CCR7+ cells were sorted from CD19- CD16- CD14- CD8- CD4+ human cells. Cells 
were stored at -80⁰C in in Buffer RLT (Qiagen) containing 1% β-mercaptoethanol (Sigma-
Aldrich). 
2.5.4 Equipment and Analysis 
All sample acquisition for flow cytometric analysis was performed on the LSRFortessa 4 or 
5 (BD Biosciences), except for sorted cells which were sorted using the FACSARIA III (BD 
Biosciences). CBA analysis was performed using FCAP array software (Soft Flow, MN, 
USA). Cellular analysis was performed using FlowJo software (Version 9 and 10, TreeStar, 
OR, USA). 
2.6 Ex-vivo assays 
2.6.1 Polarisation  
Either naïve CD4+ T cells were isolated from splenic leukocytes by flow cytometric sorting, 
or total CD4+ T cells were isolated from murine splenic leukocytes using the Miltenyi mouse 
CD4+ T cell isolation kit, according to manufacturer’s guidelines. 4x105 CD4+ T cells were 
then cultured with αCD28 (1µg/mL, clone 37.51, BioLegend) and plate bound αCD3 (wells 
coated with 1µg/mL for 4 hours at 37⁰C, 5% CO2, clone 145-2C11, BioLegend) in a 96-well 
plate, for 5 days (3 days for Tr1 and any comparative conditions) at 37⁰, 5% CO2. Cells were 
cultured in m.cDMEM (or m.cRPMI for Tr1 conditions) supplemented with Th0 (10ng/mL IL-
2), Th1 (10ng/mL IL-2, 10ng/mL IL-12, 10ng/mL αIL-4), Th2 (10ng/mL IL-2, 40ng/mL IL-4, 
10ng/mL αIFNγ), Th17 (20ng/mL IL-6, 1ng/mL TGFβ, 10ng/mL IL-23, 10ng/mL IL-1β, 
10ng/mL TNFα, 10ng/mL αIL-4, 10ng/mL αIFNγ), Tfh (10ng/mL IL-2, 20ng/mL IL-6), Treg 
(10ng/mL IL-2, 10ng/mL TGFβ), or Tr1 (10ng/mL IL-2, 10ng/mL IL-12, 10ng/mL αIL-4, 
50ng/mL IL-27) polarising cytokines (eBioSciences, unless specified otherwise) and 
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antibodies. After 5 days (3 days in the case of Tr1 cultures) culture supernatants were 
assessed for cytokine concentrations using the BD Biosciences Cytokine Bead Array or Flex 
Set, and cells were assessed via flow cytometry. 
2.6.2 Antibody blockade 
Check-point molecule blockade in Mouse L. donovani splenocyte cultures 
1x105 mouse splenocytes were cultured with 2x106 L. donovani amastigotes and various 
blocking antibodies in m.cRPMI for 72 hours, at 37⁰C, 5% CO2. Supernatant was harvested 
from cultures at 24 hours and stored at -20⁰C. Cells were analysed by flow cytometry at 
72hours.  Antibodies used: mouse anti-LAG-3 (20ug/mL, Bio-Excel) and its isotype control 
IgG1 (clone: MAC49, made in house). 
Check-point molecule blockade in CHMI PBMC cultures 
4x105 human PBMCs were cultured with 2.25x105 infected red blood cells (iRBCs) and 
various blocking antibodies in h.cRPMI for 72 hours, at 37⁰C, 5% CO2. Supernatant was 
harvested from cultures at 24, 48 or 72hours and stored at -20⁰C. Cells were analysed by 
flow cytometry at 72hours. Antibodies used: human anti-CTLA4 (membrane bound, clone: 
L3D10, Biolegend), and its isotype control mIgG1κ (clone: MOP-C21, Biolegend), human 
anti-LAG-3 (Lag3.5-g4p.20120227, Bristol-Myers Squibb) and its isotype control IgG4 (g4P-
DT1D12, clone: 4A09_RAS_Ab, Bristol-Myers Squibb), human anti-TIM-3 (clone: F38-2E2, 
eBiosciences) and its isotype control mIgG1κ (GIR-208, Leico Technologies), and human 
anti-PD1 (Nivolumab, BMS-936558, Bristol-Myers Squibb) and its isotype control human 
IgG4(Clone: 1D12, Bristol-Myers Squibb). 
Whole blood assay: Check-point molecule blockade in Human VL PBMC cultures 
Whole blood assays were performed as previously described197. Briefly, whole blood from 
VL patients was cultured with soluble Leishmania antigen (SLA, 10ug/mL, prepared in 
house) and either αLAG-3 mAb (17B4, preservative free, Enzo Life Sciences) or isotype 
control (mIgG1, 11711, R & D Systems) for 24 hours at 37⁰C, 5% CO2. Supernatants were 
collected at 24 hours, and IFNγ levels were assessed by ELISA (kit, Biolegend). 
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2.7 Genetic, epigenetic and transcription factor analysis 
2.7.1 RNA isolation 
RNA was isolated from mouse and human CD4+ T cells stored at -80⁰C in RNAlater using 
Qiashredders and the RNeasy Mini Kit as per manufacturer’s instructions (QIAGEN). The 
Nanodrop ND-1000 UV-Vis Spectrophotometer (Thermo Fisher Scientific) was used to 
determine RNA concentration and quality. RNA was stored at -80⁰C until used. 
2.7.2 qPCR 
RNA transcript levels were assessed using the iTaq™ Universal SYBR® Green Supermix 
(Bio-Rad, NSW, Australia) according to manufacturer’s instructions. qPCR was run on the 
QuantStudio 5 Real-Time PCR System (Applied Biosystems) using the PCR system settings 
in Table 2.7.1. Results were analysed using the Relative Quantification App on the Thermo 
Fisher Cloud (Thermo Fisher Scientific). The following primers were used to detect genes 
of interest: Sigma primers for mouse Ifnγ (Fwd: 5’ GGATATCTGGAGGAACTGGCAA, Rev: 
5’ TGATGGCCTGATTGTCTTTCAA),  QIAGEN RT² qPCR Primer Assays for Mouse Bcl6 
(PPM04965C), Ccr2 (PPM03176A), Ccr5 (PPM03150B), Cxcr3 (PPM03145F), and 
QIAGEN QuantiTect Primer Assays for Mouse Lgals3 (QT00152558), Lag3 (QT00113197), 
Havcr2 (QT00120652), Il10 (QT00106169), Hprt (QT00166768), Ctla4 (QT00103929), and 
Human CXCL8 (QT00000322), HPRT (QT00059066), ACTB (QT00095431). 
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Table 2.7.1 | qPCR system settings 
Step Temperature Time 
1 95⁰C 2:00 
2 95⁰C 0:05 
3 60⁰C 0:30 
+ plate read 
4 Repeat steps 2-3 x39 
5 95⁰C 0:05 
6 Melt curve: 65⁰C to 95⁰C, increment of 0.5⁰C 
+ plate read 
END 
2.7.3 Nanostring 
RNA samples were assessed using the nCounter XT Gene Expression Assay on the 
nCounter platform (NanoString Technologies). The assay was performed according to 
manufacturer’s guidelines. 
NanoString data was analysed using nSolver™ Analysis Software V3.0 (NanoString 
Technologies) for quality control (QC), background subtraction, and normalisation. Default 
settings were used for all samples. These values are presented in Table 2.7.2. In summary, 
after QC assessment and background subtraction, count values were normalised using the 
geometric mean of housekeeping genes. These normalised count values served as input 
for differential gene expression analysis (DGE) using the Edge R package 198,199. In brief, a 
generalised linear model (GLM) was applied where both time and volunteers served as 
explanatory variables. Subsequently, likelihood ratio testing (LRT) was used to determine 
significantly (α = 0.05) differentially expressed genes between specific time points. Principle 
Component Analysis was performed using “R” packages “FactoMineR” and “factoextra 
”200,201. 
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Table 2.7.2 | Quality control and normalisation parameters used in NanoString 
analysis 
Variable Value 
Imaging QC FOV registration > 75% 
Binding Density QC 0.05 – 2.25 
Positive Control Linearity QC R2 > 0.95 
Positive Control Limit of Detection QC 
5fM positive control > 2 SD above mean 
of negative controls 
Background Subtraction Geometric Mean of Negative Controls 
Positive Control Normalisation 
Geometric Mean normalisation factor 
within 0.3 – 3 
Housekeeping Normalisation Geometric mean 
Quality control (QC) parameters default in nSolver™ Analysis Software V3.0. Field 
of view (FOV), and standard deviation (SD). 
 
2.7.4 RNAseq 
Briefly, RNA isolated from Tr1 (IFNγ+ IL-10-), Th1 (IFNγ+ IL-10+), unactivated (IFNγ- IL-10-), 
and IL10 single positive (IFNγ- IL-10+) sorted CD4+ T cells (as per section 2.5.3) was used 
to synthesise cDNA using the High-Capacity cDNA Reverse Transcription kit (Applied 
Biosciences) according to manufacturer’s guidelines. Libraries were prepared from cDNA. 
50bp single-end mRNA-sequencing was performed on the Illumina HiSeq by the Australian 
Genome Research Facility (AGRF, VIC, Australia). RNAseq data was then processed using 
the Galaxy platform (https://galaxy-qld.genome.edu.au/galaxy/)202. FastQC was used for 
quality control of data203, and reads were mapped to either the human (GRCh38/hg38), or 
mouse (GRCm38/mm10) genome using the STAR aligner204. Transcripts were then 
assembled, and reads per kilobase of transcript per million mapped reads (RPKM) were 
estimated using Cufflinks205. Cuffmerge was used to merge transcript assemblies and 
HTseq used to transform mapped reads into counts based on the GENCODE vM9 
annotation for mouse and GENCODE release 24 for human206-208. Finally EdgeR was used 
to analyse these counts for differential gene expression198. 
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2.7.5 Methylation analysis 
DNA was extracted from PBMCs stored at -80⁰C in RNAlater using the AllPrep DNA/RNA 
Mini Kit (QIAGEN). DNA quality was assessed by gel electrophoresis and the Nanodrop ND-
1000 UV-Vis Spectrophotometer (Thermo Fisher Scientific). The Illumina methylation EPIC 
BeadChip platform (Illumina, San Diego, CA) was used to examine DNA methylation of the 
PDCD1  gene in CD4+ T cells isolated from volunteers prior to infection and 7 days after P. 
falciparum infection (prior to anti-malarial drug treatment). The assay was performed on 
paired samples by Macrogen (Seoul, Korea). Array data export using Illumina 
GenomeStudio v2011.1 (Methylatioin Module v1.9.0). Probes with detection p value >0.05 
in more than 25% of samples and probes with missing values were removed from analysis. 
Data was then processed in R (background correction, BMIQ normalisation, M value 
transformed). Differential methylation was tested by Tukey's HSD test and corrected for 
multiple tests. Probe was considered differentially methylated if adjusted p-value < 0.05 and 
beta-value difference > 0.20. 
2.7.6 Chromatin immunoprecipitation 
Chromatin immunoprecipitation assays were conducted as described in Lee et al.209, with a 
sheared fragment size of 300 bp to 1kb, using anti-Pbx1 (4342, Cell Signaling Technology, 
MA, USA), anti-pol II (ab817, Abcam, Cambridge, UK) and rabbit IgG (ab37415, Abcam). 
1µl (from 30µl) of immunoprecipitated DNA was used for qPCR. Primers A-F (Table 2.7.3) 
were designed to amplify -1 to -4.593kb upstream of the IL-10 transcription start site, 
including the region where three PBX1 consensus binding sites exist. Abundance of PBX1 
or RNA Polymerase II binding is illustrated as a percent of immunoprecipitated target 
sequences relative to input chromatin. 
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Table 2.7.3 | Primers used for Chromatin immunoprecipitation 
Target 
region 
Forward primer (5’ to 3’) Reverse primer (3’ to 5’) 
hprt CCTAAATCTTGAGGAATCACATCA TTCTTTCTGAAGAAAATGGTACTGG 
il10 A GAAGAAAATCAGCCCTCTCG GGATAAATGGGCTATTCCAGA 
il10 B CAGTCAGGAGAGAGGGCAGT TTTTGGGATGTCCGTTTCC 
il10 C AAGAGGTGCTGCTTCTCCTG TGGCACTGGACAGTTCTATGA 
il10 D GGGCTTGATAACGTGTGAGTG AAGAAGTTCCCCCTGTAGCTG 
il10 E AACACTCTTCAGGGGTGAGC AGTCTGGGAGCTCTGAGTGG 
il10 F GGTTATCTGGGGTAGTCATGGA TGTGGAATTCCCCTTTGTGT 
2.8 Granuloma Immunohistochemistry 
Air dried sections were fixed in 75% Acetone/25% Ethanol for 5 min, then washed in tris-
buffered saline (TBS, 0.1 M TRIS-HCl/0.15 M NaCl in MilliQ) and incubated in BCM Sniper 
(Biocare Medical BIC-BS96MM, undiluted) for 30 min. Following this, sections were 
incubated in LV82-infected hamster serum, diluted 1:100 for 1 hr at RT. Sections were 
washed in TBS after each incubation step. Sections were then incubated in Alexa Fluor 594-
conguated goat anti-hamster IgG (InvitrogenTM, A21113) diluted 1:500 for 1 hr at RT. Finally, 
sections were mounted in ProLong Diamond Antifade with DAPI (InvitrogenTM, P36971) and 
coverslipped for imaging on the Aperio FL slide scanner (Leica). Images were analysed 
using Image Scope v.12.2.3.8013 (Leica Biosystems) and Imaris 9 4D Image Analysis 
software (Bitplane Inc.) 
2.9 Chimeras 
To generate chimeric mice, Rag1-/- recipient mice were irradiated (11Gy, 137Cs source). 
1.8x106 bone marrow cells from B6.bach2ΔT and B6.bach2fl/fl mice were then intravenously 
transferred into recipient mice at a ratio of 50:50 or 70:30 (Fig. 2.9.1). Recipient mice were 
maintained with neomycin sulfate (1g/L, Sigma Aldrich) in their drinking water for two weeks. 
Cell engraftment was assessed by flow cytometry 8 weeks post-transplant. Chimeras were 
infected 8-12 weeks post-transplant. 
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Figure 2.9.1 | Time line of chimera development, as described in section 2.9.  
Timeline indicates number of days post-cell transfer. 
2.10 Adoptive transfer 
CD4+ T cells were isolated from B6.Pbx1ΔT mice and their litter mate controls via CD4+ T cell 
isolation kit (Miltenyi Biotech, Germany). 1x106 of these cells were transferred into Rag1-/- 
mice via intravenous injection in RPMI/PS. 24 hours post-cell transfer, mice were infected 
with L. donovani. Assessment of parasite burden, and cellular analyses were performed 14 
days post-infection. 
2.11 Statistical analysis 
2.11.1 Sample size 
Sample size was calculated based on specific variables. 
Mouse: For the most variable parameters i.e. spleen parasite burden and cytokine levels, 
there is a requirement for 10 mice per group to achieve statistical significance with 80% 
power at a 5% type I error rate, or 5 mice per group for comparison of cre+ and cre- litter 
mates. For gene expression 5 mice are needed per group to reach statistical significance 
with 90% power at a 5% type I error rate. 
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Human: Cellular assays require a samples size of 10 for statistical significance with 98% 
power at a 5% type I error rate, and gene studies require a sample size of 17 for statistical 
significance with 80% power at a 5% type I error rate. 
2.11.2 Significance and graphical presentation 
Results were statistically analysed and graphically presented using GraphPad Prism 
software, unless otherwise specified. Where normality was not assessed data was assumed 
to be non-parametric for statistical testing. Specific tests used are described in the results. 
*P≤0.05, **P≤0.01, ***P≤0.001. 
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3.0.1 Candidate’s contributions to authorship 
Chapter 3 includes the following publication:  
Edwards CL, Ng SS, Corvino D, Montes de Oca M, Rivera FL, Nones K, Lakis V, Waddell 
N, Amante FH, McCarthy JS, Engwerda CR. Early changes in CD4+ T cell activation 
following blood-stage Plasmodium falciparum infection. The Journal of infectious diseases, 
jiy281-jiy281, doi:10.1093/infdis/jiy281 (2018). 
https://academic.oup.com/jid/article-abstract/218/7/1119/4995051 
Contribution by candidate Edwards CL: 
Analysis and interpretation (80%) 
I performed all of the data analysis with the exception of figures 3.1A, 3.2, .3.4A-C, 
3.7C. Interpretation of data was in done collaboration with my principle supervisor 
(Professor Christian Engwerda) and other laboratory members. 
Drafting and production (80%) 
I compiled the figures, methods, and sections of the results and discussion. I was 
also involved in the editing process. 
Conception and design (70%) 
I was involved in the design of all experiments in collaboration with my principle 
supervisor and other laboratory members. 
3.0.2 Contributions by co-authors 
Professor Christian Engwerda contributed significantly to all aspects of the paper. Susanna 
S. Ng and Dillon Corvino performed the bioinformatic analysis. Dr Katia Nones and Vanessa 
Lakis performed the epigenetic analysis. Professor James McCarthy with the assistance of 
Dr Fiona Amante ran the clinical trials included in this paper. Dr Fiona Amante assisted with 
collation of patient parasitemia and demographic data. Dr Marcela Montes de Oca and 
Fabian de Labastida Rivera assisted with various aspects of experiments including 
completion, design and analysis. 
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3.1 Introduction to paper 
The CD4+ T cell response to Plasmodium infection is a critical element of immune-mediated 
protection against malaria. This response involves several CD4+ T cell subsets, and 
although the Th1 cell response is predominant, no subset is solely responsible for protection. 
A number of studies have identified attributes of CD4+ T cell subsets which contribute to 
protection and pathology, some of which are exploited by vaccinations to improve 
protection69,210-212. Unfortunately, robust and long term protection against malaria remains 
elusive, with the most established vaccine candidate, RTS,S, only having an average 
efficacy of ~35%, and protection which wanes in a relatively short time 213.  
A number of studies have used transcriptional profiling of whole blood and PBMCs, from 
malaria patients and Control Human Malaria Infection (CHMI) trials, to understand how 
responses differ between unexposed and highly exposed individuals, as wells as mild and 
severe episodes of malaria. A number of these studies focused on innate immune responses 
and identified interferon (IFN) and toll-like receptor (TLR) signalling as dominant responses 
to early infection214-218. Strong induction of TCR signalling, reduced inflammation, and 
increased anti-inflammatory response have also been associated with re-exposure to 
infection and mild malaria4,219,220.  
Despite the importance of CD4+ T cells in malaria, there is limited work describing the 
changes in the transcriptional profile of human CD4+ T cells over the course of infection.  In 
the following paper “Early changes in CD4+ T cell activation following blood-stage 
Plasmodium falciparum infection”, we assessed an inflammatory and immune related 
transcriptional profile in CD4+ T cells prior to infection, during acute infection, and during 
infection resolution. These findings enhance the current knowledge of CD4+ T cell immune 
response over the course of malaria and will benefit future vaccine and therapeutic research. 
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3.2 Paper: Early changes in CD4+ T cell activation following blood-stage 
Plasmodium falciparum infection 
Chelsea L. Edwardsa,b, Susanna S. Nga,c, Dillon Corvinoa,b, Marcela Montes de Ocaa, Fabian 
de Labastida Riveraa, Katia Nonesa, Vanessa Lakisa, Nicola Waddella, Fiona H. Amantea, 
James S. McCarthya,b, Christian R. Engwerdaa 
aQIMR Berghofer Medical Research Institute, Brisbane, Australia. 
bUniversity of Queensland, School of Medicine, Brisbane, Australia. 
cGriffith University, School of Natural Sciences, Brisbane, Australia. 
3.2.1 Summary 
Transcriptional changes in CD4+ T cells during blood-stage Plasmodium falciparum infection 
were examined and the early development of an immunoregulatory CD4+ T cell phenotype 
identified. Subsequently, selective immune check point blockade was shown to modulate 
early developing anti-parasitic immune responses. 
3.2.2 Abstract 
We examined transcriptional changes in CD4+ T cells during blood-stage Plasmodium 
falciparum infection in individuals without a history of previous parasite exposure. CD4+ T 
cell CXCL8 gene (encoding IL-8) transcription was identified as an early biomarker of sub-
microscopic P. falciparum infection, with predictive power for parasite growth. Following anti-
parasitic drug treatment, a CD4+ T cell regulatory phenotype developed. PD1 expression on 
CD49b+ CD4+ T (putative type I regulatory (Tr1)) cells after drug treatment negatively 
correlated with earlier parasite growth. Blockade of PD1 but no other immune checkpoint 
molecules tested, increased IFNγ and IL-10 production in an ex vivo antigen-specific cellular 
assay at peak of infection. These results demonstrate the early development of an 
immunoregulatory CD4+ T cell phenotype in blood-stage P. falciparum infection, and show 
selective immune check point blockade may be used to modulate early developing anti-
parasitic immunoregulatory pathways as part of malaria vaccine and/or drug treatment 
protocols. 
Key words: malaria, CD4+ T cells, Plasmodium falciparum, immunoregulation 
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3.2.3 Introduction 
Malaria remains a significant health problem in tropical and sub-tropical regions of the world. 
Despite substantial progress in disease control through vector management, use of 
insecticide-treated bed nets and improved diagnosis and drug treatment, malaria is still 
responsible for more deaths than other parasitic diseases221. Critically, there is no licensed 
vaccine, and the emergence of artemesinin-resistant parasites in the Greater Mekong region 
represents a serious threat for disease treatment and control efforts. A major impediment to 
malaria eradication is our poor understanding about host immunity against the Plasmodium 
species that cause malaria in humans. This shortcoming in knowledge is especially apparent 
given the poor performances of malaria vaccine candidates in malaria endemic areas and a 
lack of consensus on how to generate long-lasting immunity in such endemic settings. 
Seminal studies performed more than 50 years ago showed anti-parasitic antibodies can 
protect against clinical malaria and control parasite growth222. However, these responses 
take years to develop in disease endemic areas, after repeated exposure to malaria 
parasites223. Recent reports also highlight a requirement for antibodies with specific 
functional properties to mediate immunity224. The development of long-lived, anti-parasitic 
memory B and plasma cells that produce these antibodies requires CD4+ T cell help225,226. 
Specialised CD4+ T follicular helper (Tfh) cells are critical in this process by providing key 
cognate and soluble signals to B cells227,228. IFNγ production by Tbet+ CD4+ T (Th1) cells is 
also important for generating specific antibody isotypes and activating phagocytic cells for 
increased antibody- and compliment-mediated removal of parasitised red blood cells 
(pRBCs) and generating microbiocidal molecules, such as reactive oxygen and nitrogen 
intermediates229,230. However, these anti-parasitic responses are often absent, sub-optimal 
or dysfunctional in individuals living in malaria endemic areas77,78,133. The reasons are still 
unclear, but emerging evidence indicates parasite-induced development of atypical B cells, 
sub-optimal Tfh cells, and Th1 cell responses characterised by autologous IL-10 production 
(type I regulatory (Tr1) cell responses), as well as the expression of inhibitory 
molecules40,42,231-234. Therefore, unless these factors are addressed, malaria eradication will 
not be possible. 
In this study, we examined CD4+ T cell responses in healthy volunteers participating in 
controlled human malaria infection (CHMI) studies initiated with blood-stage P. falciparum. 
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We identified CD4+ T cell CXCL8 gene (encoding IL-8) expression as an early molecular 
marker of blood-stage P. falciparum infection with predictive power for parasite 
multiplication. In addition, we found a CD4+ T cell molecular signature characterised by 
expression of chemokine receptors and immune checkpoint molecules soon after anti-
parasitic drug treatment. These molecules supported the rapid acquisition of a regulatory, 
anti-parasitic CD4+ T cell response following first exposure to P. falciparum.  
3.2.4 Methods 
Please refer to the indicated sections from chapter 2 for full descriptions of each method  
Buffers, Media and other reagents (section 2.1) 
Parasites and infections (section 2.3) 
Controlled Human Malaria Infection (CHMI) studies (section 2.3.4) 
Sample processing (section 2.4) 
Human samples (section 2.4.2) 
Cell counting (section 2.4.3) 
Flow cytometry (section 2.5) 
Cellular analysis (section 2.5.2) 
Cell sorting (section 2.5.3) 
Equipment and analysis (section 2.5.4) 
Ex-vivo assays (section 2.6) 
Antibody blockade (section 2.6.2) 
Check-point molecule blockade in CHMI PBMC cultures 
Genetic, epigenetic and transcription factor analysis (section 2.7) 
RNA isolation (section 2.7.1) 
qPCR (section 2.7.2) 
Nanostring (section 2.7.3) 
Methylation analysis (section 2.7.5) 
Statistical analysis (section 2.11)  
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3.2.5 Results 
CD4+ T cell CXCL8 expression is a molecular marker for sub-microscopic P. falciparum 
blood-stage infection 
To better understand the behaviour of CD4+ T cells during blood-stage P. falciparum 
infection, we examined PBMCs from volunteers participating in CHMI studies. Subjects were 
infected with blood stage P. falciparum and treated with a trial drug at 8 days p.i. when blood 
parasite levels exceeded 5000 parasites/mL (Figure 3.1A). PBMCs were isolated from naïve 
volunteers (before infection), pre-treatment (8 days p.i., prior to administration of drug 
treatment), post-treatment (15 days p.i.) and 28 days p.i.. PBMCs were isolated and CD4+ 
T cells were assessed by flow cytometry (Figure 3.1B). Despite variation in individual CD4+ 
T cell numbers (Figure 3.1C), major CD4+ T-helper cell subset frequencies remained 
relatively constant over the course of infection and recovery (Figure 3.1D).  
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Figure 3.1 | CD4+ T cell subset frequency over the course of P. falciparum infection.  
Naïve healthy individuals received 2,800 viable P. falciparum parasites via i.v. injection. 
Subjects received a drug treatment at 8 days post infection (p.i.). A) Parasite burden was 
assessed in the peripheral blood by PCR on days 0, 4, 5, 6, 7, 8, 15 and 28 p.i., and B) 
Chapter 3  
 
42325972 76 
PBMCs were isolated and CD4+ T cells were assessed by flow cytometry at 0, 8, 15 and 28 
days p.i. : C) Total CD4+ T cell numbers/mL of blood, D) Frequencies of activated CD45RA- 
CD3+ CD4+ T helper cell subsets – regulatory T (Treg; FoxP3+), Tr1 (LAG3+ CD49b+), Tfh 
(CXCR5+ CXCR3-), Th1 (CXCR5- CXCR3+), and Th17 (CCR6+ CXCR5- CXCR3-), the 
remaining population which did not fit into any of these categories was also analysed. Cohort 
4, n=7, mean ± SEM (A, C-D). 
 
CD4+ T cells were isolated and RNA was extracted for the digital measurement of 130 
selected immune-related gene transcripts and 5 house-keeping control genes (Appendix 4). 
A comparison of naïve (baseline; prior to infection), pre-treatment (acute infection; days 7-8 
p.i.) and post-treatment (resolving infection; days 13-14 p.i.) CD4+ T cells revealed a number 
of changes in gene expression (Figure 3.2). Few of these changes occurred prior to drug 
treatment, with only 4 differentially expressed genes (DEGs) identified between baseline 
and pre-treatment samples, including a significant increase in TNFSF10, GZMB, HLA-DRA 
and CXCL8 (IL-8) mRNA (Figure 3.2A). Given the dramatic increase in CD4+ T cell CXCL8 
mRNA at a time when blood parasitemia was sub-microscopic, we examined whether there 
was any association with parasite multiplication rate (PMR). Interestingly, we observed a 
significant, negative correlation (R = -0.63, P = 0.03) between the fold change in CD4+ T cell 
CXCL8 mRNA (baseline versus infected samples) and PMR (Figure 3.3A). No significant 
correlations between changes in CD4+ T cell TNFSF10, GZMB and HLA-DRA mRNA and 
PMR were found (Appendix 5). We also measured IL-8 in plasma and found a small, but 
significant (P < 0.001) increase pre-treatment (Figure 3.3B). However, in contrast with the 
change in CD4+ T cell CXCL8 mRNA, we found a significant, positive correlation (R=0.44, 
P=0.04) between PMR and plasma IL-8 levels at pre-treatment (Figure 3.3C), possibly 
reflecting contributions of IL-8 production by other cell sources. Thus, early CD4+ T cell 
CXCL8 expression was a molecular marker of sub-microscopic P. falciparum blood-stage 
infection with predictive power for early parasite multiplication. 
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Figure 3.2 | Inflammatory and immunoregulatory CD4+ T cell signature associated 
with P. falciparum infection. 
NanoString analysis was used to digitally assess differential expression of genes from CD4+ 
PBMCs, which were isolated from whole blood at baseline (day 0), pre-treatment (days 7-8) 
and post-treatment time points (days 13-14 p.i.). Log2 fold-change in gene expression from 
A) pre-treatment versus baseline , B) post-treatment versus pre-treatment, and C) post-
treatment versus baseline. Cohorts 1,2, and 3, n=12, mean value. 
Control of P. falciparum infection is associated with a CD4+ T cell signature characterised 
by inflammatory and immunoregulatory gene expression 
DEG analysis comparing CD4+ T cells at all three time points showed that most 
transcriptional changes occurred after drug treatment (Figure 3.2 and Figure 3.4A). 
Furthermore, principal component analysis (PCA) showed baseline and pre-treatment 
samples to be clustered together while post-treatment samples were separated along 
dimension (dim) 1 (Figure 3.4B). The top 50 genes contributing to dim 1 (Figure 3.4C), 
included genes such as IFNG and TBX21, which encode IFNγ and Tbet, respectively 235. 
PCA also showed that individual samples within each time point were separated along dim 
2, indicating the genes contributing to this dimension influence donor variation. These genes 
included MAF and EOMES, which encode transcription factors associated with Tr1 cells 236-
238 (Figure 3.4C). Pathway analysis using genes differentially expressed between pre- and 
post-treatment revealed major Th cell pathways linked to the anti-parasitic immune response 
during Plasmodium infection (Figure 3.4D). These included T helper cell differentiation, 
ICOS-ICOSL signalling in T helper cells, and IL-10 signalling. Of note, CXCL8 expression 
was the most down-regulated gene during this period and returned to pre-infection levels 
(Figure 3.2B).  
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Figure 3.3 | CXCL8 is a marker of early P. falciparum infection. 
A) Parasite multiplication rate (PMR) negatively correlated with Log2 fold change in CXCL8 
mRNA levels in CD4+ PBMCs (as determined by NanoString analysis) from 0 to 8 days p.i., 
Cohorts 1, 2, and 3, n=12, Spearman correlation. B) Plasma IL-8 protein levels at 0 and 8 
days p.i., cohorts 4, 6, and 7, n=22, ***P≤0.001, Wilcoxon matched-pairs signed rank test. 
C) PMR positively correlated with IL-8 protein concentration (pg/mL) in plasma 8 days p.i., 
cohorts 4, 6, and 7, n=22, Spearman correlation. 
Expression of several Th1 cell-associated genes were up-regulated post-treatment 
(IL12RB2, TBX21, and IFNγ), as well as cytotoxic genes (GZMH, GZMA and PRF1), 
suggesting a pro-inflammatory gene signature. However, increased expression of immune 
checkpoint genes was also observed (LAG3, PDCD1 (PD1), HAVCR3 (TIM3) and CTLA4), 
indicating a rapidly developing immunoregulatory signature following drug treatment. These 
molecules have previously been identified as inhibitory receptors in rodent models of malaria 
and other human malaria studies 239-242. We also found significant changes in chemokine 
receptor gene expression following drug treatment, including increased expression of 
CXCR6, CCR5 and CXCR3 and decreased expression of CXCR5 and CCR9, indicating 
alterations to tissue homing properties of CD4+ T cells during resolution of infection. 
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Figure 3.4 | Change in CD4+ T cell gene expression during P. falciparum infection. 
NanoString analysis was used to digitally assess differential expression of genes from CD4+ 
PBMCs, which were isolated from whole blood, taken at baseline (day 0), pre-treatment 
(days 7-8) and post-treatment time points (days 13-14 p.i.). A) Heat map of significantly 
differentially expressed genes, blue represents a z-score of -4, and red a z-score of 4. B) 
Principal component analysis of differentially expressed genes across the three time points 
in each subject. C) Top 50 genes which exceeded the expected average contribution (red 
line) towards dimensions 1 (Dim1) and 2 (Dim2) of B. D) Top 10 canonical pathways 
significantly association with genes differentially expressed post-treatment in comparison to 
pre-treatment. Shown by –log(P-value) (Dotted line, left Y axis), and percentage of pathway 
genes up or down regulated in sample (bar chart, right Y-axis). Cohorts 1,2, and 3, n=12, 
analysed using Ingenuity Pathway analysis (QIAGEN). 
Changes in immune checkpoint and chemokine receptor expression by CD4+ T cell subsets 
We next examined peripheral blood CD4+ T cell subsets for expression of selected immune 
checkpoint and chemokine receptors using flow cytometry. Specifically, we measured PD1, 
LAG3, TIM3, CTLA4, CCR5 and CXCR3 expression by CD4+ T cells prior to infection, and 
during acute infection, resolving infection, and 32 days p.i. (Figure 3.5). We found, as 
indicated earlier by mRNA levels, frequencies and intensities (median fluorescence intensity 
(MFI), and fluorescence index) of these markers were increased with resolution of infection 
(post-treatment), with the exceptions of LAG3 which was reduced in frequency and 
fluorescence index after drug treatment (Figure 3.5B,D), and CXCR3 and PD1 which had 
reduced MFIs (Figure 3.5C). We next examined the expression of the immune checkpoint 
molecules (PD1, LAG3, TIM3 and CTLA4) on regulatory T (Treg; FoxP3+), Tr1 (LAG3+ 
CD49b+), Tfh (CXCR5+ CXCR3-), Th1 (CXCR5- CXCR3+), Th17 (CCR6+ CXCR5- 
CXCR3-) and all remaining CD4+ T cells, including Th2 cells (Figure 3.6A). No single CD4+ 
T cell subset was a dominant contributor to PD1 expression. However, Treg cells were the 
most prominent source of CTLA4 and TIM3, and both Tr1 and Treg cells contributed 
substantially to LAG3 expression. Despite multiple subsets contributing to PD1 expression, 
only fold-change in expression of PD1 by Tr1 cells (between pre- and post-treatment) 
associated with PMR (negative correlation, Figure 3.6B), suggesting that PMR influences 
the phenotype, and potentially function, of Tr1 cells during parasite clearance. Interestingly, 
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early (pre-treatment) blockade of PD1 signalling, but not CTLA4, LAG3 or TIM3 (data not 
shown), in PBMCs restimulated with P. falciparum  antigen in vitro, enhanced antigen-
specific production of IFNγ  (Figure 3.7A) and IL-10  (Figure 3.7B). Although, the cell 
populations producing these cytokines were not identified, Tr1 cells have been shown to co-
produce both cytokines in previous studies using this cell culture system 41. One potential 
reason for the selective impact of PD1 blockade but not inhibition of other immune 
checkpoints is that CD4+ T cell PDCD1 gene was poised for early expression following 
encounter with parasite antigen by changes in DNA methylation. However, we found no 
significant changes in DNA methylation in CpG sites located in the PDCD1 gene in CD4+ T 
cells in the first 7 days of infection (Figure 3.7C).  
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Figure 3.5 | CD4+ T cell expression of infection-associated chemokine receptor and 
immune checkpoint markers. 
PBMCs were isolated from volunteers 0, 8, 15, and 28 days p.i. and assessed by flow 
cytometry. A) Marker expression on CD4+ T cells (CD3+ CD4+) as B)  frequency, C) median 
fluorescence intensity (MFI), and D) Fluorescence index; MFI multiplied by the frequency of 
CD4+ T cells expressing a specified marker. Cohort 4, n=7, mean ± SEM, *P≤0.05, **P 
≤0.01, ***P ≤0.001, Turkey’s multiple comparisons test. 
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Figure 3.6 | Expression of regulatory markers on CD4+ T helper cell subsets. 
Expression of CTLA4, PD1, LAG3, and TIM3 on CD4+ T (CD3+ CD4+) cell subsets was 
assessed by FACS of PBMCs isolated from volunteers. A) Marker expression was 
calculated as a fluorescence index  for each T-helper cell subset at 0, 8, 15, and 28 days 
post-infection, as described in Figure 5. B) PMR negatively correlated with fold-change in 
fluorescence indices of PD1 in the Tr1 cell subset between 8 and 15 days post-infection. 
Cohort 4, n=7, mean ± SEM (A), Spearman correlation (B). 
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Figure 3.7 | PD1 blockade enhances antigen specific immune responses at sub-
microscopic parasitemia. 
 A) IFNγ, and B) IL-10 concentrations (pg/mL) in cell culture supernatants from PBMCs 
isolated from volunteers 7 days p.i. and cultured for 72 hours with either media alone, 
uninfected red blood cells (nRBC), or P. falciparum infected red blood cells (pRBC), as well 
as either Nivolumab (αPD1) or its isotype control (ISO-PD1). Cohort 5, n=8, *P≤0.05, **P 
≤0.01, Wilcoxon matched-pairs signed rank test. C) DNA methylation levels in the PDCD1 
gene in CD4+ T cells pre-infection (Day 0) and 7 days after P. falciparum infection (prior to 
drug treatment). Methylation was measured at CpGs located 1500 base pairs (bp) and 
200bp from the gene translation start site (TSS1500 and TSS200, respectively), 5’ 
untranslated region (UTR), first exon, gene body and 3’ UTR. Beta value represents the 
level of methylation, where 1 means complete methylation and 0 means no methylation.  
Cohorts 7 and 8, n=9 paired samples. 
3.2.6 Discussion 
In this study we identified a distinct CD4+ T cell molecular signature induced by sub-
microscopic P. falciparum infection. This signature included upregulation of inflammatory 
molecules as early as days 7 or 8 p.i. (pre-treatment), and induction of a regulatory 
phenotype with infection resolution after drug treatment. The genes up-regulated early in 
infection (CXCL8, CCL4, HLA-DRA, and TNFSF10) are known to play roles in chemotaxis, 
inflammation, and antigen presentation4,243-245. We also found increased plasma IL-8 levels 
corresponding with increased CD4+ T cell CXCL8 expression. Interestingly, IL-8 was also 
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up-regulated in young children from endemic areas with malaria246, and in adults after long 
periods of no exposure247, suggesting IL-8 is an early marker of malaria in individuals with 
low parasite exposure. This may be especially relevant for young children who have had 
minimal exposure to Plasmodium and military personnel and civilian travellers who are 
infrequently exposed. IL-8 levels may act as a preliminary identification of malaria in these 
individuals when blood parasitemia is sub-microscopic. Interestingly, we also found a 
positive correlation between plasma IL-8 levels and PMR, indicating that IL-8 is not only a 
marker of early infection but may also contribute to infection progression, and consequently 
disease severity, as supported by previous genetic and biochemical studies248,249. 
Despite the inflammatory milieu often seen in acute malaria, CD4+ T cell responses are 
generally suboptimal; characterised by exhaustion and terminal differentiation, with an 
inability to efficiently form immunological memory77,78. In this study, we found a prominent 
regulatory signature within the CD4+ T cell population which may contribute to this 
constrained immune response. Immune checkpoint molecules, including PD1, CTLA4, 
TIM3, and LAG3, were up-regulated at the mRNA and protein level in association with drug-
mediated resolution of infection. Additionally, pathway analysis indicated changes in IL-10 
signalling during this time. IL-10 is important for limiting immune pathology caused by pro-
inflammatory, anti-parasitic immune responses37. Tr1 cells are a major source of this 
cytokine in parasitic infections37,42,155, and PD1, CTLA4, TIM3, and LAG3 are also known to 
regulate antigen-specific T cell responses and can be markers of cellular exhaustion in 
infectious diseases, including malaria233,239,250-252. We also observed increased expression 
of several genes associated with cytolytic activities after drug treatment, including 
granzymes A, B, H and K, and perforin, as has previously been reported for a subset of 
cytolytic CD38+ CD4+ T cells in CHMI studies that were positively associated with increased 
control of parasite growth253. It should be noted that none of the 4 different drugs used in 
our studies (see clinical trial registration numbers for details) have a known effect on human 
lymphocyte function in the doses tested. 
Blockade of several immune checkpoint molecules, as well as IL-10, has previously been 
shown to improve anti-parasitic T cell responses233,239,250-252. We found that blocking PD1 at 
pre-treatment, when blood parasitemia was sub-microscopic, enhanced antigen-specific 
IFNγ and IL-10 responses. This was despite no significant increase in expression in CD4+ T 
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cell PD1 mRNA or cell surface protein at this time, suggesting that PDCD1 gene expression 
is poised and rapidly activated following encounter with parasite antigen. However, we found 
no change in the level of DNA methylation of the PDCD1 gene over the first 7 days of P. 
falciparum infection, indicating other epigenetic modifications may be responsible for the 
effects of PD1 blockade. It is also possible that the frequency of cells responding to PD1 
inhibition was too small to allow detection of changes in CD4+ T cell PDCD1 gene 
methylation. Alternatively, the changes in cytokine production after PD1 blockade in our ex 
vivo antigen re-stimulation assays may have resulted from effects on other cells in the PBMC 
cultures. Regardless, these results show that conditioning of cells towards suboptimal 
functionality begins early in infection. 
Interestingly, we found that changes in expression of PD1 by Tr1 cells after drug-mediated 
control of parasites negatively correlated with PMR up to the time of anti-parasitic drug 
treatment, suggesting that rate of parasite growth influences the polarisation of T cells 
towards a regulatory phenotype and in particular Tr1 cells. This is noteworthy since PD1 
blockade enhanced production of IFNγ and IL-10, cytokines which are commonly co-
produced by Tr1 cells4,40,47. Despite LAG3 being a marker of Tr1 cells254, blocking LAG3 ex 
vivo in pre-treatment samples did not impact antigen-specific cytokine production. Of note, 
attempts to block LAG3, as well as PD1, CTLA4 and TIM3, on PBMCs in ex vivo antigen re-
stimulation assays after anti-parasitic drug treatment (i.e., days 13-15 p.i.), failed to result in 
any consistent change in cytokine production across cohorts. However, changes in cytokine 
production by individuals following selected immune checkpoint blockade were observed. It 
is also possible that effects may have occurred in specific immune cell populations, but were 
not detected because we only measured cytokine production by all PBMCs in our assays. 
Together, these data indicate that despite increased expression of several known immune 
checkpoint molecules soon after anti-parasitic drug treatment, their influence on subsequent 
development of anti-parasitic immunity is highly variable across individuals, with the 
exception of CD4+ T cell PD1 expression in response to parasite antigen exposure early in 
infection. However, as mentioned above, we cannot exclude the possibility that specific 
immune cell subsets were impacted by immune checkpoint blockade in a more consistent 
manner. 
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Anti-PD1 therapy is used to treat cancer by improving T cell function to promote clearance 
of diseased tissue255. Since early PD1 blockade enhanced antigen-specific cytokine 
production in our ex vivo cell culture system, blockade early in infection may be used to 
reduce the regulatory and exhausted phenotype seen in T cells in malaria, and not only 
improve parasite clearance but also the development of long term memory. This could be 
considered as a novel immunomodulatory intervention in at-risk groups. Alternatively, this 
strategy may have potential for improving vaccine efficacy, whereby PD1 blockade could be 
used in combination with malaria vaccination. This approach has been found to improve 
efficacy of both viral and cancer therapeutic vaccines via improvement of CD8+ T cell 
function256,257 and may prove beneficial for Plasmodium vaccine regimes where protection 
is suboptimal and wanes within a few years. However, the increase in IL-10 production 
observed following PD1 blockade may be problematic given its potent anti-inflammatory 
properties. Therefore, strategies to overcome this effect on IL-10 production, while boosting 
selected anti-parasitic activity may be required. 
In summary, we found that P. falciparum infection influences CD4+ T cell phenotype early in 
infection. CD4+ T cell CXCL8 gene transcription may be used to identify P. falciparum 
infection early, particularly in patients with low P. falciparum exposure. Additionally, we show 
that early infection influences later CD4+ T cell response, inducing a regulatory phenotype 
which can be manipulated by early PD1 blockade. Together, these findings highlight the 
need to incorporate strategies that avoid or overcome dominant anti-parasitic regulatory 
immune responses established during prior infection into malaria vaccine and drug 
treatment protocols. 
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3.3 Concluding remarks 
Few studies have investigated the CD4+ T cell response to Plasmodium infection at a 
transcriptomic level. In using a top-down approach to explore the changes which occur in 
CD4+ T cell phenotype over the course of exposure to P. falciparum parasites, we’ve shown, 
to the best of our knowledge, for the first time, that very early infection, though it does not 
impact on early CD4+ T cells expression profiles, influences later CD4+  cell responses to 
infection. As such, it appears that there is an important preliminary stage to T cell activation 
and effector function where T cell genes become poised to respond to antigen stimulation. 
This is important as it offers the opportunity for early intervention and modification of the 
immune response to parasite invasion. As discussed in this paper, these findings also 
identify potential approaches for modifying and improving immune responses to vaccines 
and other therapeutic interventions.  
We also showed that infection resolution induced marked changes in the CD4+ T cell 
transcriptome which is characterised by an immune regulatory signature. This confirms 
findings from cellular and molecular studies in the field showing the induction of regulatory 
molecules in CD4+ T cells during malaria 251,258. It further suggests that not just one or two, 
but a whole suite of regulatory markers are induced early in infection, identifying an 
opportunity to intervene at an earlier timer point to protect against immune suppression. 
These findings offer the potential to improve vaccine efficacy. Blocking specific immune 
regulatory molecules as an early intervention when patients present with early symptoms 
may also improve current and long-term immune responses. 
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4.1 Introduction 
BACH2 (BTB and CNC Homology 1, Basic Leucine Zipper Transcription Factor 2) is a 
leucine zipper transcription factor, that is most well-known for its role in B cell development. 
It is also involved in antibody class switch recombination and somatic hypermutation259. 
More recently, it has been associated with T cell function in a number of inflammatory 
diseases, and as such, it is considered to be a master regulator within the T cell 
compartment. 
4.1.1 BACH2 in disease 
BACH2 dysregulation is associated with a number of immune disorders. It is an important 
tumour suppressor and can control B cell lymphomas260. However, in some cancers it is 
mutated or fused with other genes leading to dysregulated expression of BACH2 or the 
protein it is fused to261,262. Bach2 is often down-regulated in inflammatory disorders. For 
example, in patients with coeliac disease, CD4+ T cells have increased expression of genes 
associated with inflammation, which is also associated with down-regulated expression of 
BACH2263. Interestingly, IFNγ is highly expressed in CD4+ T cells from coeliac patients, 
which may suggest that BACH2 plays a role in regulating IFNγ expression, however, this 
would need to be confirmed by further investigation. 
Several genome wide association studies have identified BACH2 as a susceptibility gene 
for inflammatory diseases, including rheumatoid arthritis, Crohn’s disease, asthma, and 
multiple sclerosis264-267. In a mouse model of multiple sclerosis (experimental autoimmune 
encephalomyelitis – EAE), Bach2 was down-regulated in Th17 cells and expression was 
negatively associated with disease severity268. Another study showed that Bach2 was 
significantly down regulated in all T cells during EAE, and this was correlated with increased 
Foxp3 methylation and reduced Foxp3 expression, suggesting that BACH2 influences 
epigenetic modification of the Foxp3 promoter region to support Treg cell development and 
expansion to prevent autoimmune disease269. However, to date, there has been very little 
mechanistic and/or functional data on the role of BACH2 in disease. 
4.1.2 BACH2: T cell master regulator 
T cells play an important role in inflammation and disease. BACH2 has been described as 
a T cell master regulator, and in some cases a super-enhancer, because of its role in 
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modulating cell lineage transcription factors270-272. BACH2 has been known to suppress 
terminal differentiation in CD8+ T cells by controlling accessibility of transcription factor 
binding sites in T cell receptor (TCR) associated genes, thereby inhibiting their 
expression273. BACH2 is also thought to inhibit IL-2 expression in CD4+ T cells by a similar 
mechanism274. It is highly expressed on naïve T cells, and is lost with T cell activation and 
differentiation during autoimmune disease, suggesting that it inhibits development of effector 
T cells and/or maintains naïve T cell phenotypes268,275. BACH2 has also been shown to 
suppress CD4+ T memory cell formation275, and prevent CD4+ T cell senescence which is 
associated with overt inflammation276. In particular, BACH2 suppressed production of IFNγ 
and IL-4276. This was not surprising given that BACH2 supports Treg cell development 
and/or maintenance272 which would inhibit effector CD4+ T cell differentiation and promote 
immune suppression and tolerance.  
In B cells BACH2 binds to the promoter regions of a number of genes important for plasma 
cell differentiation277. For example, BACH2 represses Prdm1 (BLIMP1) gene expression via 
epigenetic regulation, which prevents plasma cell development and B cell antibody class 
switch recombination277. Interestingly, BLIMP1 expression is increased in T cells from 
Bach2-/- mice, suggesting that BACH2 also supresses BLIMP1 in the T cell compartment275. 
BLIMP1 also plays roles in T cell memory development and terminal differentiation of CD8+ 
T cells, while impairing their memory and recall response278,279. In contrast, BACH2 had the 
opposite affect and promoted memory CD8+ T cell development during viral and bacterial 
infection, and suppressed terminal differentiation, allowing cell survival and memory 
maintenance. Additionally, BACH2 is important for expansion of memory CD8+ T cells 
following antigen exposure259,273,280. Again, BACH2 facilitated these activities by 
transcriptional regulation of the Prdm1 and the Inhibitor of DNA Binding 3 (Id3) gene which 
influence cell cycle and survival, respectively280. Therefore it is likely that BACH2 acts 
upstream of BLIMP1 to influence terminal differentiation or memory cell development. 
Recently, several studies have reported roles for BACH2 in the regulation and homeostasis 
of the T cell compartment272,275,281. Bach2 expression is essential for the stability and 
function of the Treg cells, but also plays a role in the differentiation of CD4+ T cells into 
effector lineages such as Th1, Th2 and Th17 cells272,275,281. This is seen in Bach2 knock out 
mice suffering from lung disease associated with enhanced Th2 cell cytokine production and 
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lung inflammation281, which suggest a requirement for BACH2 in controlling Th2 cell 
differentiation and/or tissue recruitment. Bach2 has also been shown to promote Th1 cell 
responses, over Th2 cell responses, during Listeria monocytogenes infection275. One 
mechanism by which BACH2 may impact CD4+ T cell differentiation is by suppression of 
BLIMP1 expression, which normally down-regulates Th1 cell lineage genes, such as Ifng, 
Tbx21, and Bcl6 to promotes Th1 cell differentiation282. In spite of the role of BACH2 in 
effector CD4+ T cell function, BACH2 promotes a CD4+ T cell regulatory phenotype over all 
other CD4+ T cell subsets. This is supported by the unrestrained Th2 cell-mediated wasting 
disease observed in Bach2 knock out mice, along with upregulation of Th1, Th2 and Th17 
cell differentiation genes, when CD4+ T cells from these mice were polarised under Th1, Th2 
and Th17 conditions272. Additionally, BACH2 is critical for expression of FOXP3 and inhibits 
inflammation by supressing inflammatory gene expression272,281. As such BACH2-mediated 
suppression of effector CD4+ T cell responses will likely affect the outcome of infectious 
diseases such as malaria, where these responses are essential for pathogen clearance.   
Treg cells are a critical part of the immunoregulatory network that protects tissues from 
inflammation. More recently, Foxp3- IL-10-producing CD4+ T (type 1 regulatory; Tr1) cells 
have been identified, and recognised to play important regulatory roles in a number of 
infectious diseases, including malaria, leishmaniasis and toxoplasmosis37,40,42,47. It is 
unknown whether BACH2 regulates the function of these cells. IL-10 production by Tr1 cells 
has been shown to be governed by BLIMP139. We recently showed that BLIMP1 expression 
by T cells enhanced Tr1 cell development, while suppressing Th1 cell expansion37. This was 
association with enhanced parasite burden and increased morbidity in mouse models of 
both malaria and leishmaniasis37. Because BACH2 is known to suppress BLIMP1 
expression277, we hypothesised that BACH2 would antagonise BLIMP1 activity in these 
diseases, resulting in opposing outcomes to BLIMP1-deficient mice. BACH2 has 
predominantly been investigated using Bach2-deficient mice, which haven’t allowed 
investigators to establish the importance of cell, tissue or temporal expression of BACH2. 
Therefore, we used a T cell-specific Bach2 knockout mouse to investigate the role of BACH2 
in parasitic infection, and further understand its role in T cells. 
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4.2 Methods 
Please refer to the indicated sections from chapter 2 for full descriptions of each method  
Buffers, Media and other reagents (section 2.1) 
Mice (section 2.2) 
Parasites and infections (section 2.3) 
Assessing Plasmodium parasite burden in mice (section 2.3.1) 
Plasmodium chabaudi chabaudi AS (P. chabaudi) and Plasmodium berghei ANKA 
(P. berghei) (section 2.3.2) 
Leishmania donovani in mice (section 2.3.3) 
Sample processing (section 2.4) 
Mouse samples (section 2.4.1) 
Cell counting (section 2.4.3) 
Flow cytometry (section 2.5) 
Cytokine analysis (section 2.5.1)  
Cellular analysis (section 2.5.2) 
Equipment and analysis (section 2.5.4) 
Ex-vivo assays (section 2.6) 
Polarisation (section 2.6.1) 
Chimeras (section 2.9) 
Statistical analysis (section 2.11) 
4.3 Results 
4.3.1 T cell-specific BACH2 inhibits effector T cell differentiation and facilitates 
Treg cell development. 
To study the role of BACH2 in CD4+ T cells, we used a T cell-specific Bach2 knock out 
(B6.Bach2ΔT) mouse, produced by crossing transgenic B6.Cd4-cre mice with B6.Bach2-
floxed animals. Littermates lacking the Cd4-cre transgene (B6.Bach2fl/fl) were used as 
controls. CD4+ T cells were isolated from the spleens of naïve B6.Bach2fl/fl and B6.Bach2ΔT 
mice and then cultured with αCD3 and αCD28 mAbs in the presence of neutral (Th0), Th1, 
Th2, Th17, Tfh or Treg cell polarising cytokines. CD4+ T cell Bach2-deficieny promoted Th2, 
Th17 and Tfh cell development, while inhibiting Treg cell development (Fig. 4.1). Production 
Chapter 4  
 
42325972 95 
of the Th2 cell cytokines IL-4 and IL-13 was significantly higher in Th2 cell polarised cultures 
of B6.Bach2ΔT CD4+ T cells, compared to controls (Fig. 4.1A). IL-4 was included in Th2 
culture conditions, however, this does not appear to have influenced day 5 IL-4 levels 
significantly as IL-4 is at similar levels in Th0 cultures which received no IL-4.  B6.Bach2ΔT 
CD4+ T cells had increased frequencies of Th17 (RORγ+) cells and IL-17A production in 
Th17 polarising conditions, compared with controls (Fig. 4.1). Similarly, B6.Bach2ΔT CD4+ T 
cells developed more Tfh (CXCR5+ PD1+) cells under Tfh polarising conditions, but levels 
of the Tfh-associated cytokine IL-6 were reduced, compared with control CD4+ T cells (Fig 
4.1). As with IL-4, IL-6 levels may have been influenced by IL-6 being included in Tfh culture 
conditions; the reduced IL-6 levels at day 5 may reflect increased IL-6 consumption, or 
reduced IL-6 production, as such assessment of Tfh surface markers CXCR5 and PD1 is a 
more reliable marker of the influence of BACH2 on Tfh development. B6.Bach2ΔT Treg 
(Foxp3+) cell frequencies were reduced during Treg cell polarisation, relative to controls (Fig. 
4.1B), supporting an important role for BACH2 in Treg cell development272. We also 
observed a significant increase in IL-10 levels in all culture conditions with B6.Bach2ΔT CD4+ 
T cells, compared with controls (Fig 4.1A, Appendix 6). Given that BLIMP1 is critical for 
CD4+ T cell IL-10 production37, this finding suggests that BACH2 may inhibit CD4+ T cell 
BLIMP1-dependent IL-10 production. These findings also indicate that increased IL-10 
production by B6.Bach2ΔT CD4+ T cells may compensate for reduced Treg cell development 
under some physiological conditions. 
Interestingly, the increased cytokine production by B6.Bach2ΔT CD4+ T cells was observed 
in multiple polarisation conditions. This included elevated levels of IL-10 and IL-13 under all 
cell polarising conditions, elevated levels of IL-4 under Tfh cell polarising conditions and 
increased levels of IL-17A in Treg cell polarising conditions, compared with controls 
(Appendix 6). These results support a role for BACH2 as a master regulator of T cell cytokine 
production. They also indicate a role for BACH2 in promoting Treg cell, but inhibiting Th17 
and Tfh cell development. 
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Figure 4.1 | Bach2 inhibits Th17 and Tfh cell differentiation while promoting Treg cell 
differentiation. 
CD4+ T cells were purified from spleens of B6.Bach2ΔT or B6.bach2fl/fl mice and cultured 
with αCD28 and αCD3 mAbs for 5 days under either Th0 (white), Th1 (blue), Th17 (teal), 
Tfh (red), Treg (pink), or Th2 (yellow) cell polarising conditions. A) Cytokine levels measured 
in cell culture supernatants after 5 days of polarisation, compared to cytokine levels 
produced by CD4+ T cells under Th0 conditions. B) Frequencies of CD4+ T cells expressing 
lineage transcription factors under the various CD4+ T cell polarising conditions were as also 
assessed after 5 days of polarisation. n=5 mice per condition in duplicate, *P<0.05, 
**P<0.01, significance assessed by Mann-Whitney U test.  
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4.3.2 The role of BACH2 in malaria 
The outcome of malaria and leishmaniasis is significantly influenced by CD4+ T cell 
responses128,133,164,173. They produce pro-inflammatory cytokines, such as IFNγ and TNF 
that help phagocytic cells capture and kill parasites, and in malaria, they help B cells produce 
anti-parasitic antibodies needed to control infection and protect against future 
disease122,132,188,230. CD8+ T cells are important for parasite killing, but also directly cause 
immune pathology, particularly in the brain during malaria107. Since BACH2 influenced base-
line ratios of effector CD4+ T cell subsets, and Treg polarisation, our hypothesis was that 
BACH2 would influence cellular response to infection, and consequently infection 
progression and/or outcome.  
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Figure 4.2 | T cell-specific BACH2 supports T cell expansion and survival. 
A) Gating strategy for CD4+ T, CD8+ T, Th1 (IFNγ+, Tbet+), Tr1 (IFNγ+ IL10+), Treg (Foxp3+), 
and antigen experienced (CD49d+ CD11a+) cells in the spleens of B6.Bach2ΔT (green) and 
B6.Bach2fl/fl (black) mice infected with P. chabaudi at 0, 7 and 14 days post-infection. B) 
Frequencies of these cells were assessed in the B) CD4+ T cell population and in the C) 
Th1 cell population. D-E) Total numbers of these cells were also calculated. n=5-7 mice per 
time point, mean ± SEM, *P<0.05, **P<0.01, significance assessed by Mann-Whitney U test.  
T cell specific BACH2 influences development of non-T cell splenic populations. 
To determine the role of BACH2 in T cells during malaria, we infected B6.Bach2ΔT mice and 
controls with Plasmodium chabaudi chabaudi AS (P. chabaudi). There was no change in 
the number of splenic CD4+ or CD8+ T cells in B6.Bach2ΔT mice prior to infection, although 
a small decrease in frequency was noted, compared to controls (Fig. 4.2B,D). This latter 
change was associated with increased frequencies of B cells and monocytes in the spleens 
of naive B6.Bach2ΔT mice, compared to controls (Fig. 4.3B). Thus, BACH2 appears to 
influence the ratio of leukocyte subsets in the spleens of naïve animals. 
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Figure 4.3 | T cell-specific BACH2 regulates the development of non-T cells. 
A) Gating strategy for B cells, monocytes and neutrophils, B) frequencies and, C) total 
numbers were assessed in P. chabaudi infected B6.Bach2ΔT (green) or B6.Bach2fl/fl (black) 
mice, at 0 and 14 days post-infection. D0 n=3 mice, mean ± SEM, Day 14 n=7 mice, *P<0.05, 
**P<0.01, significance assessed by Mann-Whitney U test.  
T cell specific BACH2 is important for T cell maintenance during chronic parasitic infection. 
P. chabaudi infection has an acute phase (day 0-7) and a chronic phase (day 7 onwards). 
In P. chabaudi infected B6.Bach2ΔT mice the initial expansion of CD4+ T cells, but not CD8+ 
T cells, during acute infection was reduced, relative to controls (Fig. 4.2D). However, during 
the chronic phase of P. chabaudi infection, there was a significant reduction in both CD4+ 
and CD8+ T cell numbers in B6.Bach2ΔT mice, compared with controls (Fig. 4.2D), 
suggesting a role for BACH2 in either T cell expansion and/or survival. However, despite 
the fall in splenic CD4+ T cell numbers by day 14 p.i., the frequencies of Th1 and Tr1 cells 
continued to increase in the absence of BACH2 (Fig. 4.2C). This same increase was not 
reflected in cell number due to the dramatic decrease in overall CD4+ T cell numbers at this 
time point in B6.Bach2ΔT mice (Fig. 4.2E).  Therefore, BACH2 helped regulate CD4+ and 
CD8+ T cell numbers in steady state, as well as during malaria, but also suppressed Th1 
and Tr1 cell expansion during infection. Remarkably, there was no change in Treg cell 
numbers over the course of infection in B6.Bach2ΔT mice, relative to controls (Fig. 4.2E), 
indicating an important role for BACH2 in the expansion of this CD4+ T cell subset. Together, 
these results identify diverse roles for BACH2 in Th1, Tr1 and Treg cell development during 
malaria. 
T cell-specific BACH2 does not influence disease outcome in a non-lethal malaria model. 
Despite the above Bach2-dependent changes in CD4+ T cell phenotypes in P. chabaudi-
infected mice, we observed no differences in pathology (i.e. splenomegaly) or blood 
parasitemia between B6.Bach2ΔT and B6.Bach2fl/fl mice (Fig. 4.4). These findings suggest 
that compensatory mechanisms develop to offset the loss of Bach2, preventing changes in 
disease outcome. 
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Figure 4.4 | T cell-specific BACH2 does not influence disease outcome in a non-lethal 
malaria model. 
A) Blood parasitemia was measured on days 1-8 p.i. (n=12 mice per group), and days 9-14 
p.i. (n=6 mice per group). B) Whole body, spleen weights, and C) numbers of splenic 
leukocytes were measured in B6.Bach2ΔT (green) and B6.Bach2fl/fl (black) mice infected with 
P. chabaudi at days 0, 7 and 14 p.i. (n = 7 B6.Bach2ΔT and 5 B6.Bach2fl/fl mice at each time 
point, mean ± SEM, significance assessed by Mann-Whitney U test.  
4.3.3 The role of BACH2 in severe malaria 
Plasmodium berghei ANKA (P. berghei) is a murine model of severe malaria in which acute 
infection rapidly progresses to cerebral malaria, anaemia, and death. Cerebral pathology 
during malaria has been shown to be significantly dependent on anti-parasitic CD8+ T cells 
which target parasites using cytotoxic molecules such as granzyme B, and perforin, but 
which also damage surrounding cells and tissue107. BACH2 is known to play an important 
role in CD8+ T cell development and homeostasis273, and given its importance in CD8+ T 
cell maintenance and/or survival during P. chabaudi infection (Fig. 4.2), we postulated that 
T cell-specific BACH2 deficiency would likely affect the outcome of P. berghei infection.  
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Figure 4.5 | BACH2 influences the outcome of P. berghei infection. 
B6.Bach2ΔT (dark blue), B6.Bach2fl/fl mice (light blue) and C57Bl/6J mice were infected with 
P. berghei and A) clinical score, (n=6-10 mice per group), and B) frequency of infected red 
blood cells in the peripheral blood, (n=6-10 mice per group) and C) survival (n=10-18 mice 
per group, 3 experiments pooled) were assessed. Log-rank Mantel Cox test, mean ± SEM, 
*P<0.05, **P<0.01, ***P<0.001. 
B6.Bach2ΔT and B6.Bach2fl/fl mice were infected with P. berghei and the course of disease 
was monitored. Mice lacking BACH2 expression by T cells had decreased clinical score, 
reduced blood parasitemia and improved survival, compared to C57BL/6 controls (Fig. 4.8). 
However, when B6.Bach2ΔT mice were compared to B6.Bach2fl/fl litter mate controls, these 
changes were no longer apparent. Therefore, the genetic background of the B6.Bach2fl/fl 
mice or changes to Bach2 as a result of introducing flow alleles appeared to be responsible 
for the increased disease resistance observed. 
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Figure 4.6 | T cell-specific BACH2 regulates non-T cell development during VL. 
A) Gating strategy for splenic B cells, monocytes and neutrophils. B6.Bach2ΔT (green) and 
B6.Bach2fl/fl mice (black) mice infected with L. donovani and the B) frequency and C) number 
of cells in the spleen, as well as the D) frequency and E) number of cells in the liver were 
measured at 0, 7 and 14 days p.i.. n=3-7 mice per group per time point, mean ± SEM, 
*P<0.05, significance assessed by Sidak’s multiple comparisons test. 
4.3.4 The role of BACH2 in visceral leishmaniasis  
We also investigated the role of BACH2 in visceral leishmaniasis (VL) caused by infection 
with the human parasite Leishmania donovani. This model is characterised by an acute, 
resolving infection in the liver, while chronic infection develops in the spleen145.  
T cell specific BACH2 influences development of non-T cell splenic populations. 
Similar to what we had observed in P. chabaudi infection, T cell-specific BACH2 deficiency 
was associated with changes in other non-T cell leukocyte populations during L. donovani 
infection (Fig. 4.6). Specifically, we found that the frequency of splenic monocytes was 
elevated at day 27 p.i., while neutrophil frequency was increased in the liver at day 14 p.i. 
(Fig 4.6B, D). 
T cell-specific BACH2 supports the expansion and/or survival of antigen specific T cells 
during L. donovani infection. 
B6.Bach2ΔT and B6.Bach2fl/fl mice were infected with L. donovani and CD4+ or CD8+ T cell 
frequency and number was measured (Fig. 4.7). We found that T cell-specific BACH2 
deficiency resulted in a significant reduction in the frequency of antigen experienced 
(CD49d+, CD11a+) CD4+ T cells at day 14 and 28 p.i. in the liver, but not the spleen (Fig. 
4.7B, E). This finding indicates a role for BACH2 in the expansion and/or survival of CD4+ T 
cells entering the infected liver. 
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Figure 4.7 | T cell-specific BACH2 influences Treg and antigen experienced cells. 
A) Gating strategy for CD4+ T, CD8+ T, Treg (CD4+ Foxp3+) and antigen experienced 
(CD11a+ CD49d+) T cells in the spleen. B6.Bach2ΔT (green) and B6.Bach2fl/fl mice (black) 
mice infected with L. donovani at 0, 7 and 14 days p.i. Frequencies and total numbers of 
these cells were assessed in the B-D) spleens, and E-G) livers of mice. B, E) Frequency of 
total leukocytes. C, F) Frequency of CD4+ T cells. D,G) Total number of cells in the organ. 
n=3-7 mice per group per time point, mean ± SEM, *P<0.05, **P<0.01, ***P<0.001, 
significance assessed by Sidak’s multiple comparisons test. 
T cell-specific BACH2 is required for Treg cell expansion in the spleen during L. donovani 
infection. 
One of the striking features observed in our P. chabaudi studies was the lack of splenic Treg 
cell expansion in B6.Bach2ΔT mice during infection (Fig. 4.2E). We found a similar pattern 
in the spleen, but not liver, of L. donovani-infected B6.bach2ΔT mice, relative to control 
B6.Bach2fl/fl mice (Fig. 4.6B-E). These differences were observed at day 14 p.i. in the spleen, 
but were no longer apparent at day 28 p.i. Unlike our prior observations in P. chabaudi 
studies, we found differences in splenic Treg cell frequencies in naïve B6.bach2ΔT mice, 
compared to controls (Fig. 4.7B). This difference may have been caused by differences in 
the age of mice used or unidentified environmental changes, as the experiments were 
performed at different times. Nevertheless, our findings in L. donovani infection are 
consistent with those with P. chabaudi infection and indicate an important role for BACH2 in 
Treg cell expansion in the spleen during infection.  
T cell-specific BACH2 does not influence disease outcome in a VL model. 
Again, despite the above Bach2-dependent changes in CD4+ T cell phenotypes in L. 
donovani-infected mice, we observed no differences in pathology (i.e. spleen and liver 
weight) or tissue parasite burdens between B6.Bach2ΔT and B6.Bach2fl/fl mice (Fig. 4.8). 
These findings, similar to those in experimental non-lethal malaria, suggest that 
compensatory mechanisms develop to offset the loss of Bach2, preventing changes in 
disease outcome. 
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Figure 4.8 | BACH2 does not influence pathology or parasite burden during L. 
donovani infection. 
B6.Bach2ΔT (green) and B6.Bach2fl/fl mice (black) mice were infected with L. donovani and 
assessed for parasite burden and pathology at day 0, 7, and 14 p.i.. Parasite burden in the 
A) spleen and D) liver, were determined by PCR normalised to organ weight. Pathology was 
assessed by B) spleen weight, E) liver weight, and G) whole body weight. Total number of 
leukocytes in the C) spleen, and F) liver were also measured. n=3-7 mice per group per time 
point, mean ± SEM. 
A cell intrinsic role for BACH2 in a VL model. 
Several findings from studies in experimental malaria and VL indicated a cell intrinsic role 
for BACH2 in T cell subset development and/or survival. To examine this further, we 
generated B6.Bach2ΔT (CD45.2) : B6.Bach2fl/fl (CD45.1) (50:50) mixed bone marrow 
chimeric mice by injecting a 30:70 mix of bone marrow from B6.Bach2ΔT and B6.Bach2fl/fl 
mice into irradiated B6.Rag1-/- mice (Fig. 4.9). To generate animals with an approximate 
50:50 mix of leukocytes, we had to increase the ratio of B6.Bach2ΔT bone marrow because 
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these cells did not engraft as well as control cells when injected in an equal ratio (Appendix 
7), suggesting a role for BACH2 in the efficient reconstitution of immune systems following 
lethal irradiation. 
Following 12 weeks of engraftment and similar leukocyte reconstitution (Fig. 4.9), we still 
found a reduction in CD4+ T cells and CD8+ T cell numbers in the spleens of naïve mice 
(Fig. 4.9A, B, D and E). This reduction was maintained following infection with either P. 
chabaudi (Fig. 4.9A-B) or L. donovani (Fig. 4.9D-E) infection, indicating a T cell intrinsic role 
for BACH2 in T cell development. We also observed similar suppression of CD4+ and CD8+ 
T cell expansion in the liver during L. donovani infection (Fig. 4.9G and H).  We next 
measured Treg, Th1 and Tr1 cell frequencies in mice over the course of P. chabaudi or L. 
donovani infection. In the non-lethal model of malaria, we found small reductions in Bach2-
deficient, splenic Th1 and Tr1 cells at days 7 and 14 p.i., respectively. In contrast, a small 
increase in Bach2-deficient splenic Treg cells was observed at day 14 p.i. compared to 
controls (Fig. 4.9C). These results may have been influenced by the overall reduction in 
CD4+ T cells, however, there were no differences in these populations in naïve mice, 
therefore these differences are likely subtype specific. In the VL model, we found tissue-
specific differences in these CD4+ T cell subsets. Surprisingly, Bach2-deficiency resulted in 
an increased proportion of Treg cells in the livers of naïve chimeras which was maintained 
throughout L. donovani infection (Fig. 4.9I). However, no differences in Treg cell proportions 
were observed in the spleen (Fig. 4.9C, F and I). BACH2 had little influence over Th1 cell 
development in both liver and spleen. However, reduced proportions of Bach2-deficient Tr1 
cells in the spleen and liver at day 14 p.i. and at day 28 p.i. in the spleen were observed, 
relative to controls (Fig. 4.9F and I). Together, these data indicate relatively subtle and 
tissue-specific roles for BACH2 in CD4+ T cell subset reconstitution after lethal irradiation, 
as well as expansion during experimental malaria and VL.  
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Figure 4.9 | Cell intrinsic BACH2 supports T cell development and expansion. 
B6.bach2ΔT (CD45.2) : B6.bach2fl/fl (CD45.1) (50:50) mixed bone marrow chimeric mice 
were generated by injecting a 30:70 mix of bone marrow from B6.bach2ΔT and B6.bach2fl/fl 
mice into irradiated B6.RAG1-/- mice. Following 8-12 weeks of engraftment, chimeras were 
infected with either A-C) P. chaubaudi or D-I) L. donovani . CD8+ T, CD4+ T, Th1 (Tbet+ 
IFNγ+ CD4+), Tr1 (IFNγ+ IL10+ CD4+), and Treg (Foxp3+ CD4+) cell frequency and numbers 
were measured at days 0, 7, 14, and 28 p.i., as indicated. A,D,G) The frequencies of 
B6.bach2ΔT and B6.bach2fl/fl leukocytes in irradiated recipients, B,E,H) number of CD8+ and 
CD4+ T cells, and C,F,I) frequency of Treg, Th1 and Tr1 cells within the B6.bach2ΔT and 
B6.bach2fl/fl CD4+ T cell populations. n=6 mice per group per time point. Mean ± SEM, 
*P<0.05, **P<0.01, significance assessed by Mann-Whitney U test 
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4.4 Discussion 
Our studies on BACH2 in T cell-specific knock out mice have demonstrated a T cell intrinsic 
role for BACH2 in the development and maintenance of Treg cells, as well as CD4+ T cell 
polarisation. Our data also suggests that T cell BACH2 can influence the development of B 
cells, neutrophils and monocytes. In addition to this, T cell intrinsic BACH2 supported T cell 
expansion and survival during chronic infection, especially in the Treg cell compartment. 
These findings are consistent with those reported in other studies272,273,283, and add to our 
knowledge about the role of BACH2 in various CD4+ T cell subsets. Our results indicate that 
T cell specific BACH2 deficiency mainly affects Th17 and Th2 cell development and 
maintenance. However, malaria and leishmaniasis are not strongly influenced by Th17 and 
Th2 cells, which may explain why a relatively minor effect on disease outcome was found in 
the experimental malaria and VL models we employed. The differences in outcome of 
severe malaria in wild-type (C567BL/6J) and litter mate control (B6.Bach2fl/fl) mice also 
suggest a deviation in the genetic background of B6.Bach2fl/fl mice, or a change in the 
expression of the Bach2 gene as a result of flow allele introduction, which increases disease 
resistance, this may mask the effect of a loss of T cell specific BACH2 in B6.Bach2ΔT mice. 
Future studies on T cell BACH2 using these mice might best be directed towards disease 
where these CD4+ T cell subsets are more important, such as multiple sclerosis or asthma, 
which are strongly Th17 or Th2 cell-dependent, respectively. 
NanoString assessment of CD4+ T cells from human peripheral blood showed that BACH2 
was down regulated during P. falciparum infection (see Chapter 3, Fig 3.2B). This is 
consistent with results from other studies that indicate that BACH2 needs to be down 
regulated to allow T cells to be activated and function effectively272,273,284. Hence, we may 
not have seen major changes in mice with Bach2-deficient T cells during infection because 
the gene was already down regulated. Any differences would likely to occur during the initial 
response to infection, and therefore, studying earlier time points after infection might reveal 
these effects. Also, given the down-regulation of Bach2, it may be informative to examine 
the impact of Bach2 over-expression during infection. 
We found that T cell-specific Bach2 expression suppressed Th2, Th17 and Tfh cell 
development and/or activation. Similar results have been observed in experiments involving 
cells from mice with ubiquitous Bach2-deficiency272,281. However, a problem with interpreting 
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results from these experiments was the difficulty in eliminating the possibility that Bach2-
deficiency in a non-T cell population impacted T cell development, and was therefore 
responsible for changes observed. Our data suggests that T cell intrinsic BACH2 plays an 
important role in regulating Th2 cell cytokine production. This result may have been skewed 
by our use of Th2 cytokines in Th2 culture conditions, however, this is unlikely as IL-4 is at 
similar levels in Th0 cultures which received no IL-4.  Other studies have shown that BACH2 
also supresses Th1 and Th17 cytokine production272,284. Our data supports this role for T 
cell intrinsic BACH2 in Th17 cells, albeit not as clearly as in Th2 cells, but we find a limited 
effect on Th1 cell cytokine production. Previous work has also shown the potential for a role 
of BACH2 in Tfh cell development, as it influences IL-6 expression285. Our data supports this 
finding by showing that BACH2 is needed for optimal T cell IL-6 production. BACH2 works 
in synergy with BCL6 in germinal center B cells to coordinate gene expression286, and since 
Bcl6 is a Tfh cell lineage marker, it is also possible that BACH2 interacts with Bcl6 in a similar 
manner to influence Tfh cell development. However, rather than supporting Tfh cell 
development, our findings suggested that BACH2 suppressed the development of CXCR5+ 
PD1+ Tfh cells under Tfh cell polarising conditions in vitro. The apparent need of BACH2 for 
optimal IL-6 production is at odds with these observations, indicating a more complex role 
for BACH2 in Tfh cell development. IL-6 levels in culture may also have been influenced by 
the inclusion of IL-6 in Tfh polarisation conditions, as such assessment of Tfh surface 
markers CXCR5 and PD1 is likely a more reliable marker of the influence of BACH2 on Tfh 
development. Our results also suggest that wild-type cells have superior proliferation or 
survival capability than cells lacking Bach2 expression, this may also influence the amount 
of cytokine produced in culture giving rise to the conflicting cellular and cytokine data. 
Further experiments assessing amount of cytokine produced on a per cell basis would be 
helpful in discerning this. This was not evaluated here, but will be important to measure in 
future experiments. Given the minimal impact of T cell-specific Bach2 deficiency in malaria 
and VL, it may be productive to investigate the role of BACH2 in Tfh cell development in 
diseases such as rheumatoid arthritis and multiple sclerosis, where Tfh cells play a 
prominent role. 
Current evidence from others272,275, along with our results, indicates that BACH2 has the 
most prominent role in Treg cell development and maintenance. We showed that T cell 
intrinsic BACH2 was important for Treg cell development and/or maintenance during malaria 
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and VL. Intriguingly, our results suggest that BACH2 has tissue-specific effects on Treg 
cells, whereby Bach2-sufficient Treg cells appear to have a developmental advantage in the 
spleen, but are outcompeted by Bach2-deficient Treg cells in the liver. Given that these two 
organs have different infection outcomes during L. donovani infection, it is possible that 
acute, resolving hepatic infection and chronic splenic infection may contribute to these 
differences in Treg cell BACH2 requirement. 
There is little information regarding the mechanism by which BACH2 influences Treg cell 
development and/or maintenance. One possibility is that BACH2 regulates BLIMP1 
activities287. However, Kallies et al. showed that BLIMP1 was not required for Treg cell 
development and function in a model of colitis, even though it was essential for their 
production of IL-10 288. We previously showed that BLIMP1 does not influence Treg function 
in VL, although BLIMP1 was needed for Treg cell IL-10 production37. This was supported by 
results from others showing that BLIMP1 drove IL10 production by a mucosal population of 
Treg cells in an IRF4-dependent manner289. Therefore, although BACH2 may interact with 
BLIMP1 to influence CD4+ T cell development and differentiation287, our results indicate that 
this interaction is not important for Treg cell development and/or maintenance. 
As mentioned earlier, BACH2 impacts the terminal differentiation of CD8+ T cells by 
controlling availability of transcription factor binding sites, and in particular, by controlling 
AP-1 availability273. It is possible that BACH2 acts in a similar manner to influence 
development of different CD4+ T cell populations. NF-kB and AP-1 family members are 
required for full Th2 cell differentiation, and the Th2 cell cytokines IL-4, and IL-13 have AP-
1 binding sites in their promoters290,291. Thus, BACH2 may inhibit the expression of these 
genes by preventing AP-1 binding, and therefore prevent their transcription and subsequent 
expression. Support for this mechanism came from studies using an AP-1 decoy molecule, 
which was used to block IL-4 and IL-13 production, and ameliorate disease symptoms in a 
model of asthma292. NF-kB/AP-1 binding was also increased in rheumatoid arthritis 
patients293, and similarly, NF-kB/AP-1 expression was correlated with type-1 diabetes 
pathogenesis294. Given that both diseases are associated with BACH2 dysregulation264,295, 
this may contribute to aberrant NF-kB/AP-1 expression. Lesniewski et al. also hypothesise 
that the homology between BACH2 and AP-1 sequences may allow BACH2 to bind in place 
of AP-1 in umbilical cord blood, where BACH2 was shown to regulate IL-2 expression296. 
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Therefore, one mechanism by which BACH2 may influence T cell differentiation and disease 
outcome is by competing with AP-1 for DNA binding. 
The loss of Treg cells in the absence of T cell-specific BACH2 may involve changes in the 
regulation of apoptosis, as the JNK/AP-1 pathway has been associated with apoptosis in 
synovial cells in rheumatoid arthritis297, and several studies have implicated BACH2 in 
promoting apoptosis. For example, in B cells, BACH2 facilitates apoptosis by suppressing 
anti-oxidative and anti-apoptotic genes298,299. However, Roychoudhuri et al. showed that 
BACH2 was essential for development and homeostasis of Treg cells272. They also showed 
that a loss of BACH2 resulted in CD8+ T cell apoptosis 5-10 days after viral infection273. This 
role for BACH2 may help explain the loss of Bach2-deficient Treg cells we observed in the 
spleen during P. chabaudi infection. Roychoudhuri et al. also found apoptosis to be 
associated with reduction in anti-apoptotic Bcl-2 family proteins Bcl-xL and Mcl-1273. 
Interestingly, BACH2 has been associated with Bcl-2 and Mcl-1 in other disease settings295. 
Therefore, although BACH2 is pro-apoptotic in B cells, it appears to act in an anti-apoptotic 
manner in CD8+ T cells, and if it exists in a similar role in CD4+ T cells, this may explain 
some of our findings.  
In this Chapter, we showed BACH2 to be an important intrinsic factor in CD4+ T cells during 
cell differentiation in vitro and during parasitic infection, and has been described in an article 
recently accepted for publication. We showed that T cell-specific BACH2 modulates Th2, 
Th17, Tfh, and Treg cell differentiation, and suppressed effector CD4+ T cell responses 
during infection. However, BACH2 appeared to be important for the expansion and/or 
maintenance of splenic Treg cells during infection, and a possible mechanism for this role 
may be via regulation of AP-1 binding to cell lineage-specific genes and anti-apoptotic 
genes. 
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5.1 Introduction 
Immune regulation determines the balance between immunopathology and disease 
resolution. Many factors contribute to immune regulation and immunosuppressive cytokines 
are particularly important as they temper the functions of inflammatory cells. One such anti-
inflammatory cytokine is IL-10. 
5.1.1 IL-10 is an important immune regulator 
IL-10 plays an important role in immune regulation and is produced by a number of innate 
and adaptive immune cells, including DCs, NK cells, eosinophils, neutrophils, B cells and T 
cells (reviewed in137). It signals via a heterodimeric receptor (IL10R1/2) to activate the 
JAK/STAT pathway and acts mainly on leukocytes to suppress their differentiation and 
inflammatory functions (reviewed in137). IL-10 is critical for protection against excessive 
inflammation and deficiencies result in a number of autoimmune diseases, including 
spontaneous colitis300 and arthritis301.  IL-10 also protects against systemic lupus 
erythematosus302, and experimental autoimmune encephalitis303 (EAE) in mice, and is 
positively associated with reduced severity of many inflammatory diseases in humans304,305. 
Regulatory T cells are prominent producers of IL-10. Foxp3+ CD4+ T cell derived IL-10 is 
important for regulation of inflammation at environmental interfaces such as the lung, gut 
and skin306. Chronic antigen stimulation can also induce IL-10 production in Foxp3- CD4+ T 
cells, such as effector Th1 and Th17 cells155,307. It has been suggested that this is a self-
limiting response which protects against excessive inflammation. In this chapter, the focus 
will be on Th1-like IL-10-producing cells (Tr1 cells) which are implicated in a number of 
diseases, but also have the potential to be manipulated to improve disease outcome. 
5.1.2 Tr1 cells: immune regulators during disease 
Tr1 cells have been identified in a number of diseases where they play an 
immunosuppressive role which protects against immunopathology. However, in infectious 
diseases, this can also be to the detriment of pathogen clearance. 
Tr1 cells have been identified among tumour infiltrating lymphocytes (TILs) in various 
cancers and are likely part of the anti-tumour repertoire induced by cancerous cells as they 
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are immunosuppressive and become more prevalent at tumour sites as disease 
progresses308,309. They are 50-fold more suppressive than their Foxp3+ Treg counterparts in 
colorectal cancer, a characteristic which is attributed to their co-production of IL-10 and 
TGFβ308. IL-10 and TGFβ also confer suppressive function to Tr1 cells in a number of other 
cancers309-311, and other TILs are known to promote a Tr1 suppressive phenotype, including 
pDCs which may mediate upregulation of IL-10 in Tr1 cells via ICOS-ICOSL signalling310.  
Tr1 cells are also induced during parasitic infection. They are the main source of IL-10 in 
VL152, Toxoplasma gondii infection42 and Plasmodium-filariasis co-infection312. IL-10 
production by Tr1 cells prevents excessive inflammation and is critical for host survival in T. 
gondii and T. cruzi infections, where they prevent fatal immune pathologies like 
myocarditis313. They may also contribute to protection against severe malaria seen in 
individuals in malaria endemic regions40. Unfortunately, Tr1 cell-specific IL-10 has also been 
shown to suppress macrophage and effector T cell mediated parasite killing37. 
Tr1 cell-specific IL-10 also plays a role in autoimmune disease and transplant tolerance. IL-
10-dependent immune suppression prevented rejection of allogeneic islet transplants in 
diabetic mice314 and was vital for tolerance of bone marrow transplants236. IL-10 has also 
been actively induced in CD4+ T cells using a lentiviral system to reduce graft-versus-host 
disease315. In autoimmune diseases like inflammatory bowel syndrome, disease can be 
ameliorated by transfer of Tr1 cells316. These cells were required to maintain long term 
tolerance and mediated their protective effect by IL-10. In a mouse model of asthma, Tr1 
cells were also able to suppress allergen-induced effector CD4+ T cell responses and 
consequently protect against airway inflammation317, and Tr1 cells were able to ameliorate 
experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis318. 
Interestingly, environmental factors like sun exposure also influence the role of Tr1 cells in 
autoimmune diseases like multiple sclerosis319. In the majority of cases where Tr1 cells 
suppressed immunopathology, IL-10 expression was a critical factor in reducing 
inflammation. 
5.1.3 Molecular characteristics of Tr1 cells 
A number of studies have contributed to the characterisation of Tr1 cells. They are primarily 
described as being IL-10+ Foxp3- CD25lo IL-2lo IL-4lo CD4+ T cells. They are distinct from the 
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Foxp3+ (Treg cell) lineage, and appear to a have a complimentary role to Treg cells. In a 
number of reports, Tr1 cells co-express IL-10 and IFNγ, and in some cases they 
circumstantially switch between IL-10 and IFNγ production40,42,320. Their potent 
immunosuppressive characteristic is primarily attributed to IL-10, which is known to widely 
suppress inflammatory responses. However, they also express other regulatory molecules, 
including TGFβ, ICOS, and LAG-3254,308,317. In addition to their classical suppressive 
functions, TGFβ and ICOS can act in a positive feedback loop to enhance and maintain IL-
10 production by Tr1 cells, though they are not essential for IL-10 initiation237,238.  
A number of studies have aimed to identify definitive Tr1 cell markers. LAG-3 and CD49b 
co-expression have been used to define a population of human memory CD4+ T cells which 
expressed high levels of IL-10 and low levels of FOXP3254. These markers were also used 
to identify Tr1 cells induced in vitro with IL-10 and IFNα, and in mouse models with colitis or 
helminth infection. Latency-associated peptide (LAP) also defines highly suppressive intra-
tumoral Tr1 cells308. However, Tr1 cell-specific expression of this molecule hasn’t been 
confirmed in other systems. Tr1 cells have also been shown to have increased expression 
of CD226, CTLA-4, HLA-DR and IL-2/-15RB which are predominantly important for Tr1 
mediated cell functions251,254,321. 
5.1.4 Tr1 cell induction 
A number of techniques have been developed to actively induce Tr1 cells. The majority of 
these methods involve in vitro stimulation with αCD3 and αCD28 mAbs along with various 
supplementary cytokines, all of which activate different arms of Tr1 cell differentiation. IL-2 
is an essential growth factor for Tr1 cells and also promotes IL-10 production322. IL-15 has 
been used in combination with IL-2 to enhance Tr1 cell-specific proliferation, an effect which 
has been attributed to higher IL2/IL15Rβ and Rγ chain expression on Tr1 cells, compared 
to Th1 and Th2 cells321. IL-27 has been shown to induce Tr1 cell-associated transcription 
factors like cMaf, Blimp1, and AHR, and is used in combination with αCD3 and αCD28 mAbs 
to induce mouse Tr1 cells237,238,323-325.  
Tr1 cells are often described as being TGFβ producers, but this cytokine can have a 
regulatory effect on Tr1 cells, and in other settings promotes FOXP3+ Treg cell 
development139. As such, it is likely that this cytokine influences the balance between Tr1 
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and Treg cells. IL-10 also acts in an autocrine manner to induce production of IL-10 by Th1 
cells326,327, and is commonly used as a co-factor in Tr1 cultures and stimulation. It is 
sufficient to induce IL-10, but this effect was potentiated when combined with IFNα326.  
CD3 and CD28 stimulation in conjunction with stimulation of other co-stimulatory molecules 
is important for Tr1 cell differentiation. Most effective Tr1 cell induction occurs with chronic 
antigen stimulation; two or three week cell cultures of naïve human CD4+ T cells with DCs 
induced substantial numbers of Tr1 cells254. Antigen presentation in combination with IL-10 
signalling is particularly important138, and exogenous IL-10 in combination with allogeneic 
monocytes has been shown to induce high levels of IL-10 production by CD4+ T cells328. 
Additionally, a recently described subset of IL-10 producing DCs (DC-10) has been shown 
to induce Tr1 cells329. Interestingly, pDC can also induce Tr1 cells, and this may be facilitated 
by their ability to produce IFNα330. 
Other mechanisms of Tr1 cell induction have included forced expression of IL-10 via 
lentiviral transduction315 and in vivo use of the mTOR inhibitor rapamycin, which induced 
Tr1 cell differentiation314. There are many different pathways represented in these Tr1 cell 
induction techniques, suggesting that the development of these cells can be triggered in 
many different settings. These observations also shows the need for a more integrated 
understanding of Tr1 cell biology. 
5.1.5 Tr1 cell transcription factors and cytokines 
As illustrated by the plethora of Tr1 cell induction strategies, defining a pathway for Tr1 cell 
induction has been difficult. A number of cell signalling and transcriptional signatures have 
been identified as being important for Tr1 cell induction. Unlike classical CD4+ T cell subsets, 
Tr1 cells do not appear to have a sole transcription factor governing their differentiation.  
IL-10 is the primary defining factor for Tr1 cells. Various transcription factors have been 
shown to directly, or indirectly activate IL-10 transcription in Tr1 cells. BLIMP1 is a well-
known inducer of IL-10 in vitro and during parasitic infections and binds directly to the IL-10 
promoter139. cMAF and AHR are also important for IL-10 production in Tr1 cells238. These 
transcription factors act in synergy with each other and other transcription factors like IRF4 
to activate IL-10 transcription289,317. cMAF and AHR also trans-activated the IL-21 gene 
promoter which acts in a positive feedback loop to induce cMAF, AHR, which in turn 
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potentiates IL-10 production238. The STAT family of transcription factors is heavily 
associated with Tr1 cell development. IL-10 is able to be induced via phosphorylation of 
STAT1, and activation of STAT3 leads to the induction of IL-10 via cMAF, AHR, IRF4 and 
IL-21325,331. STAT3 also activates the ERG-2/BLIMP1/IL-10 pathway in Tr1 cells332, and 
STAT4 is associated with epigenetic changes in the IL-10 promoter139. 
A variety of cytokines induce these different transcriptional pathways. IL-27 is best 
described, and induces most of the Tr1 cell transcriptional pathways139,323-325. IL-27 is critical 
for the initial burst of IL-10 in Tr1 cells, while other molecules like IL-10, TGFβ, and ICOS 
maintain IL-10 expression. Other cytokines important for IL-10 production include IL-12, 
which induces IL-10 via STAT4 and BLIMP1, and IL-6 which induces STAT3 and STAT5 
pathways322,332. 
5.1.6 Tr1 cells: a further differentiated population 
Our current knowledge of Tr1 cells suggests that they are a further differentiated T cell 
population, rather than a distinct T cell lineage. This is indicated by the fact that a unique 
transcription factor has not been identified for these cells. Additionally, Tr1 cells require 
chronic stimulation to be induced in vivo, suggesting that an earlier developed population 
gains Tr1 cell characteristics with time138. Interestingly, EOMES, which also induces IL-10 
expression in Tr1 cells, was initially activated by the Th1 transcription factor TBET, and in 
addition to IL-10 induction, down-regulates other T helper lineage transcription factors, 
including GATA3 and RORγT, suggesting that Tr1 cells are part of the Th1 cell lineage236. 
It is also likely that effector T cells are induced to produce IL-10 under specific 
circumstances. For example, melatonin levels impacted Tr1 cell development via RORα, 
cMAF, AHR and IL-21, and alter the severity of rheumatoid arthritis in a seasonal manner319. 
Studies in colitis and EAE have also shown that metabolic status influences Tr1 cell 
differentiation331,  offering added complexity to the development of these cells. 
5.1.8 Characterising Tr1 cells in parasitic infection 
Many different pathways influence Tr1 cell differentiation. Work is still needed to define the 
core Tr1 cell signature. It is hypothesised that Tr1 cells differentiate from the Th1 cell 
population. Here, we used RNAseq to compare gene signatures in Tr1 and Th1 cells from 
human volunteers participating in CHMI studies with Plasmodium falciparum, as well as from 
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mice with experimental VL caused by infection with Leishmania donovani, to define a Tr1 
profile which is independent of host and infection type. Furthermore, we validated the 
expression of a number of the molecules identified, which included a variety of chemokine 
receptors, immune checkpoint inhibitors, and transcription factors. We identified the PBX1 
transcription factor as an important regulator of Th1 cell cytokine production in our studies. 
Additionally, LAG-3 was up-regulated in Tr1 cells at both the RNA and protein level. We 
showed that blockade of LAG-3 modulated Tr1 cell function. During experimental VL, both 
ex vivo and in vivo blockade of LAG-3 reduced Tr1 cell numbers which corresponded with 
reduced parasite burden in vivo. Additionally, LAG-3 blockade increased parasite-specific 
IFNγ production in VL patient whole blood assays, as well as antigen-specific IFNγ and TNF 
by murine splenocytes. Together these data identify LAG-3 as a potential immune 
checkpoint target for modulation during parasitic diseases like malaria and VL. 
5.2 Methods 
Please refer to the indicated sections from chapter 2 for full descriptions of each method  
Buffers, Media and other reagents (section 2.1) 
Mice (section 2.2) 
Parasites and infections (section 2.3) 
Leishmania donovani in mice (section 2.3.3) 
In-vivo antibody blockade 
Controlled Human Malaria Infection (CHMI) studies (section 2.3.4) 
Blood collection from human Visceral Leishmaniasis study (section 2.3.5) 
Sample processing (section 2.4) 
Mouse samples (section 2.4.1) 
Human samples (section 2.4.2) 
Cell counting (section 2.4.3) 
Flow cytometry (section 2.5) 
Cytokine analysis (section 2.5.1) 
Cellular analysis (section 2.5.2) 
Cell sorting (section 2.5.3) 
Equipment and analysis (section 2.5.4) 
Ex-vivo assays (section 2.6) 
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Polarisation (section 2.6.1) 
Antibody blockade (section 2.6.2) 
Check-point molecule blockade in Mouse L. donovani splenocyte cultures 
Check-point molecule blockade in CHMI PBMC cultures 
Whole blood assay: Check-point molecule blockade in Human VL PBMC 
cultures 
Genetic, epigenetic and transcription factor analysis (section 2.7) 
RNA isolation (section 2.7.1) 
qPCR (section 2.7.2) 
RNAseq (section 2.7.4) 
Chromatin immunoprecipitation (section 2.7.6) 
Granuloma immunohistochemistry (section 2.8) 
Adoptive transfer (section 2.10) 
Statistical analysis (section 2.11)  
5.3 Results 
5.3.1 Sorting Tr1, Th1 and unactivated CD4+ T cell populations 
To identify a molecular signature which was unique to Tr1 cells, and in particular, different 
to Th1 cells, we isolated Th1 (IFNγ+ IL-10-) cells, Tr1 (IFNγ+ IL-10+) cells and unactivated 
(IFNγ- CCR7+) CD4+ T cells from subjects taking part in CHMI studies (Fig. 5.1). Cells were 
isolated from CD14- CD16- CD19- CD8- CD4+ PBMCs at 14 days post-infection using MACS 
purification, followed by cell sorting. We initially aimed to sort these populations based on 
their expression of the Tr1 markers LAG-3 and CD49b254. However, these markers did not 
consistently define Tr1 cells in our samples. Therefore, we used a cytokine capture assay 
to identify IL-10- and IFNγ-producing cells. This method avoided the loss of nucleic acid 
integrity caused by standard intracellular staining. qPCR was used to validate the identity of 
the sorted populations (Fig. 5.2).  
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Figure 5.1 | Methodology for identifying a Tr1 cell-specific transcriptional signature. 
Human PBMCs were purified from whole blood taken from subjects at day 14 of P. 
falciparum infection. CD4+ T cells (CD14- CD16- CD19- CD8- CD4+) were then sorted from 
this population by MACS purification, and stimulated in culture at 37⁰C with PI media (see 
table 2.1.1) for 5 hours prior to being sorted into unactivated (IFNγ- CCR7+), effector 
(IFNγ+IL-10-) and Tr1 (IFNγ+IL-10+) cell populations using flow cytometry. Mouse 
lymphocytes were purified from the spleens of C57BL/6J mice at day 14 of L. donovani 
infection. CD4+ T cells (CD4+ CD8-) were then sorted from splenic lymphocytes by MACS 
purifications, and simulated in culture at 37⁰C with PI media (see table 2.1.1) for 3 hours 
prior to being sorted into unactivated (IFNγ- IL-10-), effector (IFNγ+IL-10-) and Tr1 (IFNγ+IL-
10+) cell populations using flow cytometry. Messenger RNA extracted from these cells was 
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then sequenced and bioinformatic analysis was used to identify genes differentially 
expressed (DEGs) between Th1 and Tr1 cells. Mouse and human DEGs were then 
compared to determine a core gene signature commonly differentiated in Tr1 cells in 
comparison to Th1 cells across different hosts and diseases. Figure drawn by: S. Ng, 
Immunology and Infection Laboratory, QIMR Berghofer.  
5.3.2 A human Tr1 cell signature 
We next used RNAseq to assess the transcriptional profiles of human Tr1 cells. 
Bioinformatic analysis revealed Tr1 and Th1 cells to be very similar (Fig. 5.3 A-C). 10.7% 
(1443/13,448) of assessed genes were differentially expressed between the two 
populations. 614 of these were up-regulated in Tr1 cells, while 829 were down-regulated. 
IL-10 was most differentially regulated between the two populations, while IFNγ was 
commonly expressed, again validating the integrity of the sorted populations. Some of the 
genes most differentially regulated in Tr1 cells included RASGRP4, KRT8, and ABCB1. 
 
Figure 5.2 | Validation of IL-10 and IFNγ expression on sorted Th1 and Tr1 cells.  
IL-10 and IFNγ expression levels were confirmed in A) human and B) mouse unactivated, 
Th1 and Tr1 cells by qPCR. Expression was relative to the mean expression of the house 
keeping genes HPRT1 and GAPDH, n=2, human cohort 9. 
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Ingenuity Pathway Analysis (IPA) of the differentially expressed genes (DEGs) predicted a 
number of pathways to be differentially regulated in these cells (Fig. 5.3 D-F). Analysis of 
canonical pathways showed that a significant proportion of genes were differentially 
regulated in 226 pathways (P>0.05, or –Log(P-value)>1.3, Fig. 5.3D). Of these, 156 
pathways were able to be assessed for patterns in regulation. 68 of these were predicted to 
be significantly up- or down-regulated in Tr1 cells, relative to Th1 cells (Z-score less than -
2 or greater than 2). Some of the most significantly changed pathways were cell signalling 
pathways, including NF-kB, cancer and cytokine signalling. Analysis of disease and function 
pathways showed that over 500 pathways had a significant proportion of genes which were 
differentially regulated between Tr1 and Th1 cell populations (P>0.05, or –Log(P-value)>1.3, 
Fig. 5.3). Pathways related to organismal injury and abnormalities, cancer, cell death and 
survival, and haematological system development and function were most highly 
represented (Fig. 5.3E). Of the top 500, 327 were able to be assessed for patterns in 
regulation. 64 of these were predicted to be down-regulated in Tr1 cells, relative to Th1 cells 
(Fig. 5.3F). No disease and function pathways were up-regulated. Some of the pathways 
predicted to be most significantly changed (Z-score less than -2 or greater than 2) included 
cell movement and migration, and development of haematopoietic and bone marrow cells. 
Interestingly, DNA binding and interaction were also included in the top 20 pathways, 
suggesting that there may be epigenetic differences between these populations.  
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Figure 5.3 | Human Tr1 cell signature. 
A) Human unactivated, effector and Tr1 cell populations were sorted from PBMCs 14 days 
after P. falciparum infection (see figure 5.1 for details). B-C) Comparative analysis showed 
1,443 DEGs in Tr1 cells in comparison to Th1 cells. Genes with a –log(P-value) >1.3 were 
considered to be significantly differentially expressed, N=6. 614 genes were up-regulated in 
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Tr1 cells while 829 were up-regulated in Th1 cells, 12,005 genes were similarly expressed 
between the two populations. D) Top 15 IPA canonical pathways predicted to be 
differentially regulated in Tr1 cells, E) IPA disease and function categories most influenced 
in Tr1 cells. Most influenced categories were defined as those which were used with the 
most frequency to classify significantly affected disease and function pathways (P<0.05, z-
score not accounted for). Total number of significantly affected disease and function 
pathways = 500. F) Top 20 IPA disease and function pathways predicted to be differentially 
regulated in Tr1 cells. Pathways were ranked by most significant z-score where P<0.05 (-
Log(P-value) of 1.3, marked by black dotted line), Z-score was considered significant if it 
was less than -2 or greater than 2. Square symbols mark –Log(P-values) against the upper 
x-axis, grey bars mark z-scores against the lower x-axis. Cohorts 10 and 13-15. 
5.3.3 A mouse Tr1 cell signature 
To further refine a signature specific to Tr1 cells we assessed this population in a second 
host (mouse) and disease (VL). Tr1 cells develop during VL, and play an important role in 
controlling inflammation37. We isolated Th1 (IFNγ+ IL-10-) cells, Tr1 (IFNγ+ IL-10+) cells and 
unactivated (IFNγ- IL-10-) CD4+ T cells from the spleens of C57BL/6J mice infected with L. 
donovani, 14 days post-infection. IFNγ- IL-10- CD4+ T were presumed to be unactivated as 
the dominant CD4+ T cell response in leishmaniasis is a Th1 response, therefore any IFNγ- 
cells were likely unactivated (including naïve) as opposed to other T cell subsets such as 
Th17 or Tfh cells, however, there is the possibility that these populations were included in 
the IFNγ- IL-10- population; this must be taken into consideration when interpreting results.  
RNAseq analysis of these cells revealed only 99 genes out of 11,954 (0.8%) were 
differentially expressed in mouse Tr1 cells in comparison to Th1 cells (Fig. 5.4A-C). 79 of 
these were up-regulated in Tr1 cells and the remaining 20 were down-regulated. As was the 
case for the human Tr1 cells, IL-10 was most significantly up-regulate in mouse Tr1 cells in 
comparison to Th1 cells. Other up- or down-regulated genes included Havcr2, Gzmb, 
Prdm1, and Ap4b1. IPA of these DEGs predicted a significant proportion of genes to be 
differentially regulated in 195 canonical pathways (P>0.05, or –Log(P-value)>1.3). Of the 
122 pathways which were able to be assessed for patterns of regulation, only 12 were 
predicted to be significantly differentially regulated in Tr1 cells, compared to Th1 cells (Z-
score less than -2 or greater than 2, Fig. 7.4D). Ten of these were also predicted to be 
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similarly changed in the human data set (Fig. 5.5 A). Over 500 disease and function 
pathways were significantly influenced. Out of the top 500, 452 were able to be assessed 
for regulation patterns. 46 of these were predicted to be up- or down- regulated in Tr1 cells, 
compared to Th1 cells. Again, organismal injury and abnormalities, cancer, cell death and 
survival, and haematological system development and function classifications were most 
represented among disease and function pathways (Fig. 5.4E-F). However, none of these 
pathways were predicted to be similarly up- or down-regulated in humans. Two pathways 
overlapped between mouse and human data sets, however, activation was predicted in 
opposite directions; Leukocyte migration and leukopoiesis were predicted to be up-regulated 
in mouse Tr1 cells, but down-regulated in human Tr1 cells. 
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Figure 5.4 | Mouse Tr1 cell signature. 
A) Unactivated, Th1 and Tr1 cell populations were sorted from splenic cells 14 days after L. 
donovani infection in C57BL/6J mice (see Fig. 5.1 for details). B-C) Comparative analysis 
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showed 99 DEGs in Tr1 cells in comparison to Th1 cells. Genes with a –log(P-value) >1.3 
were considered to be significantly differentially expressed, N=5. 79 genes were up-
regulated in Tr1 cells, while 20 were up-regulated in effector cells. 11,855 genes were 
similarly expressed between the two populations. D) IPA canonical pathways predicted to 
be differentially regulated in Tr1 cells, E) IPA disease and function categories most 
influenced in Tr1 cells. Most influenced categories were defined as those which were used 
with the most frequency to classify significantly affected disease and function pathways 
(P<0.05, z-score not accounted for). Total number of significantly affected disease and 
function pathways = 500. F) Top 20 IPA disease and function pathways predicted to be 
differentially regulated in Tr1 cells. Pathways were ranked by most significant z-score where 
P<0.05 (-Log(P-value) of 1.3, marked by black dotted line). Z-score was considered 
significant if it was less than -2 or greater than 2. Square symbols mark –Log(P-values) 
against the upper x-axis, grey bars mark z-scores against the lower x-axis.  
5.3.4 A core Tr1 cell signature: independent of host and parasitic infection. 
We next compared mouse and human DEG data sets to identify a Tr1 cell signature which 
was independent of host and disease type. In doing this, we found a core signature of 26 
DEGs which were similarly differentially regulated in both mouse and human Tr1 cells (Fig. 
5.5 B-C). Genes in this list had a wide variety of functions and included extracellular matrix 
proteins, chemokine receptors, immune checkpoint molecules, histone proteins, and 
transcription factors – indicating broad spectrum differences in the profiles of these two 
populations. Reassuringly, this list also included some molecules which are already known 
to be associated with Tr1 cells, including MAF and LAG-3. 
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Fig. 5.5 | Core Tr1 cell signature. 
A) Canonical pathways predicted to be similarly differentiated in both human and mouse Tr1 
cells. Square symbols mark –Log(P-values) against the upper x-axis, -Log(P-value) of 1.3 
(P<0.05) marked by black dotted line), grey bars mark z-scores against the lower x-axis. B) 
Comparative analysis showed 26 DEGs between Th1 and Tr1 cells in both Human P. 
falciparum and Mouse L. donovani infection. C) Fold change in commonly differentially 
expressed genes, in Tr1 cells in comparison to Th1 cells, in Human (black) and Mouse 
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(white) samples. D) qPCR validation of select DEGs in mouse samples 14 days post L. 
donovani infection. Relative fold change (RFC) in gene expression in Tr1 cells in comparison 
to effector cells, normalised to the house keeping genes HPRT and β-actin, assessed by 
qPCR, where a RFC above 1 is an increase, RFC below one is a decrease. n=6. Cohorts 
10 and 13-15. 
5.3.5 LAG-3 regulates Tr1 cells in blockade enhanced parasite control. 
To further investigate molecules with the potential to modulate Tr1 cell function we selected 
cell surface molecules which are known to influence cell functions including chemokine 
receptors CCR5, and CCR2, and immunoregulatory molecules TIM-3 (Havcr2), CTLA-4, 
Galectin-3 (GAL-3), and LAG-3. qPCR confirmed in both mouse and human Tr1 cells that 
RNA levels for all molecules followed similar patterns of up- and down-regulation seen in 
the RNAseq data, with the exception of CCR5 (Fig. 5.5 D). We then went on to investigate 
the expression of these molecules at the protein level in Tr1 and Th1 cells from mice infected 
with L. donovani for 14 days (Fig. 5.6 A-B), and humans infected with P. falciparum for 14 
days (Fig. 5.6 C-D). LAG-3, CTLA-4, CCR2 and CCR5 were consistently up-regulated in 
Tr1 cells, irrespective of host and infection. GAL-3 and TIM-3 were varied in their expression 
across hosts in multiple experiments, and as such, were excluded as reliable Tr1 cell 
markers.  
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Fig. 5.6 | Protein validation of commonly differentially expressed genes in effector 
and Tr1 cells. 
A) Mouse, and C) Human Tr1 and Th1 cells were incubated with PIB for 3 hours or BFA for 
5 hours, respectively, and assessed for surface expression or Galectin-3, LAG-3, TIM-3, 
CTLA-4, CCR2, and CCR5 using flow-cytometry. B and D) Marker expression was 
measured by fluorescence index, which was defined as frequency of positive cells multiplied 
by the median fluorescence index of the population. B) Mouse, 14 days post L. donovani 
infection in C57BL/6J mice, n=5. D) Human, 16 days post P. falciparum infection, n=7, 
cohorts 10-12 and 14. Paired T-test used where data was normally distributed (as assessed 
by Shapiro-Wilk normality testing, P>0.05), Wilcoxon test was used if otherwise *P≤0.05, 
**P≤0.01, ***P≤0.001 Representative of 2 experiments (except for mouse Gal3). 
A number of these molecules are known to regulate T cells333,334 and pose as potential 
targets for modulation of Tr1 cell function. To investigate the role of these molecules in Tr1 
cells in vitro, we re-stimulated human PBMCs from day 14 post-P. falciparum infection with 
P. falciparum antigen (iRBC) and concurrently blocked either CTLA-4, LAG-3, TIM-3, or 
Galectin-3 using mAbs against these molecules (Fig. 5.7). We then assessed CD4+ T cell 
frequencies and cytokine levels in cell culture supernatants. Blocking these molecules on 
their own or in combination (combination data not shown) did not influence Th1 or Tr1 cell 
frequencies (Fig. 5.7B-C); neither did it influence production of the Tr1 and Th1 cell 
cytokines IFNγ and IL-10 (Fig. 5.7D-E), suggesting that these molecules do not have a 
functional role in antigen specific CD4+ T cell response to Plasmodium. However, 
restimulating splenocytes from mice infected with L. donovani with parasite antigen (fixed 
amastigotes) in combination with αLAG-3 mAb induced elevated levels of TNF and IFNγ in 
culture supernatants, indicating that LAG-3 can suppress antigen-specific inflammation 
(Fig.5.8A-B). Concurrently, Tr1 cell frequencies dropped, suggesting that LAG-3 may 
function through Tr1 cells to mediate this suppression of inflammation (Fig.5.8C). In support 
of this, in vitro blockade of LAG-3 in whole blood cultures from human VL patients in India 
also resulted in increased in IFNγ levels in response to parasite antigen stimulation (Fig. 
5.8D), and in vivo blockade of LAG-3 was able to reduce liver parasite burden in murine VL 
in conjunction with reduced Tr1 cell frequencies (Fig. 5.8E-F). 
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Figure 5.7 | Blocking immune checkpoint molecules at 14 days post-P. falciparum 
infection doesn’t impact Tr1 cell expansion. 
Human PBMCs isolated at 14 days post-infection were cultured on their own, or with naïve 
RBCs (nRBC), or with P. falciparum infected RBCs (iRBC) with blocking mAbs antibodies 
(αCTLA4, αGalectin-3, αTIM-3, αLAG-3, or their respective isotype controls), as indicated. 
A) Th1 and Tr1 cells were assessed at 72 hours by flow cytometry. Frequency of B) Th1 
cells and C) Tr1 cells. D) Concentration of IFNγ in culture supernatants after 24 hours. E) 
Concentration of IL-10 in culture supernatant after 72 hours. N=7, representative of 2 
experiments. Cohorts 10-12 and 14. 
5.3.6 PBX1 binds the IL-10 promoter in Tr1 cells 
In addition to chemokine receptors and regulatory molecules, a few transcription factors 
were also up-regulated in both mouse and human Tr1 cell RNAseq data sets. Currently, Tr1 
cells are not defined by a unique transcription factor, though a number do contribute to their 
function and phenotype. MAF is one of these, and was up-regulated in our RNAseq data 
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sets. Other transcription factors and molecules with DNA binding capacity up-regulated in 
both our mouse and human RNAseq data sets included PBX1, NEAT1 and ZMYND8 (Fig. 
5.5 C). PBX1 has been shown to bind the IL-10 promoter and control IL-10 expression in 
macrophages following stimulation with apoptotic cells335. Therefore, it has the potentially to 
function in a similar manner to control IL-10 expression in Tr1 cells. To determine whether 
or not this was the case, ChIP PCR was used to assess the binding of PBX1 to the IL-10 
promoter in Tr1 cells pooled from multiple mice, where CD4+ T cells had been polarised in 
vitro under Tr1 cell conditions (Fig. 5.9). PCR analysis identified 3 putative PBX1 consensus 
binding sites -3358, -2949, and -2047 bp from the IL-10 transcriptional start sight (TSS) (Fig. 
5.9A). ChIP PCR showed PBX1 binding within this region (Fig. 5.9B). Additionally, RNA 
Polymerase II was also found to bind just ahead of PBX1 (Fig. 5.9C), indicating that this site 
is transcriptionally active.  
 
Fig. 5.8 | LAG3 blockade in VL. 
A-C) Mouse splenocytes taken at day 28 post-infection were stimulated with L. donovani 
antigen (LV9) plus control mAb (MAC49) or LAG3 blocking mAbs, as indicated, n=6. A-B) 
After 24 hours TNF and IFNγ were measured in cell culture supernatants, Paired T-test. C) 
After 72 hours the frequencies of Th1 and Tr1 cells were measured, Paired T-test. D) IFNγ 
concentration in the supernatant of whole blood cultures after 24 hrs, from human L. 
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donovani patients, n=6, Wilcoxen test. E-F) Day 28 of L. donovani infection in C57BL/6J 
mice, after treatment with αLAG-3 or isotype control mAbs every three days from day 14 
onwards, n=6. E) Total number of Tr1 cells in the liver, Unpaired T-test. F) Liver parasite 
burden, Unpaired T-test.  *P < 0.05, **P < 0.01, ***P < 0.001. 
5.3.7 PBX1 inhibits parasite control in the liver in association with inhibited 
CD4+ T cell inflammatory response and antigen specificity. 
Since PBX1 bound the IL-10 promoter in Tr1 cells in association with transcriptional 
activation, we employed a T cell specific PBX1-deficient mouse on a C57BL/6J background 
(B6.Pbx1ΔT), produced by in-house crossing of transgenic B6.Cd4-cre mice with B6.Pbx1-
floxed animals (see methods section 2.2 for breeder details), to assess how this molecule 
affected the phenotype and function of Tr1 cells, and whether or not this influenced the 
outcome of parasitic infection. Littermates lacking the cd4-cre transgene (B6.Pbx1fl/fl) were 
used as controls. 
 
Figure 5.9 | PBX1 binds the IL-10 promoter in Tr1 cells in association with promoter 
activation. 
Tr1 cells were sorted from C57BL/6J mouse splenocytes which had been cultured under 
Tr1 cell polarising conditions. Tr1 cells were assess via ChIP for PBX1 and RNA polymerase 
II (RNA Pol II) binding upstream of the IL-10 TSS in the promoter region. A) PBX1 consensus 
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binding sites in the IL-10 promoter, and recruitment of B) PBX1 and C) RNA Pol II across 
the IL-10 promoter (A-F) and in a control region of the genome (HPRT). Data are from 7 
pooled animals, run in technical triplicates. 
 
 
Figure 5.10 | T cell-specific PBX1 deficiency alters CD4+ T cell cytokine production. 
CD90.2+ CD44- CD62L+ CD25- CD4+ T cells were cultured with αCD28 and plate bound 
αCD3 for 24 hours. Concentrations of TNF, IFNγ and IL-10 were measured in cell culture 
supernatants of naïve B6.Pbx1ΔT and litter mate control (B6.Pbx1fl/fl) cultured either under 
neutral conditions (Th0, IL-2 only) or Tr1 cell polarising conditions (IL-2, IL-12, αIL-4, and IL-
27)(described in full detail in section 2.6.1), N=2 technical replicates. 
CD4+ T cells deficient in PBX1 showed a reduced capacity to produce TNF, IFNγ and IL-10 
when stimulated under Tr1 polarising conditions (Fig. 5.10A). We saw a similar trend in 
serum IL-10 levels in B6.Pbx1ΔT mice 14 days post-L. donovani infection. Additionally serum 
IL-17A showed a similar pattern in reduction; however, TNF and IFNγ levels were 
unchanged (Fig. 5.11A). In contrast to in vitro Tr1 cell polarisation, T cell-specific PBX1-
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deficiency during L. donovani infection resulted in an increase in IFNγ and TNF positive cells 
in the liver, while Tr1 cell frequencies and total numbers were unchanged and total leukocyte 
numbers were reduced (Fig. 5.11B-E). This corresponded with increased frequencies and 
total numbers of antigen-specific Th1, TNF+ CD4+ T, and IFNγ+ TNF+ CD4+ T cells, and 
reduced parasite burden in the livers of infected mice (Fig. 5.11E-H), indicating that PBX1 
suppressed CD4+ T cell inflammatory responses. 
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Figure 5.11 | T cell-specific PBX1 deficiency inhibits parasite control and CD4+ T cell 
inflammatory response. 
B6.Pbx1ΔT mice and their litter mate controls (B6.Pbx1fl/fl) 14 days post-L. donovani infection. 
A) Serum cytokine levels. B) Total number of hepatic leukocytes. C) Th1 (IFNγ+ Tbet+), 
TNF+, IFNγ+ Tbet+, and antigen specific (PEPCK+ CD44+)  CD4+ T cells in the liver were 
assessed by flow cytometry. D) Frequencies and E) total numbers of Th1, TNF+, IFNγ+ Tbet+, 
and antigen specific cells within the hepatic CD4+ T cell population. F) Frequencies and G) 
total numbers of Th1 (IFNγ+ Tbet+), TNF+, and IFNγ+ Tbet+ cells within the hepatic, antigen-
specific cell population. H) Liver parasite burden (LDU). N=3-5, an Unpaired T-test with 
Welch’s correction was used where data was normally distributed (as assessed by Shapiro-
Wilk normality testing, P>0.05), otherwise a Mann-Whitney test was used, *P<0.05, 
**P<0.01, ***P<0.001. 
Infection control in the liver is dependent on granuloma formation and function. Since 
infection control was improved with PBX1-deficiency, we assessed granuloma development 
in Rag1-/- mice. These mice lack T and B cells and therefore do not develop granulomas and 
do not control L. donovani infection. Transfer of CD4+ T cells into these mice restored 
infection control in conjunction with granuloma formation. Transfer of PBX1-deficient CD4+ 
T cells into Rag1-/- mice improved liver parasite control in comparison to PBX1-sufficient 
CD4+ T cells (Fig. 5.12A). However, we saw no difference in granuloma numbers or maturity 
(Fig. 5.12B-J), indicating that PBX1 regulates a different aspect of liver parasite control. 
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Figure 5.12 | T cell-specific PBX1 deficiency does not influence hepatic granuloma 
development. 
PBX1 sufficient (B6.Pbx1fl/fl) and PBX1 deficient (B6.Pbx1ΔT) CD4+ T cells were adoptively 
transferred into B6.Rag1-/- mice. Recipient mice were infected with L. donovani and 
assessed 14 days post-infection. Livers were assessed for A) parasite burden (LDU), B) 
number of granulomas per um2, C) ratio of mature granulomas (calculated as number of 
mature granulomas (size>8,000μm2) divided by total number of granulomas), D) number of 
infected Kupffer cells per μm2. E-J) Fluorescent imaging of Liver sections: blue defines 
cellular nuclei, red marks L. donovani, yellow boxes define analysed areas, yellow numbers 
count infected Kupffer cells, light-blue outlines define granulomas, scale bars 200um, E-F) 
RAG1-/-, G-H) B6.Pbx1fl/fl, I-J) B6.Pbx1ΔT **P<0.01, Welch T-test. 
5.4 Discussion 
Using RNAseq we were able to identify molecular signatures which differentiated Tr1 cells 
from Th1 cells in humans with P. falciparum infection, and in mice with L. donovani infection. 
Tr1 signatures spanned involvement in cell movement, death and survival, development, 
growth, and proliferation. We were able to use host specific signatures to further clarify what 
Tr1 cells looked like irrespective of host and parasitic infection. Molecules in this core 
signature included chemokine receptors and regulatory molecules which were also up-
regulated in Tr1 cells at the protein level. Some of these impacted the outcome of VL. The 
regulatory molecule LAG-3 was able to modulate Tr1 cell development and function in VL, 
while the transcription factor PBX1, though it didn’t influence Tr1 cell development or 
expansion, did suppress CD4+ T cell inflammatory responses and parasite clearance during 
murine VL. 
Th1 and Tr1 cells have distinct effector and regulatory functions, respectively. However, our 
data showed that these two populations were transcriptionally very similar. Additionally, Th1 
and Tr1 cells didn’t differentially regulate any of the T-helper lineage master transcription 
factors suggesting that they have a common progenitor. This is supported by current 
literature which suggests that Tr1 cells differentiate from Th1 cells138,236. Our data further 
supports this, as Tr1 cells showed a more mature phenotype, with down-regulation of cell 
survival pathways and upregulation of immune checkpoint markers, such as CTLA-4 and 
LAG-3.  
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In both mouse and human Tr1 cell signatures, a number of signalling pathways were 
predicted to be down-regulated. Some of these are known to promote cell growth and 
survival, including eIF4/p70S6K and ERK/MAPK signalling336,337. Down regulation of these is 
congruous with the Tr1 cell phenotype, which is sometimes described as being 
exhausted315,338. A number of the signalling pathways down-regulated in Tr1 cells are also 
influenced by the Tr1 cytokine IL-10, including integrin signalling, which was suppressed by 
IL-10 in Trichinella spiralis infection339, and actin cytoskeleton signalling which was altered 
by IL-10 in other immune cells340. Other signalling pathways are known to support IL-10 
production in CD4+ T cells, including ERK/MAPK, HGF, and CXCR4 signalling341-343. 
However, these were predicted to be down-regulated in both human and mouse Tr1 cells. 
A number of signalling pathways feed into IL-10 signalling in Tr1 cells. Therefore, it is likely 
that ERK/MAPK, HGF, and CXCR4 signalling pathways have other functions, leaving 
pathways such as MAF signalling to support IL-10 expression. 
Overlapping human and mouse data sets was performed to identify a core molecular 
signature for Tr1 cells which was independent of host and parasitic infection. However, there 
were instances where this method excluded host specific Tr1 genes. For example, Prdm1, 
which is critical for Tr1 cell development and function in mice, was not identified as a Tr1 
cell-specific gene in the human data set. Additionally, our analysis related specifically to 
parasitic infection; therefore, different immune challenges may induce Tr1 cells with different 
molecular signatures. Consequently, this signature is not exhaustive. Rather, in overlapping 
signatures from different hosts and infections we’ve eliminated the majority of genes which 
are variable across parasites and hosts, and highlighted genes which are likely to universally 
contribute to Tr1 cell phenotype and functions. To further validate this, it would be beneficial 
to assess the expression of these core signature genes in other diseases, such as colitis 
and cancer.  
Cellular Movement and Immune Cell Trafficking were categories frequently used to classify 
disease and function pathways differentially regulated in both mouse and human Tr1 cells. 
This change in trafficking was highlighted by 2 chemokine receptors up-regulated in the core 
RNAseq signature and at the protein level. CCR2 and CCR5 are well known for trafficking 
cells to inflamed tissue344. The up-regulation of these chemokine receptors suggests that 
Tr1 cells have a superior ability to home to sites of infection. As a result, they may be better 
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equipped to fulfil their suppressive role than effector T cells are for achieving parasite 
control. If we were to reduce Tr1 cell homing capacity, we may be able to regulate their 
suppression of anti-parasitic responses, and thereby improve parasite clearance. This was 
not assessed in the current work, but would be interesting to investigate in the future. 
Tr1 cells also had increased expression of CTLA-4, LAG-3, and in some cases TIM-3, 
suggesting cellular exhaustion. However, these molecules also have regulatory 
functions133,334. Given that Tr1 cells are immunosuppressive, this signature may not indicate 
exhaustion as much as it reflects the regulatory capacity of these cells. LAG-3 mediates its 
inhibitory effect by competing with CD4 for binding of MHCII and inhibiting down-stream T 
cell activation, including T cell expansion345,346. It is known to be up-regulated in P. 
falciparum infection239, and was more highly expressed on Treg cells than effector CD4+ T 
cells347. In our CHMI studies, we were able to show that LAG-3 was primarily expressed by 
both classical Foxp3+ Treg cells, as well as Tr1 cells during P. falciparum infection. LAG-3 
imparts regulatory function to Treg cells; it is associated with Tr1 cell-mediated amelioration 
of rheumatoid arthritis, and is hypothesised to facilitate cancer progression via Tr1 cells347-
350. However, a functional role for LAG-3 in Tr1 cells in infectious disease has not been 
defined. Here, we showed that blocking LAG-3 suppressed the Tr1 cell population in 
association with better parasite control during VL, suggesting that LAG-3 mediates a 
suppressive effect via Tr1 cells during infection. LAG-3 poses a good target for Tr1 cell 
modulation in other disease settings. Unfortunately, in vitro blockade of LAG-3 and 
combinations of LAG-3 with other regulatory blocks, including αCTLA-4 and αTIM-3 mAbs 
during P. falciparum infection, didn’t have an effect in our hands. This may not be the ideal 
assay to assess LAG-3 function. Blocking LAG-3 (in combination with αPD-1) in vivo was 
able to reverse the exhausted and immunosuppressive phenotype of chronically stimulated 
CD4+ T cells in P. yoelii infection, and enhanced effector function and parasite clearance in 
a CD4+ T cell dependent manner 239. Therefore, it would be beneficial to assess the effect 
of LAG-3 blockade on Tr1 cells in vivo during malaria. 
Tr1 cells do not have a defining transcription factor, although a number of transcription 
factors have been attributed with control of IL-10 production in these cells236,238,317. Given 
that PBX1, a transcription factor and pioneer factor351,352, was transcriptionally up-regulated 
in Tr1 cells in both humans and mice, it was possible that it functioned as a master 
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transcription factor governing the phenotype and function of these cells. However, the 
minimal effect of PBX1 deficiency on Tr1 cell expansion and IL-10 production indicated that 
it doesn’t function in the capacity of a master regulator. Interestingly, although Tr1 cells and 
IL-10 response were unchanged, the inflammatory response was increased with Pbx1-
deficiency. It is possible that PBX1 influenced other molecules in the Tr1 cell signature which 
are involved in the regulation of the effector T cell responses. For example, it may influence 
the regulatory molecule LAG-3. We did not assess this in the current study, but it would be 
worth determining if PBX1 influences the expression of LAG-3 and other inhibitory molecules 
in Tr1 cells. 
The fact that Tr1 cells have been implicated in a number of parasitic diseases, and have 
been identified as a major source of IL-10 in some of these infections, suggests that they 
are a good target for modulation, to alter disease outcome. Improved general knowledge of 
immune regulation in parasitic infection leaves us in good stead to be able to develop 
interventions which improve immune responses following vaccination or drug treatment. 
This body of work improves our understanding of the functions and phenotype of the Tr1 
cell subset which is emerging as an important arm of immune regulation. It also identifies a 
number of Tr1 cell-specific molecules which have the potential to modify immune responses 
and improve disease outcomes. Additionally, the molecular signatures which differed in Tr1 
cells between hosts and infection types offer the potential for host and disease specific 
disease modulation; it would also be valuable to investigate this further. 
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In an environment teaming with pathogens the immune system draws on a complex network 
of inflammatory and regulatory responses to combat an unceasing barrage of exogenous 
and endogenous pathogens. Ideal pathogen clearance and protection relies on a broad 
innate response, followed by targeted adaptive immunity and memory cell response; 
unfortunately, this is often sub-optimal. This is evident in malaria which is characterised by 
overt inflammation which causes pathologies like cerebral malaria133. But at the same time 
there is the emergence of an immune response which is exhausted, suppressive, and which 
does not develop into persistent memory78,231,239,353. This leaves the immune system at a 
severe disadvantage as it works to eliminate the parasite. It also hinders work to eradicate 
the disease in a population. As such, ideal interventions aim to improve anti-parasitic 
immune responses while also inducing protection against pathology.  
The Immune system already has mechanisms in place which protect the host against 
inflammatory damage. This can be seen in experimental cerebral malaria where Treg cells 
are able to prevent brain damage caused by cytotoxic CD8+ T cells133. We also see the 
prominence of a Tr1 cell-like response in mild cases of murine malaria47 and in children with 
high malaria exposure4,40. It has been proposed that this population protects the host against 
immune-mediated pathology. Unfortunately, this regulation is not perfect as it allows 
parasites to persist47.  
Complex networks exist to facilitate very specific and ordered control of immune responses. 
Better understanding of these networks enables us to tailor immune responses to achieve 
better disease outcomes. This concept has been taken forward in the field of personalised 
medicine, predominantly with regards to cancer. It also has the potential to be useful in the 
field of infectious disease, particularly for the improvement of immune responses elicited by 
vaccination. Our work reveals in further detail the nature of the CD4+ T cell responses to 
parasitic infection. In doing so, it also highlights potential immune targets which could be 
manipulated to improve host immunity to these infections. 
Many different transcription factors govern T cell responses. BACH2 is a master regulator 
of the Treg cell population in addition to FOXP3272. Our finding, that BACH2 is intrinsically 
necessary for Treg cell development, corroborates this claim. BAHC2 may mediate this 
effect by regulating cell cycle and survival genes Pdrm1 and Id3, which it has been 
demonstrated to do in CD8+ T cells280. BLIMP1 is also known to regulate development of 
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the Th1 lineage by suppressing Th1 lineage gene expression282, and it has been suggested 
that BACH2 modulates Th1 differentiation by modulation of Pdrm1 expression287. Bach2 is 
also known to favour the Treg lineage, as such is may not only suppress Th1 lineage genes, 
but CD4+ T effector lineage genes in general, in favour of Treg cell development272. Our 
findings also suggest that up-regulation of BACH2 reduces pathology in malaria by 
increasing Treg cell frequencies. If this is the case it would provide the opportunity to develop 
targeted treatments for severe malaria which function by boosting Treg cell frequencies to 
combat cerebral and other severe pathologies; this will require further investigation and 
treatment development. We also showed that the transcription factor PBX1, suppressed the 
CD4+ T cell inflammatory response during VL. The role of PBX1 as a pioneer factor suggests 
that it also plays an overarching role in the development or function of CD4+ T cells, and 
may function by limiting suppressive molecules such as LAG-3 and CTLA-4 which we found 
to be distinctively expressed by Tr1 cells and are also known to be expressed by Treg 
cells133,347. If we can delineate the mechanism of action of PBX1 in CD4+ T cells, we may 
be able to externally modulate its expression to improve parasite clearance. As such it would 
be worth further investigating transcription factor binding in additional CD4+ T cell lineages, 
and using tools developed in this exercise to assess the effect of PBX1 modulation of CD4+ 
T cell function. Our results indicate that the transcriptional regulation which defines CD4+ T 
cell lineage differentiation is more complex than the current FOXP3/TBET/RORγt/GATA3 
lineage transcription factor paradigm, and that layers of transcriptional regulation and 
priming take place in the development of CD4+ T cell lineages. 
We have also identified potential therapeutic targets specific to the Tr1 cell population. IL-
10 is predominantly attributed with giving Tr1 cells their suppressive function37,47,310. 
However, we and others have found that these cells also express a number of other 
regulatory molecules254,308. LAG-3 is the best described regulatory marker in Tr1 cells, after 
IL-10, and has been used in multiple studies to help define Tr1 cells254,308,310. Our finding 
that LAG-3 has a functional role in modulating inflammation and parasite burden, in 
association with Tr1 cells, suggests that a number of other repressors expressed by Tr1 
cells such as CTLA-4, and TIM-3 may also contribute to Tr1 cell regulatory function. A 
number of these markers have been translated into check point blockade therapies for 
cancer, any of which could be utilised to alter immune regulation in other diseases. Our 
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results suggest that it would be pertinent to assess how these treatments influence parasitic 
diseases such as malaria. 
There is increasing recognition that immune cells are highly plastic. Our transcriptional 
profiling of Th1 and Tr1 cells indicates that Tr1 cells are likely a further differentiated Th1 
cell population, as opposed to a unique regulatory lineage like FOXP3+ Treg cells. The 
capacity of Tr1 cells to produce pro-inflammatory cytokines such as IFNγ, but also suppress 
inflammation via IL-10 and potentially LAG-3 and other regulatory molecules, emphasises 
the idea that effector populations like Th1 cells, have the capacity to self-regulate and do 
not always require the presence of traditional Treg cells to temper their response and protect 
against immune pathology. This multifunctional phenotype is also seen in other effector cell 
populations like Th17 and Th2 cells which under certain circumstances will co-produce IL-
10 along with classical Th17 and Th2 lineage cytokines (reviewed in 354). This 
multifunctionality opens up a unique opportunity for immune therapy and disease treatment. 
Since Tr1 cells have the capacity for two opposing immune functions they offer an ideal for 
achieving balance between inflammation and regulation. The challenge will be manipulating 
these cells so that their regulatory and inflammatory functions complement each other for 
favourable disease outcomes.  
Some of the biggest challenges in malaria eradication include T cell exhaustion and the 
rapid loss of immune cell memory78,79,355. This is highlighted in our results where regulatory 
and exhaustion markers are prominent in both the general CD4+ T cell response and the 
Tr1 cell response to malaria and VL. Markers such as LAG-3, CTLA-4 and TIM-3 are known 
correlates of T cell exhaustion in parasitic infection233,234,239,250. We’ve suggested that these 
check-point molecules increased the suppressive function of further differentiated T cells 
like Tr1 cells; however, they may also hinder the function of Tr1 cells. Evidence suggests 
that Tr1 cells develop as a result of chronic stimulation, consequently they may inherit 
exhaustion from their Th1 predecessors. This may functioned to limit inflammation, but may 
also have the secondary effect of limiting extreme suppression of anti-inflammatory 
responses by Tr1 cells. As such, there is potential to improve the response of Tr1 cells by 
employing strategies such as immune checkpoint blockade.  
Cell exhaustion also limits immune memory which is critical for development of immunity to 
diseases such as malaria and leishmaniasis. Our findings suggest that it would be beneficial 
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to target markers of exhaustion such as LAG-3 to improve immune response early in 
infection. This lends itself to use in vaccination strategies where there is an opportunity to 
influence the immune response in its initial stages of development. This has been pioneered 
in cancer vaccinations where it is proving to be successful257,356. However, it has not been 
explored in parasite vaccination; this would be valuable to examine in more detail as current 
parasitic vaccines, namely malaria vaccines, have a poor efficacy, combination antibody 
therapies may be an important avenue to improving efficacy. 
Although malaria morbidity and mortality continues to decrease, the rate at which they are 
decreasing is slowing. Numerous environmental, vector and anti-malaria drug interventions 
have played a significant role in reducing disease burden, but unless we can improve host 
immunity we will not be able to achieve malaria eradication. Although the immune response 
to parasitic infection is complex and our understanding of it is incomplete, it is still possible 
to have a significant impact on immunity and disease outcome by targeting what we do 
understand. The findings from our work have the potential to help design strategies that 
promote disease elimination by aiding in the improvement of host immunity to malaria and 
other parasitic diseases. 
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Appendix 1: Animal ethics approval 
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Appendix 2: Controlled Human Malaria Infection ethics approval 
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Appendix 3: Human visceral leishmaniasis ethics approval 
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Appendix 4: 
Appendix 4 | List of symbols and names of genes assessed by NanoString analysis. 
Gene 
symbol Gene name 
Gene 
symbol Gene name 
ADORA2A adenosine A2a receptor IL2 interleukin 2 
AHR aryl hydrocarbon receptor IL21 interleukin 21 
BACH2 BTB domain and CNC homolog 
2 
IL21R interleukin 21 receptor 
BCL6 B-cell CLL/lymphoma 6 IL22 interleukin 22 
CCL4 C-C motif chemokine ligand 4 IL23A interleukin 23 subunit alpha 
CCL5 C-C motif chemokine ligand 5 IL23R interleukin 23 receptor 
CCR4 C-C motif chemokine receptor 4 IL27RA interleukin 27 receptor subunit 
alpha 
CCR5 C-C motif chemokine receptor 5 
(gene/pseudogene) 
IL2RA interleukin 2 receptor subunit 
alpha 
CCR6 C-C motif chemokine receptor 6 IL2RB interleukin 2 receptor subunit 
beta 
CCR7 C-C motif chemokine receptor 7 IL32 interleukin 32 
CCR9 C-C motif chemokine receptor 9 IL33 interleukin 33 
CD160 CD160 molecule IL4 interleukin 4 
CD226 CD226 molecule IL4R interleukin 4 receptor 
CD244 CD244 molecule IL5 interleukin 5 
CD27 CD27 molecule IL6 interleukin 6 
CD28 CD28 molecule IL7R interleukin 7 receptor 
CD300A CD300a molecule IL9 interleukin 9 
CD38 CD38 molecule IRF4 interferon regulatory factor 4 
CD3D CD3d molecule ITGA4 integrin subunit alpha 4 
CD3G CD3g molecule ITGAE integrin subunit alpha E 
CD4 CD4 molecule ITK IL2 inducible T-cell kinase 
CD40LG CD40 ligand JAK1 Janus kinase 1 
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CD45R0 CD45R0 JAK2 Janus kinase 2 
CD45RA CD45RA JAK3 Janus kinase 3 
CD69 CD69 molecule JUN Jun proto-oncogene, AP-1 
transcription factor subunit 
CD8A CD8a molecule JUNB JunB proto-oncogene, AP-1 
transcription factor subunit 
CD8B CD8b molecule KLF2 Kruppel like factor 2 
CD96 CD96 molecule KLRB1 killer cell lectin like receptor B1 
CTLA4 cytotoxic T-lymphocyte 
associated protein 4 
KLRG1 killer cell lectin like receptor G1 
CXCL13 C-X-C motif chemokine ligand 
13 
LAG3 lymphocyte activating 3 
CXCL8 C-X-C motif chemokine ligand 8 LCK LCK proto-oncogene, Src 
family tyrosine kinase 
CXCR3 C-X-C motif chemokine receptor 
3 
LGALS1 galectin 1 
CXCR5 C-X-C motif chemokine receptor 
5 
MAF MAF bZIP transcription factor 
CXCR6 C-X-C motif chemokine receptor 
6 
NFATC2 nuclear factor of activated T-
cells 2 
EBI3 Epstein-Barr virus induced 3 NFKB1 nuclear factor kappa B subunit 
1 
EGR2 early growth response 2 NT5E 5'-nucleotidase ecto 
ENTPD1 ectonucleoside triphosphate 
diphosphohydrolase 1 
PDCD1 programmed cell death 1 
EOMES eomesodermin PRDM1 PR/SET domain 1 
FAS Fas cell surface death receptor PRF1 perforin 1 
FAS fatty acid synthase PTGDR2 prostaglandin D2 receptor 2 
FASLG Fas ligand PTGER2 prostaglandin E receptor 2 
FOS Fos proto-oncogene, AP-1 
transcription factor subunit 
PVR poliovirus receptor 
FOXP3 forkhead box P3 PVRIG PVR related immunoglobulin 
domain containing 
GATA3 GATA binding protein 3 RORC RAR related orphan receptor 
C 
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GFI1 growth factor independent 1 
transcriptional repressor 
RUNX1 runt related transcription factor 
1 
GNLY granulysin RUNX3 runt related transcription factor 
3 
GZMA granzyme A S1PR1 sphingosine-1-phosphate 
receptor 1 
GZMB granzyme B SELL selectin L 
GZMH granzyme H SOCS1 suppressor of cytokine 
signaling 1 
GZMK granzyme K SOCS3 suppressor of cytokine 
signaling 3 
GZMM granzyme M SOCS5 suppressor of cytokine 
signaling 5 
HAVCR2 hepatitis A virus cellular receptor 
2 
STAT1 signal transducer and activator 
of transcription 1 
HLA-DRA major histocompatibility 
complex, class II, DR alpha 
STAT3 signal transducer and activator 
of transcription 3 
ICOS inducible T-cell costimulator STAT4 signal transducer and activator 
of transcription 4 
IFNAR1 interferon alpha and beta 
receptor subunit 1 
STAT5A signal transducer and activator 
of transcription 5A 
IFNG interferon gamma STAT5B signal transducer and activator 
of transcription 5B 
IFNGR1 interferon gamma receptor 1 STAT6 signal transducer and activator 
of transcription 6 
IL10 interleukin 10 TBX21 T-box 21 
IL10RA interleukin 10 receptor subunit 
alpha 
TGFB1 transforming growth factor 
beta 1 
IL12B interleukin 12B TIGIT T-cell immunoreceptor with Ig 
and ITIM domains 
IL12RB2 interleukin 12 receptor subunit 
beta 2 
TNF tumor necrosis factor 
IL13 interleukin 13 TNFRSF18 TNF receptor superfamily 
member 18 
IL17A interleukin 17A TNFSF10 TNF superfamily member 10 
IL17F interleukin 17F ZBTB16 zinc finger and BTB domain 
containing 16 
IL18R1 interleukin 18 receptor 1 ZNF683 zinc finger protein 683 
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IL1RL1 interleukin 1 receptor like 1 
  
Panel of 135 genes selected based on their involvement in immunological responses in 
cancer, infectious and autoimmune diseases.  
 
Appendix 5: 
 
Appendix 5 | Correlation of other DEGs with PMR during early P. falciparum infection. 
A) PMR did not correlate with Log2 fold change in CCL4, HLADRA, and TNFSF10 mRNA 
levels in CD4+ PBMCs (as determined by NanoString analysis) from 0 to 8 days p.i., Cohorts 
1, 2, and 3, n=12, Spearman correlation. 
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Appendix 6: 
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Appendix 6 | BACH2 broadly regulates cytokine induction across multiple CD4+ cell 
lineages. 
CD4+ splenocytes were purified from the spleens of B6.bach2ΔT and B6.bach2fl/fl mice and 
cultured with αCD28 and αCD3 mAbs for 5 days under either Th0, Th1, Th2, Th17 or Treg 
polarising conditions. Cytokine concentrations were assessed in cell culture supernatants. 
n=5 mice per condition in duplicate, *P<0.05, significance assessed by Mann-Whitney U 
test.  
Appendix 7: 
 
Appendix 7 | Cell intrinsic BACH2 supports T cell development and expansion. 
The proportion (%) of B6.bach2ΔT (CD45.2, black bars):B6.bach2fl/fl (CD45.1, grey bars) 
leukocytes in recipients of an equal mix (50:50) of bone marrow from these mice. Leukocyte 
proportions were assessed at 12 weeks post-transplant. n=3 mice. 
 
 
